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Abstract 
Gene expression in eukaryotes is dependent on the N-7 methylguanosine cap, 
located at the 5ʼ end of RNA pol II transcripts, which marks pre-mRNA for processing, 
stabilisation and translation initiation. The enzymes that catalyse the formation of the 
N-7 methylguanosine cap are recruited to RNA pol II at the initial stages of 
transcription. The final step in this process, N-7 methylation of the guanosine cap, is 
catalysed by the RNA guanine-7 methyltransferase, RNMT. 
RNA guanine-7 methylation is an essential process for cell viability and its up-
regulation has been associated with cell transformation. However, the mechanistic 
details of RNMT function in mammalian cells remain elusive. In order to gain better 
understanding of the molecular mechanisms associated with RNA guanine-7 
methylation, cellular RNMT complexes were purified from human cells and 
constituent proteins were identified using mass spectrometry. A novel component of 
the RNA guanine-7 methyltransferase complex was identified and designated as 
RAM (RNMT activating mini-protein). The vast majority of RNMT is found in a 
complex with RAM and vice versa.  
RAM is an RNA-binding protein, promoting recruitment of RNA to RNMT. RAM 
increases recombinant and cellular RNMT cap methyltransferase activity and is 
required for cap methylation in vivo. We therefore, describe RAM as an “obligate 
activator” of the human cap methyltransferase. As expected of a protein essential for 
cap methylation, RAM is required for gene expression, and RAM depletion results in 
loss of cell viability. Current studies are being focused on determining RAM/RNMT 
crystal structure as well as determining how the RNA guanine-7 methyltransferase 
complex is regulated within cells.  
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Chapter 1:  Introduction 
1.1 Introduction to eukaryotic gene expression 
The central dogma of molecular biology, which was formulated by Francis Crick in 
1958 and revised by him in 1970 (Crick, 1970), introduced the detailed residue-by-
residue transfer of genetic information to the synthesis of a functional gene product. 
This process is called gene expression and has attracted scientific interest, as 
deregulated gene expression can be responsible for abnormal cell proliferation 
(Delgado and Leon, 2006). The regulation of gene expression is a multi-step process 
and occurs at multiple levels, in a coordinated fashion. This includes epigenetic 
alterations and transcriptional regulation of RNA production. In addition, regulation of 
RNA processing and export of the messenger RNA (mRNA) to the cytosol can alter 
gene expression profiles. Finally, gene expression regulation can occur at the level of 
mRNA silencing, mRNA translation and post-translational modification. All the above 
steps of gene expression regulation can coordinately tune protein activities within 
cells (Orphanides and Reinberg, 2002).  
N-7 methylguanosine cap formation is the first pre-mRNA processing event and has 
an essential role in gene expression (Proudfoot et al., 2002), as it is required for 
subsequent mRNA metabolic events which lead to protein synthesis (Cowling, 
2010c). This thesis focuses on understanding the mechanics of RNA guanine-7 
methylation in mammalian cells. However, before analysing the mechanics and 
functions of N-7 methylguanosine cap, a brief introduction to the gene expression 
events associated with N-7 methylguanosine cap will be presented.  
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1.1.1  Transcription initiation 
RNA polymerase II (RNA pol II) is the multi-subunit enzyme that catalyses DNA-
dependent mRNA synthesis in the presence of additional transcriptional factors 
(Woychik and Hampsey, 2002). In addition to mRNA, RNA pol II is also responsible 
for the transcription of U small nuclear RNA (U snRNA) and micro RNA (miRNA). The 
carboxyl-terminal domain (CTD) of the large subunit of RNA pol II is essential for 
RNA pol II function and consequently cell viability (Bartolomei et al., 1988). This 
domain is absent from the related subunits of RNA polymerase I and III and 
comprises tandem heptad repeats with a consensus sequence of Tyrosine1-Serine2-
Proline3-Threonine4-Serine5-Proline6-Serine7, which is conserved amongst 
eukaryotes (Bentley, 2005). The CTD serves as a binding scaffold for numerous 
mRNA processing factors, coupling transcription with pre-mRNA processing 
(McCracken et al., 1997b). However, the CTD is more than a passive landing pad 
since it can influence RNA processing factors by allosteric activation, as will be 
described later (Ho and Shuman, 1999).  
CTD heptapeptide post-translational modifications are essential for transcription 
processing. The best-characterised modifications are Serine-2 and Serine-5 
phosphorylation and the availability of monoclonal antibodies specific for these 
phosphorylations has facilitated the characterisation of their function. The 
coordinated phosphorylation of these residues is required for transcriptional 
promoter-proximal pausing and the switch to elongation. Phosphorylation of Serine-5 
residues by the cyclin-dependent kinase 7 (Cdk7), a component of the general 
transcription factor TFIIH, is greatest near the 5ʹ end of genes, and is responsible for 
the promoter-proximal pausing of RNA pol II (Egloff and Murphy, 2008).  
RNA pol II pausing is associated with the recruitment of DSIF (DRB-sensitivity 
inducing factor) and NELF (Negative elongation factor) to chromatin. DRB is a drug 
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that inhibits RNA pol II transcription elongation but not initiation. DSIF consists of two 
polypeptides named Spt4 and Spt5 (Wada et al., 1998). NELF is a complex 
consisting of five polypeptides designated as NELF A–E (Yamaguchi et al., 1999). 
NELF and DSIF together are responsible for the promoter-proximal pausing of RNA 
pol II. The Cdk9 activity of the positive transcription elongation factor P-TEFb 
phosphorylates the Serine-2 of the RNA pol II CTD domain, as well as both NELF 
and DSIF, promoting escape of RNA pol II from the stalled state (Peterlin and Price, 
2006). Serine-2 phosphorylation of the RNA pol II CTD domain is associated with 
overcoming the early elongation block and with the conversion of RNA pol II into an 
elongating form (Zhou et al., 2012). However, it should be noted that recent studies 
have demonstrated that the RNA pol II CTD post-translational modification landscape 
is far more complex than initially believed and involves additional phosphorylation, 
methylation, glycosylation and ubiquitination events (Heidemann and Eick, 2012).  
 
1.1.2  mRNA processing and translation 
Whilst the mRNA is being transcribed it is subjected to processing events that lead to 
the production of mature mRNA. The pre-mRNA processing events include N-7 
methylguanosine cap formation at the 5ʼ end of the nascent transcript, splicing and 
polyadenylation (Proudfoot et al., 2002). Splicing is the process of removing 
intervening, non-coding, intronic sequences from the pre-mRNA followed by the 
joining of the exonic RNA fragments to generate a functional message (Tollervey and 
Caceres, 2000). The molecular machinery that catalyses splicing is called the 
spliceosome and is composed of five small nuclear ribonucleoprotein particles (U 
snRNPs) associated with a large number of additional proteins (Matlin et al., 2005).  
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 Polyadenylation is a process that occurs on all protein encoding mRNAs with the 
notable exception of histone transcripts. The poly(A)-tail is synthesised at the 3ʼ end 
of mRNA transcripts and is comprised of 200–250 adenosines. It is required for many 
aspects of mRNA metabolism including transcription termination, mRNA stability, 
mRNA export and mRNA translation (Di Giammartino et al., 2011). Polyadenylation 
is a two-step process: initially the pre-mRNA is cleaved at the poly(A) site followed by 
the synthesis of the 3ʼ end poly(A)-tail (Shatkin and Manley, 2000). As most pre-
mRNA processing events occur co-transcriptionally, the N-7 methylguanosine cap 
formation is linked with splicing and polyadenylation, as will be explored in detail later 
in this introduction (Proudfoot et al., 2002).  
Once nascent pre-RNA has been transcribed and matured into mRNA, it is 
transferred from the nucleus to the cytoplasm, where it is translated (Orphanides and 
Reinberg, 2002). Recent studies in mammalian cells have linked mRNA export with 
the N-7 methylguanosine cap, as will be discussed later. The export of mRNA to the 
cytoplasm is coupled both with upstream events, such as pre-mRNA splicing, and 
downstream events like nonsense mediated decay (NMD) (Reed and Hurt, 2002). 
NMD is a mechanism that controls the quality of translated mRNAs by specifically 
eliminating potentially toxic truncated proteins (Schoenberg and Maquat, 2012). The 
second mechanism of mRNA decay can alter the abundance of specific transcripts 
for the purpose of changing gene expression profiles. The N-7 methylguanosine cap 
has been shown to influence both mechanisms of mRNA decay as will be explored 
later.  
Finally, when the message has passed the NMD quality control it is translated by the 
ribosomes to produce proteins. The N-7 methylguanosine cap plays an essential role 
in translation initiation of most transcripts, as will be discussed later. In summary, the 
N-7 methylguanosine cap possesses a critical role in gene expression, as it is 
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required in many different steps of gene expression. Before exploring in detail the 
function of the N-7 methylguanosine cap, its structure and the mechanics of its 
formation will be explored.  
 
1.2 Methyl-cap structures 
The N-7 methylguanosine cap (m7GpppN) was originally identified at the 5ʼ end of 
viral mRNA (Furuichi and Miura, 1975; Furuichi et al., 1975a) and subsequently on 
mRNA derived from HeLa cells (Furuichi et al., 1975b). The N-7 methylguanosine 
cap structure consists of a guanosine group linked to the first transcribed nucleotide 
with the unusual 5ʼ  5ʼ bond (Shatkin, 1976). The guanosine group is methylated at 
the N-7 position (Figure 1.1). The N-7 methylguanisine cap is present in the majority 
of cellular and viral eukaryotic mRNAs (Furuichi and Shatkin, 2000) but is absent in 
bacteria and archea (Shuman, 2002).  
Apart from the N-7 methylguanosine cap, which is also called Cap0, cellular mRNAs 
of higher eukaryotes have also be found to be methylated at the 2ʼ-O position of the 
first (Cap1) and second (Cap2) transcribed nucleotides (Figure 1.1) (Furuichi et al., 
1975b). 2ʼ-O ribose methylation is only present in higher eukaryotes including 
insects, vertebrates and their viruses and absent from lower eukaryotes and its 
biological significance remains elusive (Furuichi and Shatkin, 2000). Although, 
enzymatic methyltransferase activities for Cap1 and Cap2 methylation were identified 
in HeLa extracts 30 years ago (Langberg and Moss, 1981), the human 
methyltransferase enzymes responsible for these modifications were only recenty 
identified (Belanger et al., 2010; Werner et al., 2011). The Cap1 methyltransferase 
enzyme was designated as hMTr1 and the Cap2 methyltransferase as hMTr2. hMTr1 
localises in the nucleus while hMTr2 is present both in nucleus and cytoplasm and 
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neither exhibited N-7 cap methyltransferase activity in vitro (Werner et al., 2011). 
With the discovery of Cap1 and Cap2 methyltransferases it is likely that progress will 
be made to understand the mechanics and the biological purpose of these 
methylations.  
In addition to Cap0, Cap1 and Cap2, trimethylguanosine (TMG) cap (m2,2,7GpppN) 
methylation can also occur specifically to small nuclear RNAs (U snRNAs). U 
snRNAs are capped with m7GpppG during transcription by RNA polymerase II and 
further methylated to form the trimethyl cap post-transcriptionally in the cytosol. TMG 
cap is required for transport of U snRNPs from cytoplasm back to the nucleus (Reddy 
et al., 1992). The investigation of all Cap1, Cap2 and TMG methylation are beyond 
the scope of this thesis, which from now on will be focused on the characterisation of 
the N-7 methylguanosine cap. 
  
N7-methylguanosine cap!
 Cap0!
1st!
2nd!
Cap1!
-CH3 
1st!
2nd!
Cap2!
-CH3 
-CH3 
1st!
2nd!
Figure 1.1: Cap0, Cap1 and Cap2 methyl-cap structures. 
The methyl groups are indicated in red. All cap structures are methylated at the 
N-7 guanosine position. In addition, Cap1 and Cap2 structures are also 
methylated at the 2’-O ribose of the first or the first and the second transcribed 
nucleotides respectively. The biological function of Cap1 and Cap2 remains 
elusive. Conversely, Cap0 is essential for gene expression and cell viability as 
analysed in the rest of the introduction.  
18!
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1.2.1 Enzymology of N-7 methylguanosine cap 
Three enzymatic activities are responsible for the addition of the N-7 
methylguanosine cap to nascent RNA. Firstly, the 5ʼ triphosphate group of nascent 
RNA pol II transcripts, pppN, is hydrolysed by the RNA 5ʼ triphosphatase to produce 
a diphosphate at the 5ʼ end of the RNAs, (pppN  ppN). Subsequently, the RNA 
guanylyltransferase catalyses the addition of GMP to the RNAs that have a 
diphosphate at the 5ʼ end to produce the guanosine cap, (ppN  GpppN). Finally, 
the RNA guanine-7 methyltransferase catalyses the methylation of the guanosine 
cap at the N-7 position to produce the N-7 methylguanosine cap, (GpppN  
m7GpppN) (Figure 1.2) (Furuichi and Shatkin, 2000). 
Although, cap methylation occurs in all eukaryotes and eukaryotic viruses, the 
introduction of this thesis will focus on the mechanics of RNA guanine-7 methylation 
of mammalian (Homo sapiens, Mus musculus) and lower eukaryotic systems 
(Saccharomyces cerevisiae and Schizosaccharomyces pombe). With the exception 
of viruses in which N-7 methylguanosine cap formation is highly diverse and out of 
the scope of this thesis, the majority of advances characterising the biochemical 
pathway responsible for N-7 methylguanosine cap formation have been performed in 
yeast.  
The three enzymatic activities responsible for the synthesis of the N-7 
methylguanosine cap are present in three separate polypeptides in S. cerevisiae 
(Shibagaki et al., 1992; Mao et al., 1995; Tsukamoto et al., 1997) and the same is 
true for S. pombe (Shuman et al., 1994; Saha et al., 1999; Pei et al., 2001b). Cet1p 
and Pct1p are the RNA triphosphatases, Ceg1p and Pce1p are the RNA 
guanylyltransferases and Abd1p and Pcm1p are the RNA guanine-7 
methyltransferases in S. cerevisiae and S. pombe respectively (Table 1.1). All the 
above enzymes are essential for cell viability demonstrating the importance of N-7 
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methylguanosine cap formation. In mammals the RNA triphosphatase and the RNA 
guanylyltransferase activities reside in the same polypeptide called RNA 
guanylyltransferase and triphosphatase (RNGTT) (Yue et al., 1997; Yamada-Okabe 
et al., 1998; Pillutla et al., 1998a), however, the mammalian RNA guanine-7 
methyltransferase, RNMT, is a distinct protein (Tsukamoto et al., 1998; Pillutla et al., 
1998a; Saha et al., 1999; Pillutla et al., 1998b). As in yeast, human RNGTT and 
RNMT are essential for cell viability (Shafer et al., 2005; Chu and Shatkin, 2008). The 
fact that both yeast and mammalian enzymes responsible for N-7 methylguanosine 
cap formation are required for cell viability suggests that these enzymatic activities 
are not fully redundant and no other RNA triphosphatase, RNA guanylyltransferase 
or RNA guanine-7 methyltransferase are able to compensate for the loss of RNGTT 
or RNMT respectively within cells.  
 
Table 1.1: Nomenclature of the machinery involved in N-7 methylguanosine cap formation in 
different species. 
Enzymatic activities/Species S. cerevisiae S. pombe H. sapiens 
RNA 5ʼ triphosphatase Cet1p Pct1p 
RNGTT 
RNA guanylyltransferase Ceg1p Pce1p 
RNA guanine-7 
methyltransferase 
Abd1p Pcm1p RNMT 
 
 
  
pppN! ppN-RNA + Pi!
RNA!
 triphosphatase!
Pct1p!
Cet1p!
RNGTT!
GpppN-RNA + SAM! m7GpppN-RNA + SAH!
RNA!
guanineN7-!
methyltransferase!
Pcm1p!
Abd1p!
RNMT!
Ceg1p!
Pce1p!
RNGTT!
GTP + RNGTT! GMP-RNGTT + PPi!
RNA !
guanylyltransferase!
GMP-RNGT + ppN-RNA! GpppN-RNA + Pi!
Figure 1.2: Reactions that required for N-7 methylguanosine cap synthesis. 
The reaction steps are described in details in the main text. The enzymatic 
activities responsible for the reaction catalysis are indicated above the reaction 
arrows. The name of the actual enzymes in S. pombe, S. cerevisiae and H. 
sapiens are indicated bellow the reaction arrows (Adapted from Cowling, 2010c). 
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1.2.2 Structural insights into the N-7 methylguanosine 
capping machinery 
The first step of N-7 methylguanosine cap formation is the hydrolysis of the γ-
phosphate from the first transcribed nucleotide of the nascent RNA to form a 
diphosphate end (Figure 1.2). The RNA triphosphatase enzymes are not conserved 
among eukarya and can be divided into two distinct families according to their 
mechanistic and structural details. The triphosphatase activity of Cet1p in S. 
cerevisiae utilises a divalent-cation-dependent mechanism for which is optimal in the 
presence of magnesium (Lima et al., 1999). Eight antiparallel β strands form a closed 
tunnel and its interior surface consists of hydrophilic residues. The RNA 5ʼ γ-
phosphate interacts with the basic amino acid chains that point into the tunnel. The S. 
pombe Pct1p is structurally and biochemically conserved with Ceg1p (Pei et al., 
2001b).  
In mammals the triphosphatase and the guanylyltransferase activities reside in the 
same polypeptide named RNGTT. The RNGTT N-terminus (1-210) posseses the 
RNA triphosphatase activity while the C-terminal RNGTT domain (211-597) is 
responsible for the guanylyltransferase activity (Yamada-Okabe et al., 1998; Ho et al., 
1998a).  
The crystal structure of the mouse triphosphatase domain (RNGTT 1-210) revealed 
that the triphosphatase activity is metal-independent and structurally unrelated with 
the Cet1p (Changela et al., 2001). RNGTT 1-210 belongs to the cysteine 
phosphatase superfamily containing a phosphate-binding loop with an active site 
cysteine situated in a deep positively charged pocket. Due to structural differences 
between mammalian and fungi RNA triphosphatases there is a possibility of 
identifying anti-fungal drugs with minimum toxicity. 
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The second step of the N-7 methylguanosine cap formation is the addition of the 
GMP to the diphosphate located at the 5ʼ end of the RNA (pp-RNA) to produce 
capped RNA (Gppp-RNA). The guanylyltransferase enzymes responsible for the 
catalysis of this reaction are structurally related among different species (Chu et al., 
2011; Håkansson et al., 1997; Gu et al., 2010; Fabrega et al., 2003). The mechanism 
of RNA capping consists of two steps. Firstly, GTP binds to a Lysine in the active site 
of the guanylyltransferase whilst the enzyme is in an open conformation. Binding of 
GTP promotes a conformational change resulting in the closure of the enzyme and 
the generation of an enzyme-(lysyl-N)-GMP conjugate. When the enzyme opens the 
pyrophosphate (ppi) is released and the RNA binding site is exposed. The enzyme 
must close and open again in order to catalyse the ligation of GMP to diphosphate 
RNA and to release the capped RNA product (Håkansson et al., 1997).   
The final step of N-7 methylguanosine cap formation is the methylation of the 
guanosine cap (Gppp-RNA) by the RNA guanine-7 methyltransferase. Crystal 
structures of the microsporidian RNA guanine-7 methyltransferase alone and in 
binary complexes with S-adenosyl-methionine (SAM), S-adenosyl-homocysteine 
(SAH) or a cap analogue (m7GpppG) have been resolved (Fabrega et al., 2004). 
Furthermore, the crystal structures of the human catalytic domain of RNMT in binary 
complexes with either SAH or sinefugin, an inhibitor of the RNA guanine-7 
methyltransferase, have been resolved by the Structural Genomic Consortium (SGC) 
(Structural Genomics Consortium; PDB code 3BGV, 3EPP). The RNA guanine-7 
methyltransferase active site, which is structurally conserved among species, 
contains two distinct pockets for the methyl donor, SAM, and the methyl acceptor, the 
guanosine cap. Interestingly, the microsporidian methyltransferase structure revealed 
that the N-7 atom of the guanosine cap does not directly interact with the enzyme 
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suggesting that N-7 methylation is accomplished by optimising the proximity and 
orientation of the substrates (Fabrega et al., 2004). 
 
1.3 The formation of N-7 methylguanosine cap is 
predominantly co-transcriptional 
The N-7 methylguanosine cap moiety is located at the 5ʼ end of all RNAs that are 
being transcribed by RNA polymerase II (RNA pol II) (Schoenberg and Maquat, 
2009). RNA pol II is responsible for the transcription of the protein-coding genes 
(mRNAs) as well as many noncoding transcripts including the spliceosomal small 
nuclear RNAs (U snRNAs), pri-microRNAs (pri-miRNAs) and long noncoding RNAs 
(lnRNAs) (Richard and Manley, 2009). The formation of the N-7 methylguanosine 
cap occurs predominantly in the nucleus whilst RNAs are being transcribed by RNA 
pol II. In vitro transcription assays have demonstrated that the addition of the 
guanosine cap occurs whilst the nascent transcripts are between 20 and 80 
nucleotides in length (Coppola et al., 1983; Mandal et al., 2004). Furthermore, 
nuclear run-on assays on heat shock genes of Drosophila melanogaster 
demonstrated that the majority of capping occurs while transcripts are between 20-30 
nucleotides in length (Rasmussen and Lis, 1993).  
As regards to the N-7 cap methylation, labelling HeLa cells with 3H-methyl-L-
methionine for a time course indicated that cap methylation reaction occurs 
predominantly co-transcriptionally while the nascent transcripts are less than 750 
nucleotides in length (Salditt-Georgieff et al., 1980). In addition, in vitro transcription 
utilising HeLa cell extract revealed that RNAs as short as 50 nucleotides can be N-7 
methylguanosine capped (Jove and Manley, 1984). Moreover, S-adenosyl-
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homocysteine (SAH), an inhibitor of all methylation reactions, inhibited RNA pol II 
transcription initiation in HeLa cell extracts without affecting RNA pol II elongation or 
RNA pol III transcription. These results are consistent with the notion that the 
formation of the N-7 methylguanosine cap moiety is coupled to transcription initiation 
(Jove and Manley, 1982). More directly, antibodies raised against the N-7 
methylguanosine cap structure were used after in vitro pulse-chase transcription 
assay using HeLa nuclear extract to purify transcripts and it was demonstrated that 
capping occurs predominantly co-transcriptionally (Moteki and Price, 2002).  
The identification of the enzymes responsible for N-7 methylguanosine cap formation, 
initially in S. cerevisiae and subsequently in humans, facilitated the elucidation of the 
molecular mechanisms that govern its formation.  
Chromatin immunoprecipitation (ChIP) experiments in yeast and mammals have 
demonstrated that the capping machinery can be recruited to the promoter-proximal 
paused RNA pol II and it is associated with RNA pol II Serine-5 phosphorylation. 
Capping enzymes recruitment correlates with Serine-5 phosphorylation of the RNA 
pol II CTD (Glover-Cutter et al., 2008; Schroeder et al., 2000; Rodriguez et al., 2000; 
Guiguen et al., 2007). Interestingly, the essentiality of Serine-5 phosphorylation for 
cell survival can be circumvented by covalently tethering the RNA capping enzyme to 
the CTD of RNA pol II in S. pombe (Schwer and Shuman, 2011).  
N-7 methylguanosine cap formation is a highly conserved process considering that 
expression of the human RNA guanylyltransferase and RNA guanine-7 
methyltransferase can rescue the viability of S. cerevisiae strains in which the RNA 
guanylyltransferase and the RNA guanine-7 methyltransferase genes have been 
deleted (Ho et al., 1998a; Saha et al., 1999). Furthermore, the recruitment of capping 
enzyme to the nascent pre-mRNA via the interaction with the phosphorylated CTD of 
RNA pol II is a universal phenomenon (McCracken et al., 1997a; Cho et al., 1998; 
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Yue et al., 1997; Ho and Shuman, 1999; Ghosh et al., 2011).  
Although the formation of the N-7 methylguanosine cap occurs co-transcriptionally, 
there is recent evidence suggesting that cap formation can also occur at a post-
transcriptional level. Interestingly, mRNA degradation products lacking part of the 5ʼ 
end of the transcripts were detected to posses a N-7 methylguanosine cap (Lim and 
Maquat, 1992). These transcripts were detected by affinity purification of N-7 
methylguanosine capped transcripts utilising an antibody raised against the methyl-
cap structure, followed by Northern blot analysis. The N-7 methylguanosine cap 
moiety at the 5ʼ end of these mRNA degradative intermediates protected them from 5ʼ 
 3ʼ exoribonucleolytic degradation. 
Immunofluorescence and biochemical fractionation was utilised for the identification 
of a cytoplasmic RNA guanylyl-transferase in mammalian cells (Otsuka et al., 2009). 
Cytoplasmic RNGTT was co-purified in a complex with a kinase and together they 
could convert 5ʼ-monophosphate RNA into 5ʼ-GpppN RNA. The identification of the 
kinase as well as the biological significance of a cytosolic capping enzyme remains 
elusive. However, a recent report demonstrated that only a portion of the mRNA 
transcriptome is subjected to cytosolic capping (Mukherjee et al., 2012). Recapping 
of these messages stimulated their translation efficiency. In addition to cytoplasmic 
capping, in X. laevis oocytes cytoplasmic RNA guanine-7 methyltransferase activity 
has been identified (Gillian-Daniel et al., 1998). To date, there is no evidence of 
mammalian cytoplasmic RNA guanine-7 methyltransferase activity.  
Interestingly, the mechanistic details of N-7 methylguanosine cap formation vary 
between different eukaryotic systems. The next sections review the mechanistic 
details of N-7 methylguanosine cap formation in S. pombe, S. cerevisiae and 
mammals and they also explore the effect of capping machinery on transcription. 
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1.3.1 N-7 methylguanosine capping in S. pombe 
In the fission yeast S. pombe, the N-7 methylguanosine capping apparatus consists 
of three distinct proteins. The RNA triphosphatase is named Pct1p (Pei et al., 2001b), 
the RNA guanylyltransferase Pce1p (Shuman et al., 1994) and the RNA guanine-7 
methyltransferase Pcm1p (Saha et al., 1999) (Table 1.1).  
Although Pct1p and Pce1p do not physically interact with each other, they are both 
recruited to the nascent transcript by interacting with the Serine-5 phosphorylated 
CTD domain of RNA pol II. These interactions have been demonstrated by yeast 
two-hybrid assays and in vitro pull down experiments. (Pei et al., 2001a; Takagi et al., 
2002). Neither Pct1p nor Pce1p regulate each otherʼs activity or affinity for RNA pol II 
CTD domain.  
In addition, Pct1p has been demonstrated to interact with Cdk9, the kinase subunit of 
P-TEFb, which is responsible for RNA pol II CTD Serine-2 phosphorylation and the 
switch of RNA pol II from paused to elongating state. Two-hybrid screens and in vitro 
pull down experiments were employed for demonstrating this interaction (Pei et al., 
2003). Although the biological significance of the above interaction was never 
investigated, it was speculated that it may serve as the coupling of capping with 
transcription elongation.  
Finally, Pct1p and Pce1p interact with the carboxyl-terminal domain (CTD) of Spt5, 
which is part of the DSIF complex, independently of each other and independently of 
Spt5 CTD phosphorylation as shown by two-hybrid assays and in vitro pull-down 
experiments (Pei and Shuman, 2002; Schneider et al., 2010). Although the above 
results suggest that Pct1p and Pce1p may utilise Spt5 as a scaffold, in vivo 
reciprocal co-immunoprecipitations of Pct1p and Pce1p failed, suggesting that Pct1p 
and Pce1p bind mutually exclusive to Spt5 (Takagi et al., 2002). Deletion of the Spt5 
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CTD domain results in slow growth and aberrant S. pombe morphology, effects that 
are intensified by truncation of the RNA pol II CTD domain but can be rescued by 
overexpression of Pct1p and Pce1p. These results suggest that Spt5 and RNA pol II 
CTDs have overlapping roles in the recruitment of the Pct1p and Pce1p to nascent 
RNA for the capping reaction in S. pombe (Schneider et al., 2010). 
S. pombe RNA guanine-7 methyltransferase, Pcm1p has not been shown to interact 
with RNA pol II or Spt5 (Pei et al., 2006) and it remains unclear as to how Pcm1p is 
recruited to the transcription initiation site. Interestingly, Pcm1p similar to Pct1p, has 
been demonstrated to interact with Cdk9, the kinase subunit of P-TEFb, as shown by 
immunoprecipitation and size-exclusion chromatography of cellular proteins (Pei et 
al., 2006; Guiguen et al., 2007; Viladevall et al., 2009). Furthermore, Cdk9 and 
Pcm1p colocalise on the chromatin as demonstrated by ChIP (Guiguen et al., 2007). 
Cdk9 is responsible for phosphorylating both RNA pol II and Spt5 CTDs resulting in 
transcription elongation (Pei et al., 2006). Interestingly, Pcm1p depletion from S. 
pombe cells results in a reduction of Cdk9 recruitment to stalled RNA pol II and a 
decrease of Serine-2 phosphorylation of RNA pol II CTD (Guiguen et al., 2007). Cdk9 
depletion does not affect Pcm1p recruitment to chromatin suggesting that Pcm1p 
recruitment to nascent transcript occurs prior to Cdk9 recruitment. As Cdk9 kinase 
activity is responsible for promoting RNA pol II escape from promoter pausing, this 
mechanism may ensure that this only occurs after complete capping of transcripts 
(Figure 1.3a).  
 
1.3.2 N-7 methylguanosine capping in S. cerevisiae 
In budding yeast S. cerevisiae the three capping enzymatic activities reside in 
different polypeptides. The RNA triphosphatase, Cet1p (Tsukamoto et al., 1997), the 
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RNA guanylyltransferase, Ceg1p (From et al., 1992), and the RNA guanine-7 
methyltransferase, Abd1p (Mao et al., 1995) (Table 1.1). The RNA triphosphatase 
and the RNA guanylyltransferase activities are detected in the same complex 
containing two polypeptides (Itoh et al., 1987). The interaction between Cet1p and 
Ceg1p has been demonstrated by in vitro pull down assays (Ho et al., 1998b, 1999), 
co-immunoprecipitations of cellular proteins (Takagi et al., 2002) and also by co-
crystalisation of Cet1p and Ceg1p (Gu et al., 2010). The triphosphatase activity of 
Cet1p is encoded by the N-terminal domain whereas Cet1p C-terminus is able to 
bind to Ceg1p (Lehman et al., 1999). This interaction allows the colocalisation of the 
capping complex to chromatin. Cet1p/Ceg1p interaction is essential for S. cerevisiae 
viability (Takase et al., 2000; Ho et al., 1999; Lehman et al., 1999). This is partially 
because by this means Cet1p is recruited to chromatin, but also because Cet1p 
binding stimulates Ceg1p activity by altering its conformation (Gu et al., 2010; Takagi 
et al., 2002; Cho et al., 1998; Ho et al., 1998b) and also stabilises Ceg1p (Hausmann 
et al., 2001). 
Ceg1p is recruited to chromatin via an interaction with the phosphorylated CTD of 
RNA pol II on Serine-5 thereby recruiting Cet1p to RNA pol II (Cho et al., 1997; 
McCracken et al., 1997a). The interaction between RNA pol II CTD and Ceg1p is 
required for Ceg1p stability in vivo (Rodriguez et al., 2000).  
Interestingly, both Cet1p and Ceg1p are required for the efficient recruitment of 
general transcription factors as well as RNA pol II to gene promoters. This is 
probably due to the guanosine cap itself that promotes the recruitment of the cap-
binding complex that stimulates transcription initiation as will be described later 
(Lahudkar et al., 2011). However, the Cet1p/Ceg1p complex have been shown to 
have an inhibitory effect on transcription elongation in an in vitro transcription system 
(Myers et al., 2002). 
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Abd1p, RNA guanine-7 methyltransferase, is also recruited directly to the nascent 
RNA by physically interacting with the Serine-5 phosphorylated CTD of RNA pol II 
(McCracken et al., 1997a; Schroeder et al., 2000). Abd1p can be recruited to 
chromatin independently of Cet1p/Ceg1p and travels with the transcribing RNA pol II 
as far as the 3ʼ end of the genes whereas Cet1p/Ceg1p are released early during 
transcription elongation (Schroeder et al., 2000). Abd1p is also required for the 
recruitment of RNA pol II to specific promoters, however, conversely to Cet1p/Ceg1p, 
Abd1p is required for transcription elongation in a gene specific manner. These 
functions of Abd1p are independent of its methyltransferase activity (Schroeder et al., 
2004). Proteomic studies suggest that Abd1p interacts with Spt5 which may explain 
some of Abd1p transcriptional functions, however, the biological function of this 
interaction has never been investigated directly (Gavin et al., 2002; Lindstrom et al., 
2003). It is possible that RNA pol II is only able to shift to transcription elongation if 
nascent RNA is properly capped (Figure 1.3b).  
 
1.3.3 N-7 methylguanosine capping in mammals 
In mammals the RNA triphosphatase and RNA guanylyltransferase activities reside 
in the same polypeptide designated as RNA guanylyltransferase and triphosphatase 
(RNGTT) (Yue et al., 1997; Yamada-Okabe et al., 1998). Mammalian RNGTT can 
rescue the cell viability of S. cerevisiae strains in which CET and CEG genes have 
been deleted, suggesting that RNGTT mode of action is conserved in eukaryotes. 
The N-terminus of RNGTT (1-210) contains the triphosphatase activity and the C-
terminus the guanylyltransferase activity (210-597) (Yue et al., 1997; Ho et al., 
1998a). Similar to yeast, mammalian capping enzyme interacts with the Serine-5 
phosphorylated CTD of RNA pol II via the C-terminal domain as demonstrated by in 
vitro pull down assays (Yue et al., 1997; Ho et al., 1998a), chromatin 
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immunoprecipitations of RNGTT and RNA pol II (Glover-Cutter et al., 2008) and co-
crystalisation of RNGTT (227-567) with 18 amino acids of the RNA pol II CTD 
phosphorylated at Serine-5 (Ghosh et al., 2011). The interaction between RNGTT 
and RNA pol II stimulates RNGTT activity up to four-fold by enhancing enzyme 
affinity for GTP and increasing the yield of enzyme-GMP intermediate (Ho and 
Shuman, 1999; Wen and Shatkin, 1999). 
Interestingly, RNGTT interacts with Spt5, a component of DSIF, as demonstrated by 
yeast two-hybrid screen and validated by in vitro pull-down experiments (Wen and 
Shatkin, 1999). Moreover, proteomic analysis with cellular proteins in HeLa cells 
identified Spt5 as an RNGTT interactor (Cowling Laboratory; unpublished data). Spt5 
has no effect on RNGTT triphosphatase activity but can stimulate 
guanylyltransferase activity up to five-fold in vitro (Wen and Shatkin, 1999; Mandal et 
al., 2004). As RNA pol II and Spt5 are required for optimal RNGTT activity, this adds 
to the evidence that cap methylation occurs predominantly co-transcriptionally. 
RNGTT can also function as a transcription factor promoting transcription elongation 
by overcoming NELF transcriptional pausing as was demonstrated by incubating 
purified RNGTT and NELF in an in vitro reconstituted transcription system (Mandal et 
al., 2004). 
Although the human RNA guanine-7 methyltransferase, RNMT, was detected and 
purified from HeLa cells around 35 years ago (Ensinger and Moss, 1976), RNMT 
cDNA was cloned in the late 1990s on the basis of sequence homology to S. 
cerevisiae methyltransferase ABD1 (Tsukamoto et al., 1998; Pillutla et al., 1998a). 
RNMT active site is assigned to the C-terminal domain of the protein (121-476) while 
the N-terminus (1-120) was speculated to have a regulatory role (Saha et al., 1999). 
Similar to all enzymes involved in N-7 methylguanosine cap formation, RNMT is a 
nuclear protein (Wen and Shatkin, 2000) and its nuclear localisation is essential for 
 32 
cell viability (Shafer et al., 2005). RNMT sequence contains three nuclear localisation 
sites (NLS) initiating at the amino acids 80, 103 and 126. RNMT interacts with 
Importin-α, which promotes RNMT nuclear localisation. Furthermore, Importin-α 
stimulates RNMT activity in vitro (Wen and Shatkin, 2000; Shafer et al., 2005). The 
interaction between RNMT and Importin-α has been demonstrated by yeast two-
hybrid screen and in vitro pull-down assays and RNMT amino acids between 96 and 
144 are sufficient for binding to Importin-α (Wen and Shatkin, 2000). Importin-α 
increases RNMT methyltransferase activity, presumably by enhancing RNMT activity 
for capped RNA substrates (Wen and Shatkin, 2000). Importin-β, the cytoplasmic 
interaction partner of Importin-α, although does not interact with RNMT can block the 
stimulation of Importin-α upon RNMT. The biological significance of Importin-α-
dependent stimulation of RNMT activity remains unclear.  
Interestingly, RNMT interaction with RNA pol II is controversial. In vitro pull-down 
experiments suggest a weak interaction between RNMT and RNA pol II which is 
mediated by RNGTT (Pillutla et al., 1998b). However, unpublished data from the 
Shatkin Laboratory demonstrated that recombinant RNMT and RNA pol II failed to 
interact directly as detected by in vitro pull down assays and yeast 2-hybrid screen 
(Shatkin and Manley, 2000). Furthermore, proteomic studies in the Cowling Lab have 
failed to identify RNA pol II as an RNMT interactor, in contrast with the interaction 
between RNA pol II and RNGTT, suggesting that even if RNMT and RNA pol II 
interact in vivo their interaction is extremely weak. On the other hand, chromatin 
immunoprecipitation experiments demonstrate that RNMT is present on the 
chromatin and more specifically at the 5ʼ and 3ʼ ends of RNA pol II transcribed genes 
(Glover-Cutter et al., 2008). It is apparent that the mechanistic details of RNMT 
recruitment to nascent, capped RNA remain elusive (Figure 1.3c).  
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Figure 1.3: Mechanics of N-7 methylguanosine cap formation in S. pombe, S. 
cerevisiae and H. sapiens. 
The mechanistic details of N-7 methylguanosine cap formation in S. pombe (a), S. 
cerevisiae (b) and H. sapiens (c) are presented. The RNA triphosphatase enzymes 
are presented in cyan blue, the RNA guanylyltransferase in dark blue and the RNA 
guanine-7 methyltransferase in green. The details of the N-7 methylguanisne cap 
formation, which is co-transcriptional, are described in the text. 
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1.4 Regulation of RNA N-7 methylguanosine cap 
formation 
Until recently the formation of the N-7 methylguanosine cap at the 5ʼ end of RNA pol 
II transcripts was thought to be a constitutive process associated with transcription 
initiation. However, recent studies have shown that a subpopulation of mRNA 
possesses unmethylated guanosine cap at its 5ʼ end (Chang et al., 2012). 
Interestingly, growth factors have been demonstrated to stimulate the formation of 
the N-7 methylguanosine cap independently of their stimulation in total RNA levels 
(Cowling, 2010c; Jiao et al., 2010).  
N-7 methylguanosine cap formation is dependent on nutrient availability and amino 
acid starvation and glucose deprivation reduces total N-7 methylguanosine cap levels 
(Jiao et al., 2010). This provided the first evidence that demonstrated that 
environmental conditions can modify the levels of guanine-7 methylated mRNA. 
In addition to environmental factors, overexpression of the transcription factor and 
oncogene c-Myc upregulates the guanine-7 methylated mRNA levels within cells 
(Cowling and Cole, 2007; Cole and Cowling, 2009; Fernandez-Sanchez et al., 2009). 
c-Myc is a proto-oncogene which is upregulated in response to growth factors and is 
required for cell growth and proliferation (Cole and Cowling, 2008). c-Myc is a rather 
weak transcription factor but with a broad range of effects since it coordinately 
upregulates ribosomal, transfer and a large proportion of messenger RNAs, 
effectively regulating protein synthesis (Cowling, 2010b). As will be described in 
details later, the mechanism by which c-Myc overexpression upregulates guanine-7 
methylation coordinately involves the upregulation of mRNA guanylylation (capping) 
and guanine-7 methylation. 
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In addition to c-Myc, overexpression of the E2F1 transcription factor also results in 
upregulation of mRNA cap methylation (Cole and Cowling, 2009; Aregger and 
Cowling, 2012). Although E2F1 overexpression is accompanied with a minor 
increase in RNA pol II Serine-5 phosphorylation, the mechanism by which E2F1 
increases cap methylation remain elusive (Aregger and Cowling, 2012).  
 
1.4.1 Regulation of RNA guanylyltransferase and 
triphosphatase 
As has been described previously, RNGTT physically interacts with Serine-5 
phosphorylated CTD of RNA pol II as well as Spt5. Both interactions are required for 
optimal RNGTT guanylyltransferase activity. Interestingly, the stimulation of RNA 
guanylylation by RNA pol II and Spt5 is not additive and it is unclear whether RNGTT 
can bind RNA pol II CTD and Spt5 simultaneously (Wen and Shatkin, 1999).  
As mentioned previously, c-Myc overexpression increases guanine-7 cap methylation 
in a subset of its target genes. This is partially due to an increase in TFIIH 
recruitment to Myc-target gene promoters, after c-Myc overexpression, which is 
accompanied by an increase of RNA pol II Serine-5 phosphorylation (Cowling and 
Cole, 2007). The increase of Serine-5 phosphorylation has been demonstrated to be 
required for the recruitment of RNGTT to transcription initiation sites via RNA pol II 
interaction and to stimulate RNGTT activity as described previously. Therefore, c-
Myc overexpression can presumably stimulate RNGTT recruitment and activity at the 
site of transcription initiation (Figure 1.4).  
An additional level for putative RNGTT regulation is the cytoplasmic RNGTT complex 
(Otsuka et al., 2009). The cytoplasmic capping complex is required for re-capping 
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uncapped transcripts during the recovery period after stress conditions. The 
molecular mechanisms involved in this regulation pathway remain unclear. 
 
1.4.2 Regulation of the RNA guanine-7 methyltransferase 
RNMT regulation mechanisms have attracted scientific interest since overexpression 
of RNMT in mammary epithelial cells promotes their transformation in vitro (Cowling, 
2010a). Furthermore, RNMT overexpression can enhance c-Myc induced cell 
transformation as explored below.  
S-adenosyl-methionine (SAM) is the methyl donor of all cellular methylation reactions. 
During RNA guanine-7 methylation, RNMT catalyses the methylation of the 
guanosine cap using a methyl group derived from SAM which is subsequently 
converted to S-adenosyl-homocysteine (SAH). Elevated levels of SAH by-product 
inhibit RNMT as all cellular methyltransferases. SAH hydrolase (SAHH) converts 
SAH to Adenosine and Homocysteine, relieving SAH-mediated repression of 
methyltransferases (Chiang et al., 1996). SAHH is a Myc target gene and Myc 
overexpression results in an increase of SAHH transcripts and protein levels. SAHH 
upregulation correlates with a reduction of SAH levels and an increase of cellular 
RNMT activity (Figure 1.4) (Fernandez-Sanchez et al., 2009). Interestingly, Myc-
induced SAHH upregulation is essential for Myc-induced cell growth suggesting that 
upregulation of cap methylation is an essential feature of Myc function.  
In X. laevis oocytes the enzyme SAHH has been demonstrated to physically interact 
with the RNA guanine-7 methyltransferase (Radomski et al., 2002). Furthermore, 
SAHH has been detected to colocalise with RNA pol II on nascent transcripts 
(Radomski et al., 1999). During gastrulation X. laevis SAHH is translocated from the 
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cytoplasm to the nucleus and it stimulates mRNA cap methylation (Radomski et al., 
1999).  
Importin-α has been demonstrated to interact with RNMT by two-hybrid screen and in 
vitro pull down assays and to stimulate both RNMT methyltransferase activity and 
affinity for RNA binding in vitro (Wen and Shatkin, 2000). Importin-α and Importin-β 
form a complex that transports NLS containing proteins from the cytoplasm to the 
nucleus. Importin-β alone neither binds to RNMT, nor affects the interaction between 
Importin-α and RNMT, but inhibits Importin-α enhancement of RNMT activity. Nuclear 
RanGTP causes the dissociation of the Importin-α/Importin-β complex, which 
suggests that Importin-α-mediated stimulation of RNMT activity may be specifically 
located to the nucleus (Wen and Shatkin, 2000).  
Finally, in S. cerevisiae overexpression of the enzyme responsible for SAM synthesis, 
SAM synthase, was found to rescue the viability of a yeast strain with defective 
Abd1p in a genetic screen. This was due to enhanced levels of SAM since addition of 
SAM exogenously could also rescue the viability of this strain at a restrictive 
temperature (Schwer et al., 2000). Furthermore, in the same screen overexpression 
of Cdc34p, a ubiquitin conjugation enzyme was also detected to rescue the viability 
of Abd1p defective strains, however, the mechanism by which this rescue was 
mediated was not explored further (Schwer et al., 2000).  
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Figure 1.4: Mechanisms of Myc-induced RNA guanine-7 methylation in H. 
sapiens. 
The mechanics by which Myc induces N-7 methylguanosine cap formation are 
presented. Myc increases the recruitment of the RNA guanylyltransferase, RNGTT, 
to the nascent transcript and stimulates its activity. Furthermore, Myc stimulates 
the activity of RNA guanine-7 methyltransferase, RNMT. In more details, Myc 
interacts with TFIIH and increases its recruitment at transcription initiation sites 
promoting Serine-5 phosphorylation of the carboxyl-terminal domain of RNA 
polymerase II (RNA pol II). RNA pol II Serine-5 phosphorylation increases the 
recruitment of RNGTT to the nascent transcripts and stimulates RNGTT activity. In 
addition, Myc induces the expression of SAHH, which is an enzyme that converts 
SAH to Adenosine and Homocysteine (Hcy). SAH is an inhibitory by-product of all 
methylation reactions. Therefore, Myc indirectly increases RNGTT recruitment to 
transcription initiation sites and stimulates both RNGTT and RNMT activities.  
Adenosine + Hcy 
38!
 39 
1.5 N-7 methylguanosine cap and its cellular 
functions 
The N-7 methylguanosine cap moiety located at the 5ʼ end of RNA pol II transcripts is 
required for transcription elongation, pre-mRNA processing including polyadenylation 
and splicing, mRNA stability, U snRNA and mRNA export, miRNA biogenesis, 
miRNA-dependent mRNA silencing, pioneer round of translation, nonsense mediated 
decay and mRNA translation. Enzymes that bind to the N-7 methylguanosine cap 
moiety promote the majority of the above functions. The biological and biochemical 
functions of the N-7 methylguanosine cap and the currently characterised cap-
binding proteins are presented in the following sections.  
 
1.5.1 N-7 methylguanosine cap and transcription 
N-7 methylguanosine cap formation occurs predominantly at the transcription 
initiation stage as discussed previously. Although the mechanistic details vary 
between different species, the capping apparatus has an active role in transcription 
elongation, which can be independent of its catalytic activity. Briefly, the capping 
machinery has been demonstrated to interact and to recruit transcription factors to 
the transcription initiation sites in a species-dependent manner (Figure 1.3). 
Furthermore, the nuclear cap-binding complex (CBC) promotes transcription initiation 
and elongation as will be explored later. 
 
1.5.2 N-7 methylguanosine cap and RNA stability 
One of the best-characterised functions of the N-7 methylguanosine cap is that it 
protects mRNA from 5ʼ end degradation by exonucleases. Microinjection of in vitro 
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transcribed RNA containing GpppG, m7GpppG or ppG at the 5ʼ end, into Xenopus 
laevis oocytes demonstrated that GpppG and m7GpppG 5ʼ end RNAs are more 
stable than ppG 5ʼ end RNAs (Furuichi et al., 1977; Green et al., 1983). It should be 
mentioned that around 60% of the transfected GpppG transcripts were N-7 
methylated within oocytes due to endogenous oocyte RNA guanine-7 
methyltransferase activity. Similar results have been observed in wheat germ extract 
as N-7 methylguanosine capped RNA were more stable than uncapped RNA 
(Shimotohno et al., 1977).  
Interestingly, in vitro transcribed RNAs with an ApppG structure at their 5ʼ end 
mimicking the guanosine cap were stable when injected into X. laevis oocytes 
suggesting that the cap functions as a blocking structure from exoribonucleolitic 
degradation rather than interacting with a protein that stabilises RNA (Inoue et al., 
1989). This was further suggested by utilising cap analogues. If a cap-binding protein 
was responsible for rendering capped RNA more stable it was predicted that 
incubation of in vitro transcribed RNA with cap analogues in cell extracts would 
increase RNA degradation because the interaction between the cap-binding protein 
and RNA would be abolished. However, this was not the case and cap analogues 
had no effect in RNA stability when included in the reaction mixture (Murthy et al., 
1991). The identification of a cellular exoribonucleolitic activity in HeLa cells that 
preferentially degraded uncapped but not capped RNA provided the mechanism 
which predisposes uncapped RNA to degradation (Murthy et al., 1991).  
N-7 methylation of the cap is also important for RNA stability. Electroporation of in 
vitro transcribed mRNAs containing GpppG or m7GpppG at the 5ʼ end within 
mammalian cells demonstrated that cap methylated transcripts are more stable than 
capped transcripts (Grudzien et al., 2006). This may be due to the 5ʼ-terminal 
unmethylated guanosine cap (GpppN-RNA) being subject to decapping by the 
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reversible capping reaction, producing (p)pN-RNA, which is susceptible to 5ʼ  3ʼ 
exoribonucleolytic degradation (Furuichi and Shatkin, 2000). In addition, the N-7 
methylguanosine cap structure is being recognised by eIF4E cap-binding protein, 
which competes with decapping enzymes for the N7-methylguanosine cap structure 
(Grudzien et al., 2006). 
The effect of the N-7 methyguanosine cap on endogenous transcripts has only been 
investigated in the budding yeast S. cerevisiae. As the capping apparatus is essential 
for cell viability, conditional temperature sensitive mutants of Ceg1p and Abd1p have 
been generated in S. cerevisiae. When RNA guanylyltransferase, Ceg1p, function 
was inactivated in S. cerevisiae strains, a dramatic decrease of endogenous mRNA 
transcript levels was observed by northern blotting (Schwer et al., 1998; Fresco and 
Buratowski, 1996; Schwer and Shuman, 1996). The decrease in mRNA levels was 
due to reduced mRNA stability since deletion of the 5ʼ  3ʼ exoribonuclease, Xrn1p, 
rescued the decrease of RNA levels (Schwer et al., 1998).  
Similar results were observed when the RNA guanine-7 methyltransferase, Abd1p, 
was inactivated in S. cerevisiae. The expression levels of endogenous transcripts 
were decreased (Schwer et al., 2000; Jiao et al., 2010). Deletion of an enzyme 
involved in GpppG-RNA degradation, Rai1p, partially rescued the reduction in 
transcript levels (Jiao et al., 2010). As has been described previously, Abd1p 
inactivation also causes transcriptional defects, which provides an explanation as to 
why the transcript levels were only modestly rescued after Rai1p inactivation.  
 
1.6 Decapping 
Messenger RNA (mRNA) decay is an essential step of gene expression regulation 
since the steady-state accumulation of any given cellular mRNA is determined by 
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both its synthesis and degradation. Decapping is a critical control point in mRNA 
degradation and also in gene expression in general since mRNA decapping and 
mRNA translation are competing pathways (Franks and Lykke-Andersen, 2008). 
Multiple factors have been identified to regulate decapping activity within cells 
(Garneau et al., 2007). An extensive and detailed analysis of the decapping 
machinery and regulation is out of the scope of this thesis, however, a brief 
introduction to the major mRNA degradation pathways and the identified decapping 
enzymes in both humans and S. cerevisiae will be presented.  
Two major distinct exonucleolytic mRNA degradation pathways have been identified, 
the deadenylation-dependent and the deadenylation-independent mRNA decay 
(Garneau et al., 2007). The deadenylation-dependent pathway is initiated by poly(A)-
tail shortening, followed either by 3ʼ  5ʼ exosome degradation or by decapping and 
5ʼ  3ʼ exoribonucleolytic degradation. The exosome is a multisubunit protein 
complex that degrades mRNA exonucleolitically in a 3ʼ  5ʼ direction. The final step 
of 3ʼ  5ʼ end decay is the removal of the N-7 methylguanosine cap by a scavenger-
decapping enzyme (DcpS). The deadenylation-independent pathway is initiated by 
decapping followed by 5ʼ  3ʼ exoribonucleolytic degradation (Badis et al., 2004).  
In S. cerevisiae there are three identified decapping activities. The Dcp1p/Dcp2p 
complex is the canonical decapping enzyme, which targets mRNAs longer than 25 
nucleotides with guanine-7 methylated cap (m7GpppN-RNA -> m7Gpp + pN-RNA) 
(LaGrandeur and Parker, 1998; Dunckley and Parker, 1999). Dcp1p/Dcp2p localise 
to the processing (P) bodies, which are cytoplasmic foci of mRNA degradation (Sheth 
and Parker, 2003).  
The Rai1p/Rat1p nuclear complex was identified as having both decapping and 5ʼ  
3ʼ exonucleolytic degradation activities. Interestingly, decapping activity specifically 
targets unmethylated guanosine capped RNA and is mediated by the Rai1p (GpppN-
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RNA -> Gpp + pN-RNA). Rat1p has 5ʼ  3ʼ exonucleolytic activity and degrades the 
transcript after the removal of the unmethylated cap (Jiao et al., 2010). Furthermore, 
the recently characterised Dox1p was detected to be a cytoplasmic protein and to 
possess both decapping activity, preferentially towards unmethylated caps, but also 
5ʼ  3ʼ exoribonucleolytic activity (Chang et al., 2012). 
Finally, the cytosolic scavenger decapping enzyme, Dcs1p, removes the methylated 
cap (m7GpppN-RNA -> m7Gp + ppN-RNA) from exosome-degraded transcripts less 
than 10 nucleotides in size (Wang and Kiledjian, 2001; Malys et al., 2004). 
In humans only two decapping activities have been identified. hDcp2, the human 
homologue of yeast Dcp2p, and its associated proteins remove the N-7 
methylguanosine cap from transcripts which are subsequently degraded from the 5ʼ 
end by exoribonucleolytic activity (Wang et al., 2002; Lykke-Andersen, 2002). 
Interestingly, a recently identified cytoplasmic enzyme named Nudt16 was also 
demonstrated to have canonical decapping activity in addition to hDcp2 (Song et al., 
2010). Similar to hDcp2, Nudt16 catalyses the removal of the methylated cap at the 5ʼ 
end of the transcripts (m7GpppN-RNA -> m7Gpp + pN-RNA). hDcp2 and Nudt16 
have unique and redundant functions in mRNA decay processes, however, their 
tissue expression pattern differs (Li et al., 2011). As in yeast, the scavenger 
decapping activity also exists in mammals. DcpS, the human homologue of yeast 
Dcs1p, hydrolyses the N-7 methylguanosine cap structure of short transcripts, 
following 3ʼ end mRNA degradation by the exosome, releasing m7Gp and ppN-RNA. 
DcpS physically interacts with the exosome within cells (Liu et al., 2002; Wang and 
Kiledjian, 2001). It should be mentioned, that a similar activity with the one encoded 
by RAI1 and DOX1 genes, specifically hydrolysing umethylated cap structures, has 
not been identified in mammals.  
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1.7 N-7 methylguanosine cap-binding proteins 
and their effect on gene expression 
N-7 methylguanosine cap structure is essential for cell viability from yeast to humans 
since several cellular processes are mediated via the methyl-cap structure. The N-7 
methylguanosine cap is required for transcription, splicing, mRNA 3ʼ end processing, 
RNA stability, nuclear export, mRNA silencing and translation. The processes above 
are all mediated by proteins that specifically recognise the N-7 methylguanosine cap. 
Apart from the decapping enzymes, whose function was analysed in the previous 
section, four more cap-binding proteins have been identified. Firstly, the cap-binding 
complex (CBC), which consists of two proteins, designated Cbp20 and Cbp80 and is 
involved in most of the N-7 methylguanosine cap functions (Figure 1.5). In addition, 
eukaryotic initiation factor 4E (eIF4E) is a cap binding protein that functions in 
translation initiation as part of the eukaryotic initiation factor 4F (eIF4F) and promotes 
translation initiation of the capped mRNAs. Furthermore, eIF4E stabilises mRNAs 
and promotes their nuclear export in a transcript-specific manner. PARN 
deadenylase, which catalyses mRNA deadenylation, followed by mRNA degradation, 
has been also reported to have cap-binding affinity. Finally, Argonaute proteins have 
been reported to bind the N-7 methylguanosine cap structure and to mediate mRNA 
silencing. This last observation is a controversial aspect of silencing research, as will 
be discussed later. 
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Figure 1.5: Schematic depiction of RNA metabolism events mediated by 
cap-binding complex (CBC). 
The cap-binding complex, composed by Cbp20 and Cbp80 subunits, engages the 
N-7 methylguanosine cap located to the 5’ end of RNA pol II transcripts and 
promotes the indicated functions. 
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1.7.1 Cap-binding complex (CBC) 
1.7.1.1 Identification of a nuclear cap-binding activity 
Although nuclear proteins with cap-binding activity have been reported in the 1980s 
(Patzelt et al., 1983; Rozen and Sonenberg, 1987), it was only at the beginning of 
1990 that the composition of the nuclear cap-binding complex was determined. Initial 
experiments using denaturing purification steps identified a single nuclear protein of 
80 kDa (Cbp80) that binds specifically to guanine-7 methylated RNAs (Ohno et al., 
1990; Izaurralde et al., 1992). Competition experiments with various cap analogues 
confirmed that Cbp80 binding to RNA was mediated by the N-7 methylguanosine cap 
structure, although increased amounts of GpppG cap analogue could also abolish 
Cbp80/RNA interaction to a lesser extent (Izaurralde et al., 1992).  
When non-denaturing conditions were used for the purification of proteins that bind to 
the N-7 methylguanosine cap, an additional protein of 20 kDa (Cbp20) was co-
purified with Cbp80 (Izaurralde et al., 1994, 1995a). Cbp20 and Cbp80 can be 
purified to homogeneity from HeLa extracts using different chromatography columns 
as well as immunoprecipitation suggesting that they exist in the same complex, 
designated cap-binding complex (CBC) (Izaurralde et al., 1994). The interaction 
between Cbp20 and Cbp80 has also been demonstrated by co-crystalisation of the 
CBC (Mazza et al., 2001; Calero et al., 2002; Mazza et al., 2002).  
Immunodepletion of the Cbp80 subunit results in the co-depletion of Cbp20 in both 
mammalian and yeast cells, suggesting that there is no monomeric Cbp20 within 
these cells (Izaurralde et al., 1994; Lewis et al., 1996a). This is further supported by 
the fact that the Cbp20 subunit is unstable in the absence of Cbp80, both in 
mammalian and in yeast cells (Fortes et al., 1999b; Narita et al., 2007; Wong et al., 
2007). Conversely, as far as the author is concerned, there is no evidence 
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demonstrating whether Cbp80 can exist as a monomer or not. Interestingly, Cbp20 is 
not required for Cbp80 stability, as demonstrated in yeast cells (Wong et al., 2007). 
An alternatively spliced isoform of Cbp20, unable to bind both Cbp80 and N-7 
methylguanosine cap, was recently identified, however, the biological significance of 
this alternative isoform remains elusive (Pabis et al., 2010). Cbp80 is predominantly 
a nuclear protein and contains a nuclear localisation site that is required for Cbp80 
nuclear localisation (Izaurralde et al., 1995b; Visa et al., 1996). Cbp20 has been 
suggested to be co-imported to the nucleus with Cbp80 (Lewis and Izaurralde, 1997).  
RNA band-shift assays suggested that Cbp20 and Cbp80 act synergistically for N-7 
methylguanosine cap binding, since none of Cbp20 or Cbp80 can bind the N-7 
methylguanosine cap as a monomer (Izaurralde et al., 1994; Kataoka et al., 1995; 
Izaurralde et al., 1995a). The crystal structure of the CBC revealed that the N-7 
methylguanosine cap-binding pocket resides in Cbp20, and this was further validated 
by mutational analysis (Mazza et al., 2001). The m7GpppG is positioned between 
two conserved tyrosines (Tyrosine-20 and 43) on the Cbp20 subunit (Calero et al., 
2002; Mazza et al., 2002) and biophysical studies have indicated that these residues 
are essential for N-7 methylguanosine cap binding (Calero et al., 2002; Worch et al., 
2009). Cbp80-mediated conformational changes in the Cbp20 subunit are required 
for the CBC to bind the cap. The affinity of the CBC for N-7 methylguanosine cap 
moiety is 25% higher than eIF4E, as shown by biophysical assays (Worch et al., 
2005).  
Cbp80p deletion in yeast cells results in a significant change in the gene expression 
pattern, with around 370 genes exhibiting at least a 2-fold change by microarray 
analysis (Hossain et al., 2009). However, in S. cerevisiae, both CBP80 and CBP20 
are not essential for cell viability (Uemura and Jigami, 1992; Abovich et al., 1994; 
Fortes et al., 1999b) but are required for cell growth (Das et al., 2000). Furthermore, 
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deletion of either or both CBP20 and CBP80 results in reduced vegetative growth 
rates (Fortes et al., 1999b). However, yeast gene expression is not highly dependent 
on splicing, which may explain the dispensability of CBC for cell viability in yeast. As 
will be discussed later, arguably one of the most important functions of CBC is in 
splicing, by promoting the removal of the first intron of pre-mRNAs and also 
stimulating the processing of the U snRNAs that are required for splicing. In addition, 
yeast CBC is involved in fewer mRNA metabolic functions than the mammalian CBC, 
as will be described later (Flaherty et al., 1997; Fresco and Buratowski, 1996). To the 
authorʼs knowledge there are no reports of CBP80 or CBP20 gene deletion in 
mammalian systems. However, siRNA depletion of CBC results in reduced cell 
proliferation rates in mammalian cells (Narita et al., 2007).  
 
1.7.1.2 CBC and RNA pol II transcription  
Chromatin immunoprecipitation (ChIP) experiments have demonstrated that CBC 
can localise to chromatin both in mammalian and in yeast cells. Cbp20 and Cbp80 
subunits have been detected at the 5ʼ end as well as within the gene bodies 
(Listerman et al., 2006; Narita et al., 2007; Glover-Cutter et al., 2008; Zenklusen et 
al., 2002; Lahudkar et al., 2011). Furthermore, immunoelectron microscopy has 
exhibited that CBC interacts co-transcriptionally with the nascent Balbiani ring pre-
mRNA particle (Visa et al., 1996). CBC is recruited to nascent RNA pol II transcripts 
by interacting with the N-7 methylguanosine cap structure and the chromatin 
recruitment of CBC does not occur in Abd1p defective yeast cells (Wong et al., 2007). 
The fact that CBC is recruited to nascent transcript by interacting with the N-7 
methylguanosine cap is further supported by the fact that CBC is recruited to 
chromatin as a complex, since monomeric Cbp20 or Cbp80 subunits fail to be 
recruited (Wong et al., 2007; Lahudkar et al., 2011). ChIP profiling demonstrated that 
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the CBC co-migrates with RNA pol II in actively transcribed genes. Although CBC 
has been reported to interact with the large subunit of RNA pol II (Lejeune et al., 
2002), this interaction could not be detected by other groups (Listerman et al., 2006). 
Therefore, it is speculated that the major means by which CBC is recruited to the 
chromatin is by interaction with the N-7 methylguanosine cap. 
Recent publications have demonstrated that CBC plays an active role in 
transcriptional regulation (Lahudkar et al., 2011; Lenasi et al., 2011). In S. cerevisiae 
CBC physically interacts with, and promotes the recruitment of the transcriptional 
factor, Mot1p, to the 5ʼ end of the genes. Mot1p in turn recruits general transcription 
factors and RNA pol II to gene promoters, stimulating transcription initiation. 
Transcription initiation and N-7 methylguanosine cap formation promote CBC 
recruitment (Wong et al., 2007), which stimulates transcription initiation by positive 
feedback loop (Lahudkar et al., 2011). CBC, however, seems to have no effect on 
transcription elongation in S. cerevisiae (Wong et al., 2007).  
Although not the case in S. cerevisiae, in mammals the CBC is required for 
transcription elongation via the interaction and recruitment of P-TEFb to the 
promoter-proximal paused RNA pol II (Table 1.2) (Lenasi et al., 2011). As described 
earlier, P-TEFb is a complex with kinase activity that phosphorylates the CTD domain 
of RNA pol II and transcription factors, promoting transcriptional elongation. siRNA-
mediated depletion of CBC results in decreased levels of Serine-2 phosphorylation, 
leading to the accumulation of RNA pol II in gene bodies (Lenasi et al., 2011). To 
summarise, CBC is required for eukaryotic transcription although the exact molecular 
mechanism seems to be species-specific.  
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1.7.1.3 CBC and pre-mRNA splicing 
The N-7 methylguanosine cap is required for efficient pre-mRNA splicing of the 5ʼ 
proximal intron. In vitro incubation of uncapped or N-7 methylguanosine capped 
transcripts with total or nuclear HeLa extracts has demonstrated that the N-7 
methylguanosine cap moiety is required for efficient splicing (Konarska et al., 1984; 
Edery and Sonenberg, 1985; Ohno et al., 1987; Patzelt et al., 1987; Izaurralde et al., 
1994). In similar experiments, the splicing efficiency of in vitro transcribed N-7 
methylguanosine (m7GpppG) and guanosine (GpppG) capped pre-mRNA appeared 
to be the same (Edery and Sonenberg, 1985; Ohno et al., 1987). However, 
incubation of the in vitro splicing reaction with SAH inhibited the splicing of only the 
GpppG capped pre-mRNA, suggesting that methylation of the guanosine cap can 
occur during the in vitro splicing reaction, thus promoting splicing (Ohno et al., 1987). 
Furthermore, incubation of the in vitro splicing reactions with cap analogues, GpppG, 
m7GpppG and m7GTP demonstrated that m7GpppG and m7GTP cap analogues 
could inhibit the reaction more efficiently than GpppG, suggesting that a N-7 
methylguanosine cap-binding protein promotes the splicing of N-7 methylguanosine 
capped transcripts (Konarska et al., 1984; Edery and Sonenberg, 1985; Ohno et al., 
1987; Patzelt et al., 1987; Izaurralde et al., 1994).  
The effect of the N-7 methylguanosine cap upon splicing in vivo was initially 
observed in X. laevis oocytes (Inoue et al., 1989). As with the in vitro studies, in X. 
laevis oocytes the N-7 methylguanosine cap affects the splicing of the 5ʼ proximal 
intron without being required for the splicing of downstream introns (Ohno et al., 
1987; Inoue et al., 1989). In S. cerevisiae, inactivation of the capping machinery 
(Ceg1p or Abd1p) with temperature sensitive mutants revealed that, although the N-7 
methylguanosine cap enhances splicing of certain transcripts, it is not absolutely 
required. The effect of the N-7 methylguanosine cap on splicing was gene-specific 
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and dependent on specific Ceg1p or Abd1p mutations (Fresco and Buratowski, 1996; 
Schwer and Shuman, 1996; Schwer et al., 1998, 2000). Finally, in mammalian cells, 
transcripts containing N-7 methylguanosine cap were spliced more efficiently 
compared with guanosine capped or uncapped transcripts (McCracken et al., 1997a). 
Simultaneously with CBC identification it became apparent that it is not absolutely 
essential but that it stimulates the splicing reaction from HeLa cell extracts. CBC-
immunodepleted HeLa extracts do not efficiently splice pre-mRNA transcripts, and 
re-introduction of recombinant CBC to the extracts can restore splicing efficiency 
(Izaurralde et al., 1994; Lewis et al., 1996b). Similar to mammalian cells, in S. 
cerevisiae depletion of CBC from the cell extracts results in reduced in vitro splicing 
of pre-mRNA due to inhibition of spliceosome assembly (Colot et al., 1996; Lewis et 
al., 1996a). Furthermore, microinjection of antibodies raised against Cbp20 into X. 
laevis oocytes drastically decreased the splicing efficiency of microinjected in vitro 
transcribed pre-mRNA, suggesting CBC involvement in pre-mRNA splicing 
(Izaurralde et al., 1995a). The CBC has been shown to couple transcription with 
splicing, and deletion of CBC results in a reduction of the recruitment of several 
splicing factors to the nascent transcript in a gene specific manner (Görnemann et al., 
2005).  
In vitro assays using CBC-immunodepleted or mock depleted HeLa extracts 
demonstrated that CBC is required for the recruitment of U1 snRNP to the 5ʼ proximal 
intron of pre-mRNA, stimulating intron excision (Lewis et al., 1996b). Furthermore, in 
S. cerevisiae, mutation of U1 snRNP components are synthetically lethal with CBC 
double knock-out strains (Fortes et al., 1999b, 1999a). One such example is the 
deletion of Luc7p, which causes lethality in a CBC knock-out background strain 
(Fortes et al., 1999a). Luc7p is a component of U1 snRNP and it functions by 
mediating an interaction between U1 snRNP and CBC, stimulating spliceosome 
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assembly. Furthermore, the CBC has been implicated in the recruitment of U6 
snRNA to the 5ʼ splice site subsequent to U1 snRNP function (OʼMullane and Eperon, 
1998). 
The CBC has been shown to interact with hnRNP F RNA-binding protein in vitro, and 
depletion of hnRNP F from HeLa extracts decreases pre-mRNA splicing efficiency 
(Gamberi et al., 1997). However, it is not clear whether this effect is CBC mediated.  
Recently, a mechanism by which CBC can regulate pre-mRNA alternative splicing in 
mammalian cells was proposed. As described previously, CBC interacts and recruits 
P-TEFb to RNA pol II nascent transcripts. P-TEFb-mediated Serine-2 
phosphorylation at the RNA pol II CTD domain results in increased SRSF1 splicing 
factor recruitment to elongating RNA polymerase II (Lenasi et al., 2011). SRSF1 
interaction with specific transcripts stimulates constitutive as well as alternative 
splicing and the early steps of spliceosomal assembly (Long and Caceres, 2009). 
The link between CBC and SRSF1 further supports the idea that CBC is involved in 
mediating co-transcriptional spliceosomal assembly.  
 
1.7.1.4 CBC and pre-mRNA 3ʼ end processing 
The N-7 methylguanosine cap moiety has been linked with pre-mRNA 3ʼ end 
processing. The 3ʼ end of most mRNA consists of a poly(A)-tail of 200-250 
adenosines. Polyadenylation is a two-step process. Initially the pre-mRNA is cleaved 
at the poly(A) site followed by the polyadenylation of the 3ʼ end creating the poly(A)-
tail (Shatkin and Manley, 2000).  
In vitro studies have shown that pre-mRNAs containing the N-7 methylguanosine cap 
structure at their 5ʼ end were efficiently cleaved at the poly(A) sites, while the ApppG 
capped RNAs were not (Gilmartin et al., 1988; Cooke and Alwine, 1996). In addition, 
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in vitro transcribed mRNAs injected into X. laevis oocytes were more efficiently 
cleaved at the poly(A) site when possessing a N-7 methylguanosine cap moiety at 
the 5ʼ end (Georgiev et al., 1984). Furthermore, in mammalian cells, transcripts 
containing an N-7 methylguanosine cap were more efficiently cleaved at the poly(A) 
site than were guanosine capped or uncapped transcripts (McCracken et al., 1997a). 
Interestingly, a m7GpppG cap analogue could inhibit the in vitro reaction suggesting 
that a cap-binding protein is mediating this effect. This cap-binding protein was 
discovered to be the CBC (Flaherty et al., 1997). CBC-immunodepleted HeLa cell 
extracts exhibited reduced poly(A) site cleavage activity on N-7 methylguanosine 
capped RNA substrates in vitro. This effect could be rescued by the addition of 
recombinant CBC. The exact molecular mechanism by which CBC promotes pre-
mRNA cleavage at the poly(A)-site remains to be determined.  
In S. cerevisiae however, the N-7 methylguanosine cap appears to have little effect 
upon pre-mRNA 3ʼ end processing. Inactivation of the guanylyltransferase, Ceg1p, 
exhibits no effects on the mRNA polyadenylation transcript levels (Fresco and 
Buratowski, 1996). Furthermore, the CBC has been demonstrated to prevent 
cleavage and polyadenylation at weak, but not strong, transcription termination sites 
(Wong et al., 2007). At weak termination sites CBC inhibits the recruitment of 
cleavage poly(A) factors. This suggests that the effect of CBC on mRNA 3ʼ-end 
formation is not conserved during evolution (Lewis and Izaurralde, 1997).  
In mammalian cells the N-7 methylguanosine cap moiety and the CBC are required 
for efficient histone mRNA 3ʼ end processing (Narita et al., 2007; Gruber et al., 2012). 
Replication-dependent histone mRNAs, unlike other general mRNAs, do not possess 
a poly(A)-tail but instead have a conserved 3ʼ end stem-loop structure (Marzluff et al., 
2008). siRNA-mediated CBC depletion causes aberrant production of poly(A)-tailed 
histone mRNAs via two distinct mechanisms (Narita et al., 2007; Gruber et al., 2012): 
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Firstly, CBC interaction with NELF transcription complex and, more specifically, with 
the NELF-E subunit promotes the stem-loop structure formation at the 3ʼ end of 
histone mRNAs (Table 1.2). The interaction between CBC and NELF-E has been 
validated with endogenous proteins and was found not to be mediated by RNA. The 
NELF and CBC complexes physically associate with the stem-loop binding protein 
(SLBP), which is the protein promoting histone 3ʼ end processing (Narita et al., 2007). 
Secondly, through an interaction with Ars2, CBC has been implicated in the formation 
of the stem-loop structure in histone mRNA (Table 1.2). Ars2 is a CBC-interacting 
protein essential for cell proliferation and miRNA biogenesis, as will be described 
later (Gruber et al., 2009; Sabin et al., 2009). Recently, Ars2 was demonstrated to 
promote the stem-loop structure at histone mRNAs by sequestering the 7SK 
noncoding RNA which promotes the production of aberrant histone mRNAs by an as 
yet unidentified mechanism (Gruber et al., 2012).  
 
1.7.1.5 CBC and RNA pol II transcript export 
Early investigation of the N-7 methylguanosine cap structure identified its importance 
in promoting nuclear export of U snRNAs as well as in vitro transcribed RNAs in X. 
laevis oocytes (Hamm and Mattaj, 1990). Microinjection of a m7GpppG cap analogue 
resulted in inhibition of U1 snRNA export, suggesting that the export is mediated by a 
cap-binding activity (Hamm and Mattaj, 1990; Izaurralde et al., 1992). After CBC 
identification it became apparent that it is required for the nuclear export of both U 
snRNA and mRNA. 
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1.7.1.5.1 U snRNA export 
CBC is required for U snRNA export, as was originally demonstrated by 
microinjection of reporter transcripts into X. laevis oocytes (Izaurralde et al., 1995a; 
Görlich et al., 1996a). Furthermore, microinjection of antibodies raised against Cbp20 
in X. laevis oocytes resulted in inhibition of U snRNA export from the oocyte nucleus. 
Importins have been shown to mediate the export of the U snRNA. In S. cerevisiae, 
30% of Importin-α is in a complex with the CBC (Görlich et al., 1996a). The 
interaction between Importin-α and CBC has also been observed in X. laevis oocytes 
and mammalian cells (Görlich et al., 1996a; Sato and Maquat, 2009) and validated 
by co-crystalisation of CBC with Importin-α (Dias et al., 2009). Biochemical assays 
have shown that the interaction between Importin-β and Importin-α results in release 
of the N-7 methylguanosine capped RNA (Görlich et al., 1996a; Dias et al., 2009). 
This has also been observed in X. laevis oocytes. Importin-α associates with, and 
facilitates the nuclear export of, U snRNAs. In the cytosol, where the levels of RAN-
GTP are low, Importin-β interacts with Importin-α and releases the U snRNA (Görlich 
et al., 1996a; Dias et al., 2009). Importin-α/Importin-β/CBC complex is imported to 
the nucleus where the high levels of RAN-GTP promote dissociation of Importin-β 
from the complex. Importin-α/CBC can then bind to N-7 methylguanosine capped U 
snRNA and a new cycle begins. 
In order for CBC to promote U snRNA nuclear export it has to interact with PHAX 
(phosphorylated adaptor of RNA export) protein (Ohno et al., 2000; Segref et al., 
2001) (Table 1.2). PHAX is a nuclear protein (Segref et al., 2001) that interacts with 
the CBC/N-7 methylguanosine capped U snRNA complexes. Upon phosphorylation 
by the CK2 kinase, PHAX stimulates the formation of a higher order export complex 
involving the exportin protein CRM1, in a RAN-GTP-dependent manner (Ohno et al., 
2000; Kitao et al., 2008). The U snRNA export complex is translocated into the 
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cytoplasm through the nuclear pore complex and disassembles, releasing U snRNA. 
PHAX dephosphorylation as well as Importin-β, as described previously, are required 
for U snRNA release and recycling of CBC/PHAX back to the nucleus (Ohno et al., 
2000; Kitao et al., 2008) (Figure 1.6). 
 
1.7.1.5.2 mRNA export 
The nuclear export pathways responsible for U snRNA and mRNA export are distinct 
(Köhler and Hurt, 2007). The involvement of the N-7 methylguanosine cap in the 
nuclear export of mRNAs is less clear than for U snRNAs and differs among species, 
suggesting that N-7 methylguanosine cap-dependent mRNA nuclear export is not 
conserved in eukaryotes. In S. cerevisiae, inactivation of the RNA 
guanylyltransferase Ceg1p does not affect mRNA nuclear export (Fresco and 
Buratowski, 1996). However, temperature-sensitive mutants of Npl3p protein, which 
is involved in mRNA export, display synthetic lethality with Cbp80p knock-out strains 
(Shen et al., 2000). Although CBC and Npl3p interact in an RNA-mediated manner, it 
remains unclear what is the biological connection behind this synthetic lethality. 
In higher eukaryotes the N-7 methylguanosine cap moiety, as well as the CBC, is 
required for efficient mRNA export. Immunoelectron microscopy showed that CBC is 
still associated with the mRNA during nucleo-cytoplasmic translocation in the 
dipteran Chironomus tentans (Visa et al., 1996). Interestingly, CBC was located at 
the leading edge of mRNA during translocation through the nuclear pore complex, 
suggesting an involvement of the N-7 methylguanosine moiety and CBC in mRNA 
export. 
The nuclear export of in vitro transcribed N-7 methylguanosine capped mRNAs 
microinjected into X. laevis oocytes is more efficient compared to uncapped mRNAs 
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(Jarmolowski et al., 1994; Cheng et al., 2006). Furthermore, microinjection of a 
m7GpppG cap analogue along with in vitro transcribed mRNA into X. laevis oocytes 
resulted in an inhibition of mRNA nuclear export, suggesting that cap-binding 
proteins are involved in mRNA nuclear export (Dargemont and Kühn, 1992). 
Interestingly, cap-dependent mRNA nuclear export was more efficient when an 
intron-containing pre-mRNA was injected into the oocyte, suggesting that cap-
dependent mRNA nuclear export requires the involvement of the spliceosome or EJC 
(Cheng et al., 2006). This possibly explains the inability to observe an effect of the N-
7 methylguanosine cap structure upon the nuclear export of in vitro transcribed RNA 
derived from cDNA sequence (Izaurralde et al., 1995a). 
Co-immunoprecipitation experiments from mammalian nuclear extracts demonstrated 
that CBC interacts with the TREX complex (Cheng et al., 2006) (Table 1.2). TREX 
complex is a multi-subunit protein complex that links pre-mRNA splicing with mRNA 
nuclear export in mammalian cells (Köhler and Hurt, 2007). In vitro pull-down 
experiments demonstrated that the Aly component of the TREX complex interacts 
directly with the Cbp80 subunit of CBC (Cheng et al., 2006). This suggests that 
mRNA nuclear export requires the N-7 methylguanosine cap and the CBC in a 
splicing-dependent manner and is mediated via the interaction of the CBC with the 
TREX complex (Cheng et al., 2006) (Figure 1.6). 
Conversely, CBC has also been demonstrated to mediate the nuclear export of 
intronless mRNAs in mammalian cells by interacting with REF (RNA export factor) 
(Nojima et al., 2007). The interaction between CBC and REF was demonstrated by 
co-immunoprecipitation of ectopically expressed proteins and in vitro pull down 
assays, which demonstrated that REF interacts with the Cbp20 subunit of the CBC. 
Incubation of HeLa nuclear extract with excess of an m7GpppG cap analogue 
abolished the interaction of REF with in vitro transcribed, intronless, N-7 
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methylguanosine capped mRNA, suggesting that REF is recruited to intronless RNA 
via the N-7 methylguanosine cap moiety. By microinjecting purified Cbp20, REF or a 
REF mutant unable to bind to Cbp20, together with intronless, in vitro transcribed, N-
7 methylguanosine capped reporter RNA into HeLa nuclei it was demonstrated that 
the interaction between Cbp20 and REF stimulates the nuclear export of the reporter 
transcript (Nojima et al., 2007). 
In summary, although different RNA pol II transcripts are exported via different export 
pathways, U snRNA and mRNA are highly dependent on the N-7 methylguanosine 
cap for efficient nuclear export. However, literature suggests that the mRNA 
dependence on the N-7 methylguanosine cap structure for nuclear export is not a 
universal phenomenon and that it is mainly encountered in higher eukaryotes. 
As described previously, U snRNA, intron-containing and intronless mRNAs are 
dependent on different pathways for their nuclear export. However, the CBC interacts 
with all of them as long as they posses the N-7 methylguanosine cap structure at 
their 5ʼ end. Thus, an obvious question is how the CBC decides which nuclear export 
pathway to follow. A recent report demonstrated that the mechanism which facilitates 
the export of U snRNAs or mRNAs is determined by the transcript length. When CBC 
is bound to transcripts longer than 300 nucleotides, CBC interacts with hnRNP C 
which abolishes the interaction between CBC and PHAX, thus eliminating the option 
of U snRNA export pathway from the transcript (McCloskey et al., 2012). Interestingly, 
depletion of hnRNP C from mammalian cells results in nuclear accumulation of 
mRNA, suggesting a competition of RNA nuclear export factors for the CBC in order 
to promote the export of snRNA or mRNA (McCloskey et al., 2012). 
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Figure 1.6: Mechanics of CBC-dependent RNA export. 
The cap-binding complex (CBC), consisting of Cbp20 and Cbp80, engages N-7 
methylguanosine capped mRNAs and U snRNAs and promotes their nuclear 
export. For U snRNAs the CBC interacts with PHAX, which acts as a scaffold for 
binding export factors like CRM1 and RAN.GTP promoting U snRNA nuclear 
export. For transcripts longer than 300 nucleotides (mRNAs), hnRNP C interacts 
with the CBC and abolishes the interaction between CBC and PHAX, allowing the 
CBC to interact with the Aly component of the TREX complex promoting mRNA 
nuclear export.  
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1.7.1.6 CBC and miRNA biogenesis 
Recently, a poorly-characterised protein designated Ars2 was demonstrated to be 
required for miRNA biogenesis and cell proliferation in a CBC-dependent manner 
(Gruber et al., 2009; Sabin et al., 2009). Immunoprecipitation and gel filtration 
experiments indicated that Ars2 forms a complex with CBC in mammalian cells. 
Furthermore, antibodies raised against Ars2 were able to super-shift the complex 
between CBC and in vitro transcribed N-7 methylguanosine capped RNA in an RNA 
band-shift assay using HeLa extracts, suggesting that Ars2 is part of CBC complex 
(Gruber et al., 2009). 
Depletion of Ars2 as well as Cbp20 and Cbp80 from mammalian cells results in a 
decrease of miRNA biogenesis (Gruber et al., 2009, 2012). The exact molecular 
mechanism by which this occurs is unclear but the same phenomenon has been 
observed in flies and plants (Kim et al., 2008; Sabin et al., 2009). 
 
1.7.1.7 CBC and the nonsense mediated decay (NMD) 
Non-sense mediated decay is a mRNA surveillance pathway that predisposes 
aberrant mRNAs containing a premature termination codon (PTC) for rapid 
degradation (Mühlemann and Lykke-Andersen, 2010). Furthermore, alternative 
splicing coupled with NMD has been reported to be a regulatory step in gene 
expression. Mouse embryos deficient in NMD die shortly after implantation, 
demonstrating the significance of NMD for cell viability (Maquat, 2004). The major 
facilitators of NMD are the UPF proteins (UPF1, 2 and 3), which are required for the 
recognition of PTCs (Mühlemann and Lykke-Andersen, 2010). 
A genetic screen in S. cerevisiae revealed that both Cbp80p and Upf1p deletion 
exhibited the same phenotype regarding cytochrome-c stability, suggesting that CBC 
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and Upf1p may function in the same pathway (Das et al., 2000). Furthermore, 
immunoprecipitation experiments revealed that NMD factors are associated with 
Cbp80-bound, and not eIF4E-bound, mRNPs in mammalian cells, suggesting that 
Cbp80-bound mRNPs are subject to NMD (Ishigaki et al., 2001; Lejeune et al., 2002). 
Moreover, incubation of mammalian cells with cycloheximide, an inhibitor of 
translation elongation, resulted in NMD reduction of Cbp80-bound mRNAs, 
suggesting that the pioneer round of translation of Cbp80-bound mRNAs is required 
for NMD (Ishigaki et al., 2001). 
Interestingly, CBC has been demonstrated to physically interact with UPF1 via the 
Cbp80 subunit in mammalian cells (Hosoda et al., 2005; Hwang et al., 2010) and 
inhibition of the interaction between CBC and UPF1 abolishes NMD (Hwang et al., 
2010). CBC interaction with UPF1 promotes NMD machinery assembly on the 
aberrant mRNA, promoting its decay (Hosoda et al., 2005; Hwang et al., 2010). 
However, the molecular details by which the interaction between CBC and UPF1 
specifically targets aberrant and not normal mRNAs remain unclear. 
 
1.7.1.8 CBC and the pioneer round of translation 
The CBC is an essential component of the pioneer round of translation and has the 
same function as eIF4E has for steady-state translation. The pioneer round of 
translation is also referred as CBC-dependent translation (Kim et al., 2009; Choe et 
al., 2012). The main purpose of the pioneer round, in contrast to the steady-state 
cycles, of mRNA translation (which are eIF4E-mediated), is not to generate adequate 
amounts of protein but rather to control for mRNA quality. Polysome profiling has 
demonstrated that, although the eIF4E-mediated translation predominantly localises 
in heavy polysomes, CBC-mediated translation is mainly concentrated in 
subpolysomal fractions suggesting that CBC-bound mRNAs are translated less 
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efficiently than eIF4E-bound ones (Chiu et al., 2004). Messages containing 
premature termination codons (PTC) are targeted for non-sense mediated decay 
(NMD) while the qualified mRNAs replace CBC and other pioneer round of translation 
factors with eIF4E for steady-state translation initiation (Maquat, 2004; Maquat et al., 
2010). Interestingly, the pioneer round of translation is not inhibited by cellular 
stresses such as serum starvation and hypoxia, as measured by NMD efficiency, in 
contrast to the steady-state of translation which is significantly reduced (Oh et al., 
2007a, 2007b). 
Immunoprecipitation of Cbp80 from mammalian cells revealed that Cbp80-bound 
mRNPs are localized both in the nucleus and in the cytosol and that intron-containing 
pre-mRNAs are only associated with Cbp80 and not with eIF4E (Lejeune et al., 2002). 
Furthermore, Cbp80-bound mRNPs are associated with a different set of proteins 
than eIF4E-bound mRNPs. However, both complexes were associated with 
translation initiation factors and ribosomal proteins, suggesting that Cbp80-bound 
mRNPs can undergo translation (Ishigaki et al., 2001; Lejeune et al., 2002; Chiu et 
al., 2004). The proteins encountered in Cbp80 but not eIF4E-bound mRNPs are the 
UPF proteins, the exon junction complex and the PABPN1 (nuclear poly(A)-binding 
protein) (Lejeune et al., 2002; Diem et al., 2007; Sato and Maquat, 2009). As 
expected, 4E-BP1, a protein inhibitor of eIF4E-dependent translation, does not affect 
the pioneer round of translation or NMD. Conversely, Paip2, a protein that disrupts 
PABPC1 interaction with poly(A)-tail and inhibits cellular translation, is also inhibiting 
the pioneer round of translation and consequently NMD, suggesting that PABPC1 is 
involved in CBC-dependent translation (Chiu et al., 2004). 
The transition from the pioneer round of translation to the steady-state cycles is 
regulated by Importins. Importin-α, as described before, interacts with the Cbp80 
subunit of CBC (Görlich et al., 1996a; Dias et al., 2009). In the cytosol Importin-β 
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interacts with Importin-α and promotes the dissociation of the mRNA from the CBC 
(Sato and Maquat, 2009). Subsequently, eIF4E interacts with the N-7 
methylguanosine group at the 5ʼ end of the mRNA promoting eIF4E-dependent 
translation initiation. Steady-state translation also promotes the removal of EJC and 
PABPN1 from the mRNP (Sato and Maquat, 2009) (Figure 1.7a). 
The CBC-mediated pioneer round of translation was originally identified by a yeast 
synthetic lethality screen in which a S. cerevisiae strain expressing mutated eIF4G 
unable to bind eIF4E and Pab1p exhibited lethality when Cbp80 was simultaneously 
mutated (Fortes et al., 2000). Furthermore, the direct interaction of eIF4G with 
Cbp80p suggested an involvement of CBC in translation initiation (Fortes et al., 
2000). The interaction between CBC and eIF4G has been also reported in 
mammalian cells (McKendrick et al., 2001; Lejeune et al., 2004). 
However, a novel protein with amino acid similarity to eIF4G designated as CTIF 
(CBC-dependent translation initiation factor) was identified recently and shown to 
interact with Cbp80 (Kim et al., 2009). The interaction between CBC and CTIF is far 
more robust than the interaction between CBC and eIF4G and has been also 
demonstrated with endogenous proteins in an RNase A resistant manner. CTIF is a 
component of the proteins associated with CBC-bound mRNPs, and siRNA mediated 
depletion of CTIF results in reduction of NMD. CTIF is required during the initiation of 
the pioneer round of translation but is not involved in steady-state translation (Kim et 
al., 2009; Choe et al., 2012). CTIF interacts with eIF3g, which is a component of the 
eIF3 complex, and recruits the 40S ribosomal subunit to CBC-bound mRNPs for the 
pioneer round of translation (Choe et al., 2012). Depletion of CTIF causes 
redistribution of CBC from polysomes to subpolysomal fractions, suggesting that 
CTIF is an essential component of the pioneer round of translation and functions in a 
similar way to eIF4G in steady-state translation (Kim et al., 2009; Choe et al., 2012).  
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1.7.1.9 Regulation of CBC 
The CBC affinity for the N-7 methylguanosine cap moiety has been demonstrated to 
be regulated by the mTOR pathway, and to be responsive to growth factors (Wilson 
et al., 1999, 2000; Dias et al., 2009, 2010). The Cbp80 subunit can be 
phosphorylated by S6 kinase, which stimulates CBC capacity for N-7 
methylguanosine cap binding in vitro (Wilson et al., 2000). The S6 kinase is a direct 
target of mTORC1 kinase, which is activated by nutrient availability and growth 
factors (Carrera, 2004). In vivo, orthophosphate labelling demonstrated that Cbp80 
phoshorylation can be stimulated by growth factors and can be inhibited by 
rapamycin, an mTORC1 kinase inhibitor. Increased Cbp80 phosphorylation 
correlates with increased cap-dependent splicing activity (Wilson et al., 2000). 
However, it should be noted that there is no direct evidence demonstrating that 
Cbp80 phosphorylation increases CBC binding activity for the N-7 methylguanosine 
cap within cells. 
CBC function can also be regulated by Importins. In the nucleus, CBC binds to 
Importin-α via the Cbp80 subunit, which stimulates nuclear export of N-7 
methylguanosine capped U snRNA (Görlich et al., 1996a) (Table 1.2). In the cytosol, 
Importin-β interacts with Importin-α and the Cbp20 subunit, and stimulates release of 
the N-7 methylguanosine capped cargo and translocation of the Importin-α/Importin-
β/CBC complex into the nucleus. There Ran-GTP interacts with Importin-β, causing 
its dissociation from the Importin-α/CBC complex, thus enabling N-7 
methylguanosine cap binding (Görlich et al., 1996b). A simillar model has been 
proposed for the nuclear export of mammalian mRNAs and the replacement of the 
CBC with eIF4E for cap-dependent translation initiation, as will be described later 
(Sato and Maquat, 2009). 
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The interaction between CBC and Importin-α has also been demonstarted by co-
crystalisation (Dias et al., 2009). This validated the Importin-α binding to the Cbp80 
subunit. Biochemical assays suggest that Importin-β can interact with the Cbp20 
subunit in addition to Importin-α. Interestingly, the binding of Importin-α and Importin-
β to the CBC is essential for the growth factor dependent regulation of CBC and its 
growth factor-mediated stimulation for N-7 methylguanosine cap binding activity in 
vitro (Dias et al., 2009). Furthermore, the overexpression of constitutively active Ran 
within cells, which abolishes the interaction between Importin-β and CBC/Importin-α 
complex, stimulates CBC cap-binding activity in vitro (Ly et al., 2010).  
In summary, the cap-binding activity of CBC can be regulated by growth factors via 
the mTOR pathway, using phosphorylation events and Importins as mediators. To 
the authorʼs knowledge there is no evidence demonstrating any regulation of the 
interaction between Cbp80 and Cbp20 within cells.  
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Table 1.2: The major interacting proteins of cap-binding complex (CBC). The CBC subunit 
mediating the interaction is indicated. The species in which the interactions were observed and the 
cellular function of the interactions are presented.  
CBC 
subunit 
Interacting 
protein 
Species detected Function Reference 
Cbp80 Importin-α 
H. sapiens / 
S. cerevisiae / 
X. laevis 
Translocating CBC to the 
nucleus. 
Regulating the release of 
cargo from CBC. 
Regulating CBC activity. 
(Görlich et al., 1996a; 
Dias et al., 2009; Ly et 
al., 2010) 
Cbp80 Mot1p S. cerevisiae Transcription initiation. (Lahudkar et al., 2011) 
Unclear P-TEFb H. sapiens 
Transcription elongation. 
Splicing. 
(Lenasi et al., 2011) 
Unclear NELF-E H. sapiens 
Histone RNA 3ʼ end 
processing. 
(Narita et al., 2007) 
Unclear SLBP H. sapiens 
Histone RNA 3ʼ end 
processing. 
(Narita et al., 2007) 
Unclear Ars2 
H. sapiens / 
D. melanogaster 
Histone RNA 3ʼ end 
processing. 
miRNA biogenesis. 
(Ohno et al., 2000; 
Segref et al., 2001) 
Unclear PHAX 
Mammalian cells / 
X. laevis 
U snRNA nuclear export. (Cheng et al., 2006) 
Cbp80 
Aly component 
of TREX 
H. sapiens mRNA nuclear export. 
(McCloskey et al., 
2012) 
Cbp80 hnRNP C H. sapiens mRNA nuclear export. 
(Hosoda et al., 2005; 
Hwang et al., 2010) 
Cbp80 UPF1 H. sapiens Nonsense mediated decay. 
(Kim et al., 2009; 
Choe et al., 2012) 
Cbp80 CTIF Mammalian cells 
Facilitates the recruitment 
of eIF3 during the pioneer 
round of translation. 
(Narita et al., 2007) 
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Figure 1.7: Pioneer round of translation and steady-state translation mRNPs.  
(a) The pioneer round of translation, also referred as CBC-dependent translation, 
is mediated by the cap-binding complex (CBC), which consists of Cbp20 and 
Cbp80 subunits. Cbp80 interacts with CTIF that recruits the 43S ribosomal subunit  
via eIF3 to the 5’ end of the mRNA for translation initiation.  
(b) The steady-state translation is mediated by eIF4E cap-binding protein. eIF4E 
interacts with eIF4G which is a scaffold protein interacting with several translation 
factors promoting translation initiation. The details of translation initiation are 
described in the text.  
CBC-bound mRNP components that are not found in eIF4E-bound mRNPs are 
CTIF, exon junction complex (EJC) and PABPN1.  
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1.7.2 eIF4E (eukaryotic initiation factor of translation 4E) 
1.7.2.1 The effect of N-7 methylguanosine cap on mRNA translation 
Shortly after the discovery of the N-7 methylguanosine cap, it became apparent that 
it is required for the translation of mRNAs. Removal of the N-7 methylguanosine cap 
structure from the 5ʼ end of in vitro synthesised mRNA molecules abolished mRNA 
translation in cell-free systems (Muthukrishnan et al., 1975; Shimotohno et al., 1977) 
and resulted in almost a complete loss of mRNA binding to ribosomes (Zan-
Kowalczewska et al., 1977). Incubation of capped (GpppG) and N-7 
methylguanosine capped (m7GpppG) RNAs in wheat germ extracts in the presence 
of S-adenosyl-homocysteine (SAH), which is a cap methylation inhibitor, revealed 
that the methyl-cap structure is essential for protein synthesis as only RNAs with the 
m7GpppG cap were translated into protein (Both et al., 1975; Furuichi et al., 1977).  
Furthermore, the N-7 methylguanosine cap structure is required for mRNA translation 
within cells. In S. cerevisiae, temperature sensitive mutations in Ceg1p, an RNA 
guanylyltransferase, abolished protein synthesis at restrictive temperatures but this 
was found to be predominantly due to a reduction in transcript stability and levels 
(Schwer et al., 1998). Conversely, temperature sensitive mutations in Abd1p, an 
RNA guanine-7 methyltransferase, diminished protein synthesis at the restrictive 
temperature with only a mild effect on transcript stability, suggesting that the N-7 
methyl group of the guanosine cap is required for mRNA translation (Schwer et al., 
2000). In vitro synthesised luciferase mRNAs containing the N-7 methylguanosine 
cap (m7GpppG) structure at their 5ʼ end microinjected into X. laevis oocytes were 
translated more efficiently than capped (GpppG) or uncapped mRNAs. This effect 
was independent of transcript stability (Drummond et al., 1985; Gillian-Daniel et al., 
1998). Competition assays using free m7GpppG cap analogue inhibited translation 
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initiation of in vitro synthesised N-7 methylguanosine capped transcripts in a cell free 
rabbit reticulocyte lysate system as well as after injection into X. laevis oocytes 
(Gillian-Daniel et al., 1998; Michlewski et al., 2008). This indicates that the N-7 
methylguanosine cap is required for the initiation of protein synthesis.  
 
1.7.2.2 Identification of eIF4E as the N-7 methylguanosine cap 
binding protein 
The mechanism by which the N-7 methylguanosine cap is able to promote mRNA 
translation was first investigated by identifying proteins that specifically bind to the N-
7 methylguanosine cap structure. A 24 KDa protein was found to interact with the N-7 
methylguanosine cap moiety after crosslinking in vitro transcribed mRNAs with rabbit 
reticulocyte extracts. The interaction between this protein and the N-7 
methylguanosine cap structure could be inhibited by m7GDP but not by the GDP cap 
analogue. This protein was later named eIF4E (Sonenberg et al., 1978, 1979; 
Altmann et al., 1985, 1987). The interaction between eIF4E and the N-7 
methylguanosine cap structure has also been demonstrated by co-crystallisation of 
eIF4E and the m7GpppG cap analogue (Marcotrigiano et al., 1997) as well as by 
biophysical studies (Niedzwiecka et al., 2002). 
The translation of N-7 methylguanosine capped transcripts was significantly 
increased in cell-free systems when eIF4E was incubated in the reaction mixture 
(Sonenberg et al., 1979, 1980), prompting a detailed investigation by which eIF4E 
promotes cap-dependent translation.  
The eIF4E cap-binding protein is part of the eIF4F complex and, by interacting with 
the N-7 methylguanosine cap structure, eIF4E recruits the eIF4F complex to the 5ʼ 
end of the mRNA. The eIF4F complex consists of eIF4G, which interacts with eIF4E 
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and eIF4A, an ATP-dependent RNA helicase responsible for unwinding complex 
secondary structures in 5ʼ UTRs (Edery et al., 1983; Mader et al., 1995; Lamphear et 
al., 1995; Gingras et al., 1999; Sonenberg and Hinnebusch, 2009). The recruitment 
of eIF4A helicase activity to the 5ʼ end of the mRNAs via eIF4E is required for 
efficient translation (Edery et al., 1984; Koromilas et al., 1992), since eIF4A helicase 
activity is required for the displacement of RNA-binding proteins as well as the 
unfolding of the 5ʼ UTR of transcripts promoting of cap-dependent translation (Svitkin 
et al., 1996). eIF4G is a scaffold protein that possesses binding sites for eIF4E, 
eIF4A, PABP and other translation factors (Gingras et al., 1999; Hentze, 1997). The 
binding of eIF4G to eIF4E enhances the binding capacity of eIF4E for the N-7 
methylguanosine cap structure (Haghighat and Sonenberg, 1997) by an allosteric 
activation (Gross et al., 2003).  
eIF4F is responsible for recruiting the 43S initiation complex containing the 40S 
ribosomal subunit, together with several eukaryotic initiation factors of translation, to 
the 5ʼ end of mRNA to promote translation initiation. This is mediated by the 
interaction of eIF4G with eIF3, which is part of 43S (Sonenberg and Hinnebusch, 
2009; Topisirovic et al., 2011) (Figure 1.7b).  
An additional mechanism by which eIF4F complex promotes mRNA translation is by 
eIF4G interaction with PABP (poly(A)-tail binding protein), the depletion of which 
results in a significant decrease in protein synthesis (Kahvejian et al., 2005). The 
interaction between eIF4G and PABP results in the circularisation of translated 
mRNAs (Wells et al., 1998) (Figure 1.7b). This “closed-loop” mRNA configuration 
formed by eIF4G/PABP interaction is believed to enhance translation rates by 
increasing the recycling of translation factors (Wells et al., 1998; Amrani et al., 2008).  
In summary, eIF4E is essential for cap-dependent translation since it recruits the 
translation machinery to the 5ʼ end of mRNA. Thus, it is not surprising that eIF4E is 
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essential for cell viability in S. cerevisiae (Altmann et al., 1987). Interestingly, the 
effect of eIF4E on mRNA translation is transcript-specific. Recent studies have 
shown that eIF4E-mediated translation preferentially targets mRNAs containing 5ʼ 
terminal oligopyrimidine (TOP) tracts at the 5ʼ UTRs (Thoreen et al., 2012; Hsieh et 
al., 2012).  
 
1.7.2.3 eIF4E and mRNA stability 
As described previously, eIF4E can stabilise N-7 methylguanosine capped 
transcripts by interacting with the N-7 methylguanosine cap moiety. eIF4E competes 
with Dcp1p/Dcp2p for N-7 methylguanosine binding and therefore protects capped 
transcripts from decapping in vitro (Schwartz and Parker, 2000; Khanna and Kiledjian, 
2004). Furthermore, eIF4E and Dcp1p/Dcp2p compete for the N-7 methylguanosine 
cap structure in vivo, as demonstrated in yeast cells expressing a defective Dcp1p 
and a temperature sensitive eIF4E mutant (Schwartz and Parker, 2000). In addition, 
in vitro studies have demonstrated that eIF4E competes with PARN (poly(A)-specific 
ribonuclease) for N-7 methylguanosine cap-binding, protecting mRNA from 
deadenylation and subsequent mRNA degradation (Gao et al., 2000). This provides 
an explanation why m7GpppG capped transcripts are more stable than the GpppG 
transcripts within cells (Grudzien et al., 2006) (Figure 1.8). 
 
1.7.2.4 eIF4E and mRNA nuclear export 
eIF4E was originally identified as N-7 methylguanosine cap binding protein from 
cytoplasmic rabbit reticulocyte extracts (Sonenberg et al., 1978) and it was believed 
to be a cytoplasmic protein. Interestingly, a significant proportion of endogenous 
eIF4E has also been detected in the nucleus of mammalian cells by 
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immunofluorescence analysis (Lejbkowicz et al., 1992). Furthermore, subcellular 
fractionation studies confirmed the presence of eIF4E in the nucleus. Nuclear eIF4E 
concentrates in speckled regions and can be released from these by addition of 
m7GpppG cap analogue, but not GpppG or RNaseA treatment, in cell 
permeabilisation assays, suggesting that eIF4E is retained in the nucleus in a cap-
dependent manner (Dostie et al., 2000; Cohen et al., 2001).  
eIF4E nuclear function remains elusive, however, it has been reported to promote 
nuclear export in a gene-specific manner (Strudwick and Borden, 2002). 
Overexpression of eIF4E results in stimulation of the nuclear export of specific 
transcripts such as Cyclin D1 and ODC (Rousseau et al., 1996; Culjkovic et al., 
2005). Overexpression of an eIF4E mutant that can not bind the N-7 
methylguanosine cap moiety is unable to promote Cyclin D1 nuclear export (Cohen 
et al., 2001; Culjkovic et al., 2005). Interestingly, overexpression of an eIF4E mutant 
unable to promote cap-dependent translation could still stimulate the nuclear export 
of Cyclin D1 transcript, and this was followed by an increase of Cyclin D1 expression. 
Moreover, eIF4E nuclear export activity has been demonstrated to be required for 
eIF4E-dependent oncogenic transformation (Cohen et al., 2001; Culjkovic et al., 
2005). The mechanistic details of eIF4E-dependent nuclear export are unclear but 
evidence suggests that the eIF4E exported RNPs are distinct from the bulk mRNA 
export pathway, since they do not contain any general mRNA export factors 
(Topisirovic et al., 2009).  
 
1.7.2.5 Regulation of eIF4E  
eIF4E activity plays a pivotal role in gene expression as well as cell proliferation and 
survival of eukaryotic cells. Furthermore, eIF4E deregulation is associated with 
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abnormal cell proliferation in cell culture as well as tumour formation in vivo (Lazaris-
Karatzas et al., 1990; Ruggero et al., 2004).  
In mammals eIF4E is phosphorylated at Serine-209 by Mnk1 and Mnk2 kinases that 
operate via the MAPK (mitogen-activated protein kinases) signaling pathway, and the 
oncogenic activity of eIF4E is dependent on Serine-209 phosphorylation (Wendel et 
al., 2007). eIF4G binds to Mnk1 and thereby localises Mnk1 kinase activity to eIF4E 
when it is part of eIF4F (Pyronnet et al., 1999).  
In the cytoplasm, eIF4E can bind to eIF4E-binding proteins (4E-BPs) that inhibit 
eIF4E-dependent translation (Pause et al., 1994). 4E-BPs comprise a family of three 
low molecular weight proteins designated 4E-BP1, 2 and 3 (Pause et al., 1994; 
Poulin et al., 1998). 4E-BPs inhibit the formation of the eIF4F complex by competing 
with eIF4G for eIF4E binding (Mader et al., 1995; Marcotrigiano et al., 1999). 4E-BPs 
are hyperphosphorylated by mTORC1, which operates via the PI3-kinase signalling 
pathway. Hyperphosphorylation of 4E-BP abolishes the interaction between eIF4E 
and 4E-BPs and stimulates cap-dependent translation and cell proliferation (Beretta 
et al., 1996). Within cells the activities of eIF4E and 4E-BP are under homeostatic 
control (Khaleghpour et al., 1999; Yanagiya et al., 2012). eIF4E overexpression 
results in a decrease of endogenous 4E-BPs phosphorylation, rendering the 
overexpressed eIF4E inactive (Khaleghpour et al., 1999). Furthermore, depletion of 
endogenous eIF4E results in proteasomal degradation of hyperphosphorylated 4E-
BP (Yanagiya et al., 2012). Nonetheless, aberrant mTOR signalling results in tumour 
formation by stimulating eIF4E cap-dependent translational activity (Mamane et al., 
2004). Moreover, 4E-BP1 hyperphosphorylation has been correlated with poor 
clinical tumour prognosis (Rojo et al., 2007).  
In the nucleus, eIF4E can physically interact with the promyelocytic leukemia (PML) 
protein, which inhibits eIF4E activity and inhibits the nuclear export of specific 
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transcripts (Lai and Borden, 2000; Culjkovic et al., 2005). PML modulates eIF4E 
activity by reducing the affinity of eIF4E for the N-7 methylguanosine cap structure 
with concurrent reduction of eIF4E nuclear function. Interestingly, PML 
overexpression reduces eIF4E-dependent oncogenic transformation in vitro (Cohen 
et al., 2001).  
 
1.7.3 Poly(A)-specific ribonuclease (PARN) 
The poly(A)-specific ribonuclease (PARN) has also been demonstrated to be a N-7 
methylguanosine cap binding protein. PARN catalyses poly(A)-tail removal, a 
process which is called deadenylation. Deadenylation is the first step of the 
deadenylation-dependent mRNA degradation pathway (Garneau et al., 2007). PARN 
was demonstrated to bind to the N-7 methylguanosine cap moiety and to promote 
mRNA deadenylation both in vitro and within cells (Gao et al., 2000; Dehlin et al., 
2000; Martinez et al., 2000). Incubation of an m7GpppG, but not GpppG, cap 
analogue in an in vitro reaction resulted in inhibition of PARN-mediated 
deadenylation of N-7 methylguanosine capped RNA (Gao et al., 2000; Dehlin et al., 
2000; Martînez et al., 2001). 
The interaction between PARN and the N-7 methylguanosine cap moiety was 
demonstrated by employing m7GTP-sepharose pull-down and by PARN 
immunoprecipitation from HeLa or Xenopus oocyte extracts incubated with 
[32P]m7GpppG-labelled RNA. When immunoprecipitation was performed in the 
presence of m7GpppG cap analogue the interaction was abolished, suggesting that 
PARN specifically interacts with the N-7 methylguanosine cap structure (Gao et al., 
2000; Dehlin et al., 2000). Furthermore, this interaction has been validated by 
biophysical studies (Nilsson et al., 2007). 
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The eIF4E cap-binding protein has been demonstrated to compete with PARN for N-
7 methylguanosine cap-binding and to protect mRNA from degradation (Gao et al., 
2000) (Figure 1.8). CBC can also inhibit PARN activity using a different mechanism. 
The Cbp80 subunit of CBC physically interacts with PARN and abolishes PARN 3ʼ 
exoribonuclease activity independently of the N-7 methylguanosine cap structure 
(Balatsos et al., 2006). The above observations suggest that when the mRNA is 
engaged with either CBC or eIF4E in biological processes, it is protected from PARN-
mediated deadenylation-dependent degradation.  
 
1.7.4 Argonaute 
miRNA silencing is the process of targeting messenger RNA (mRNA) via short RNA 
molecules (~22 nucleotides) with complementarity to the targeted mRNA sequence, 
resulting in inhibition of mRNA expression. The inhibition occurs by mRNA 
degradation (Braun et al., 2011; Chekulaeva et al., 2011; Fabian et al., 2011) and 
translation repression (Djuranovic et al., 2012; Bazzini et al., 2012).  
Interestingly, miRNA silencing of reporter constructs or in vitro transcribed RNAs 
transfected into HeLa cells was demonstrated to be dependent on the N-7 
methylguanosine cap (Pillai et al., 2005; Thermann and Hentze, 2007; Iwasaki et al., 
2009; Iwasaki and Tomari, 2009). Several mechanisms have been proposed to 
explain this effect and most of them involve the Argonaute (Ago) proteins. Ago 
proteins bind to miRNAs and are the core protein components of RISC (RNA-induced 
silencing complex). The Ago protein family contains RNA endonuclease activity that 
catalyses miRNA-directed mRNA cleavage (Hutvagner and Simard, 2008).  
Ago2 has been reported to bind to the N-7 methyguanosine cap via a domain similar 
to the cap-binding domain of eIF4E (Kiriakidou et al., 2007). Binding of Ago2 to the 
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N-7 methylguanosine cap is required for translational repression of the mRNA. An 
obvious mechanism by which Ago2 could promote miRNA-mediated translation 
repression is by binding to the N-7 methylguanosine cap structure of the targeted 
mRNA to consequently abolish the interaction of eIF4E with the cap structure, with 
predictable effects on message translation (Kiriakidou et al., 2007). However, the 
competition between eIF4E and Ago2 for the N-7 methylguanosine cap structure has 
never been proven directly. In fact the opposite has been shown since eIF4E 
overexpression does not affect the interaction of Ago2 with the cap structure (Iwasaki 
et al., 2009; unpublished data). 
The binding of Ago2 to the N-7 methylguanosine cap structure has raised great 
controversy in the miRNA-silencing field. Biophysical and biochemical assays agree 
with the observation that Ago2 can bind to the N-7 methylguanosine cap moiety. 
However, this was only observed in the presence of miRNAs that trigger a 
conformational change in Ago2, creating a specific cap-binding site, and thus 
allosterically predispose Ago2 to be a cap-binding protein (Djuranovic et al., 2010). In 
support of this model the crystal structure of an Ago domain, on which the proposed 
cap-binding and miRNA-binding sites are located, has been solved. However, the 
above crystal structure was obtained in the absence of a cap analogue (Boland et al., 
2010). Conversely, an additional Ago2 crystal structure classified the interaction 
between Ago2 and N-7 methylguanosine cap as non-specific. Structural, biophysical 
and biochemical assays have all suggested that Ago2 is insufficient to bind to the N-7 
methylguanosine cap (Frank et al., 2011). This last observation demonstrated that 
the Ago2 does not interact with the N7-methylguanosine cap.  
Interestingly, the binding of Ago2 to the N-7 methylguanosine cap structure has been 
implicated in non-sense mediated decay (NMD). The competition of Ago2 with CBC 
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for binding to the methyl-cap has been demonstrated to be responsible for the 
reduction of NMD when Ago2 is overexpressed (Choe et al., 2010, 2011) (Figure 1.8).  
An additional mechanism has been reported for miRNA-mediated cap-dependent 
inhibition of translation. In the presence of a targeted mRNA, Ago2 was 
demonstrated to bind eIF4E cap-binding protein at the same region as eIF4G. The 
interaction between Ago2 and eIF4E abolishes the interaction between eIF4E and 
eIF4G and thus inhibits translation initiation (Iwasaki et al., 2009; Iwasaki and Tomari, 
2009).  
To summarise, many studies suggest that the N-7 methylguanosine cap is required 
for miRNA-dependent translational repression. However the mechanistic details by 
which this happens remain unclear. 
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Figure 1.8: The interplay of the cap-binding proteins for N-7 
methylguanosine cap binding. 
The CBC (Cbp20 and Cbp80) engages the N-7 methylguanosine cap structure 
and promotes a series of events for mRNA metabolism. Argonaute-2 (Ago2) 
overexpression, which also binds to N-7 methylguanosine cap, inhibits the binding 
of CBC to the N-7 methylguanosine cap. In the cytoplasm Importin-β binds to 
Importin-α and promotes the release of the RNA cargo from CBC. eIF4E engages 
to the N-7 methylguanosine cap promoting mRNA translation initiation. eIF4E 
binding to the N-7 methylguanosine cap abolishes the interaction of PARN 
deadenylase as well as DCP decapping enzyme with the N-7 methylguanosine 
cap, protecting mRNA from degradation. 
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1.8 Summary and experimental aims 
As described extensively above, the N-7 methylguanosine cap moiety is involved in 
almost all steps of gene expression regulation. The gene expression steps in which 
the N-7 methylguanosine cap has been demonstrated to be involved, as well as the 
proteins that mediate these effects are listed below: 
• RNA pol II transcription initiation and elongation (Capping machinery, CBC) 
• mRNA splicing (CBC) 
• 3ʼ end pre-mRNA processing (CBC)  
• miRNA biogenesis (CBC) 
• mRNA nuclear export (CBC, eIF4E) 
• U snRNA nuclear export (CBC) 
• mRNA stability/NMD (eIF4E, CBC, PARN) 
• miRNA mediated mRNA silencing (Argonaute) 
• mRNA translation (eIF4E, CBC) 
Since N-7 methylguanosine cap formation plays such a pivotal role in gene 
expression it is not a surprise that it is essential for cell survival and proliferation in all 
eukaryotes (Cowling, 2010c). 
Interestingly, deregulation of guanine-7 methylation can induce oncogenic 
transformation in cell culture (Cowling, 2010a). Furthermore, inhibition of N7-
methylguanosine cap formation is synthetically lethal with elevated c-Myc expression 
and abolishes c-Myc transforming activity (Fernandez-Sanchez et al., 2009).  
All the above demonstrate the importance of N-7 methylguanosine cap for cell 
viability and the potential of targeting the capping machinery for treating Myc-
dependent cancers. Nonetheless, the mechanistic details of RNA guanine-7 
methylation in mammalian cells remain elusive. In order to gain a better 
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understanding of how guanine-7 methylation occurs in mammalian cells we decided 
to purify RNA guanine-7 methyltransferase (RNMT) complexes from human cells to 
identify novel RNMT-interacting proteins. The identification of such proteins, may 
provide new insights into both the mechanics of cap methylation and its regulation. 
Furthermore, the identification of novel components involved in RNA guanine-7 
methylation may provide additional targets for inhibiting this process as means of 
cancer treatment. 
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Chapter 2:  Materials and Methods 
2.1 Materials 
2.1.1 Lab consumables 
Cell Lifter (Corning Incorporated) 
Eppendorf Tubes (Star Lab) 
Falcon Tubes (Greiner) 
Filter Units (Thermo Scientific) 
Gel Loading Tips (Star Lab) 
Pipette Tips (Star Lab) 
Pipettes (Greiner) 
 
2.1.2 Chemicals 
2-Mercaptoethanol (Sigma) 
Acetic Acid (VWR International) 
Calcium Chloride (VWR International) 
Dithiothreitol (DTT) (Formedium) 
Ethylenediamine tetraacetic acid (EDTA) (VWR International) 
Ethylene glycol tetraacetic acid (EGTA) (VWR International) 
Ethanol (VWR International) 
Glycerol (VWR International) 
Glycine (VWR International) 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes) (Sigma) 
Hydrochloric Acid (VWR International) 
Isopropanol (VWR International) 
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Magnesium Chloride (VWR International) 
Methanol (VWR International) 
3-(N-morpholino)propanesulfonic acid (MOPS) (VWR International) 
piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) (Sigma) 
Potassium Chloride (VWR International) 
Sodium Chloride (VWR International) 
Sodium Deoxycholate (Sigma) 
Sodium Dodecyl Sulfate (SDS) (Sigma) 
Sodium Fluoride (Sigma) 
Sodium Hydroxide (VWR International) 
Tris-Base (VWR International) 
TritonX-100 (VWR International) 
Tween 20 (VWR International) 
Urea (Fisher Scientific) 
 
2.1.3 Mammalian cell culture and maintenance  
100 mm Petri Dishes (Helena) 
150 mm Petri Dishes (Helena) 
6-Well Plate (Greiner) 
Blasticidin S hydrochloride (Sigma) 
clasto-Lactacystin β-Lactone (Cayman chemical) 
Cover Glass 13 mm (VWR International) 
Cryovials (Alpha Labs) 
Cycloheximide (Sigma) 
DAPI (Sigma) 
DharmaFECT 1 Transfection Reagent (Thermo Scientific) 
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Doxycycline hyclate (Sigma) 
DPBS (Invitrogen) 
Dulbeccoʼs Modified Eagle Medium (DMEM) (Invitrogen) 
Dulbeccoʼs Modified Eagle Medium Nutrient Mixture F-12 HAM (Sigma) 
Epidermal Growth Factor (EGF) (Sigma) 
Fetal Bovine Serum (FBS) E.C. Approved (Invitrogen) 
G-418 (Geneticin) (ForMedium) 
GeneJuice Transfection Reagent (Novagen) 
Hydrocortisone (Sigma)  
Hydromount (National diagnostics) 
Hygromycin B (Roche) 
Insulin Solution Human (Sigma) 
MG132 (Calbiochem) 
Penicillin/Streptomycin (Invitrogen) 
Polybrene (Sigma) 
Puromycin (Sigma) 
Trypan Blue solution (0.4%) (Sigma) 
Trypsin-EDTA solution (Invitrogen) 
Zeocin (Invitrogen) 
 
2.1.4 Molecular biology 
1 Kb DNA Ladder (Invitrogen) 
96-well PCR frame Plate (VWR International) 
Agarose (Invitrogen) 
Alkaline Phosphatase (NE BioLabs) 
All Restriction Enzymes (NE BioLabs) 
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[γ-32P]ATP (Perkin Elmer) 
cDNA Synthesis Kit (Quanta Bioscience) 
DH5α Competent E. coli Cells (DSTT) 
dNTPs (Promega) 
Ethidium Bromide (Sigma) 
Expand High Fidelity PCR System (Roche) 
GelRed (Biotium) 
Go Taq (Promega) 
PCR tubes (Axygen) 
Plasmid Maxi Kit (Qiagen) 
QIAprep Miniprep Kit (Qiagen) 
QIAquick Gel Extraction Kit (Qiagen) 
QIAquick PCR Purification Kit (Qiagen) 
QuickChange Site-directed Mutagenesis Kit (Stratagene) 
RNAse A (Sigma) 
RNeasy Mini Kit (Qiagen) 
SYBR Green Fastmix IQ (Quanta Bioscience) 
T4 DNA Ligase (NE Biolabs) 
T4 Polynucleotide kinase (PNK) (NE BioLabs) 
TRIzol Reagent (Invitrogen) 
 
2.1.5 Biochemistry 
35S Protein Labelling Mix (Perkin Elmer) 
Ammonium Acetate (Ambion) 
Cap analogue (GpppG) (NEB) 
DEPC-Water (Ambion) 
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P1 nuclease (Sigma) 
Phenol/Chloroform Premixed with Isoamyl Alcohol (Ambion) 
RNasin (Promega) 
S-Adenosyl-Homocysteine (Sigma) 
S-Adenosyl-Methionine (Sigma) 
Saturated Phenol (Ambion) 
Sodium Acetate (Ambion) 
T7 RNA polymerase (Promega) 
TLC PEI Cellulose F Sheets (Merck) 
tRNA (Sigma) 
[α-32P]GTP (Perkin Elmer) 
 
2.1.6 Protein analysis 
40% Acrylamide : Bis-acrylamide 29:1 (Flowgen Biosciences) 
Ammonium Persulfate (APS) (Sigma) 
Aprotinin (Sigma) 
BenchMark Prestained Protein Ladder (Invitrogen) 
Bio-Rad Protein Assay (Bio-Rad) 
Bovine Serum Albumin (BSA) (NE BioLabs) 
Brilliant Blue g – Colloidal Concentrate (Sigma) 
DAPI Fluorescent Stain (Invitrogen) 
Donkey Serum (Sigma) 
Dried Skimmed Milk (Marvel) 
Immobilon Transfer Membrane (Millipore) 
Leupeptin Hydrochloride (Sigma) 
N,N,N,ʼNʼ-Tetramethyletylenediamine (TEMED) (VWR International) 
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NuPAGE 4-12% Bis-Tris Gel (Invitrogen) 
Pepstatin (Sigma) 
Phosphatase Inhibitor Cocktail 2 (Sigma) 
Phosphatase Inhibitor Cocktail 3 (Sigma) 
Protein A/G PLUS-Agarose (Santa Cruz Biotechnology) 
West Pico Chemiluminescent Substrate (of HRP) (Thermo Scientific) 
X-RAY FILM (Konica Minolta) 
 
2.1.7 Recombinant protein production 
BL21 CodonPlus (DE3)-RIL Competent E. coli Cells (Roche) 
BL21(DE3) Competent E. coli Cells (DSTT) 
Cuvettes (Sarstedt) 
Gel Filtration Molecular Weight Markers (Sigma) 
Glutathione (VWR International) 
Glutathione Sepharose 4B (GE Healthcare) 
IMAC Sepharose High Performance (GE Healthcare) 
Imidazole (Sigma) 
Poly-Prep Chromatography Columns (Bio-Rad) 
PreScission Protease (Produced and provided by Daan Van Aaltenʼs lab) 
Slide-A-Lyzer Dialysis Cassette (Thermo Scientific) 
Vivaspin 20 Concentrator (Sartorius Stedim) 
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Table 2.1: List of antibodies used for the purpose of this study. The species in which the 
antibodies were raised and the retailer that provided them are indicated. All the in house 
produced antibodies were affinity-purified from sheep serum. 
Raised Against Species Retailer 
RAM (0.18 mg/ml) Sheep polyclonal In house 
RNMT (0.3 mg/ml) Sheep polyclonal In house 
RAM P-S36 (0.15 mg/ml) Sheep polyclonal In house 
Tubulin Rabbit polyclonal Santa Cruz 
GST Sheep polyclonal DSTT 
GFP 
Mixture of two Mouse 
monoclonal IgG1 
Roche 
HA Mouse monoclonal IgG1 Sigma 
HSPA1 Mouse monoclonal IgM Invitrogen 
c-MYC Rabbit monoclonal IgG Cell Signaling 
HA (Agarose conjugated) Mouse monoclonal IgG1 Sigma 
FLAG (M2 Affinity Gel) Mouse monoclonal IgG1 Sigma 
IgG agarose Mouse Sigma 
Sheep antibodies 
Rabbit anti-sheep, HRP-
conjugated 
Thermo Scientific 
Rabbit antibodies 
Goat anti-rabbit, HRP-
conjugated 
Thermo Scientific 
Mouse antibodies 
Goat anti-mouse, HRP-
conjugated 
Thermo Scientific 
Alexa-488 anti-Sheep Goat Molecular Probes 
7-methylguanosine cap Rabbit In house 
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Table 2.2: Oligonucleotide sequences employed for cloning (purchased from Eurofins 
MWG). The construct that was prepared using each set of primers is indicated in the left 
column. 
Construct Primer Set Sequence 
pGEX-6P-1-RAM WT 
Forward: 
5ʼ AAAGGATCCACTGACACTGCCGAAGCTG 3ʼ 
Reverse: 
5ʼ ACACTCGAGTCAGTAGTAACCGTAAGGAGGC 3ʼ 
pGEX-6P-1-RAM 1-90 
Forward: 
5ʼ AAAGGATCCACTGACACTGCCGAAGCTG 3ʼ 
Reverse: 
5ʼ ACACTCGAGTCAGTTGTTACCCCAGGATCGTC 
3ʼ 
pGEX-6P-1-RAM 1-55 
Forward: 
5ʼ AAAGGATCCACTGACACTGCCGAAGCTG 3ʼ 
Reverse: 
5ʼ ACACTCGAGTCAGCCTCTGTTTCTTTGGTTCC 3ʼ 
pGEX-6P-1-RAM 91-118 
Forward: 
5ʼ AAAGGATCCTACCCGCAACACAGACAAGAACC 
3ʼ 
Reverse: 
5ʼ ACACTCGAGTCAGTAGTAACCGTAAGGAGGC 3ʼ 
pGEX-6P-1-RAM 56-118 
Forward: 
5ʼ ACAGGATCCAATCGGTTGCAAGACAACAGAC 3ʼ 
Reverse: 
5ʼ ACACTCGAGTCAGTAGTAACCGTAAGGAGGC 3ʼ 
pOPC 6xHIS-RNMT 165-
476 / RAM 1-90 
RNMT Cloning 
Forward: 
5ʼ ACACATATGAGTCAAAGTCGTATTTTTTACC 3ʼ 
 89 
Reverse: 
5ʼ ACAGGATCCTCACTGCTGTTTCTCAAAGGC 3ʼ 
RAM Cloning 
Forward: 
5ʼ ACACATATGACTGACACTGCCGAAGCTG 3ʼ 
Reverse: 
5ʼ ACAGGATCCTCAGTTGTTACCCCAGGATCGT 3ʼ 
pOPC GST-RAM 1-90 / 
6xHIS-RNMT full length  
RNMT Cloning 
Forward: 
5ʼ ACACATATGGCAAATTCTGCAAAAGC 3ʼ 
Reverse: 
5ʼ ACAGGATCCTCACTGCTGTTTCTCAAAGGC 3ʼ 
RAM Cloning 
Forward: 
5ʼ ACACATATGACTGACACTGCCGAAGCTG 3ʼ 
Reverse: 
5ʼ ACAGGATCCTCAGTTGTTACCCCAGGATCGT 3ʼ 
pEGFP-N3-RAM WT 
Forward: 
5ʼ ACACTCGAGATGACTGACACTGCCGAAGC 3ʼ 
Reverse: 
5ʼ ACAGGATCCGTAGTAACCGTAAGGAGG 3ʼ 
pEGFP-N3-RAM 1-90 
Forward: 
5ʼ ACACTCGAGATGACTGACACTGCCGAAGC 3ʼ 
Reverse: 
5ʼ ACAGGATCCGTTGTTACCCCAGGATCGTC 3ʼ 
pEGFP-N3-RAM 1-55 
Forward: 
5ʼ ACACTCGAGATGACTGACACTGCCGAAGC 3ʼ 
Reverse: 
5ʼ ACAGGATCCGCCTCTGTTTCTTTGGTTCC 3ʼ 
pEGFP-N3-RAM 91-118 
Forward: 
5ʼ AAACTCGAGATGTACCCGCAACACAGACAAG 3ʼ 
 90 
Reverse: 
5ʼ ACAGGATCCGTAGTAACCGTAAGGAGG 3ʼ 
pEGFP-N3-RAM 56-118 
Forward: 
5ʼ ACACTCGAGATGAATCGGTTGCAAGACAAC 3ʼ 
Reverse: 
5ʼ ACAGGATCCGTAGTAACCGTAAGGAGG 3ʼ 
pcDNA5-HA-RNMT 1-120 
Forward: 
5ʼ ACAGGATCCATGTACCCATACGATGTTCCAGAT 
TACGCTGCAAATTCTGCAAAAGCA 3ʼ 
 
Reverse: 
5ʼ ACACTCGAGTCATCCAGTAGAAGATTTATCT 3ʼ 
pcDNA5-HA-RNMT 121-
476 
Forward: 
5ʼ ACAGGATCCATGTACCCATACGATGTTCCAGAT 
TACGCTGATGGCACTCAAAATAAGAGA 3ʼ 
Reverse: 
5ʼ ACACTCGAGTCACTGCTGTTTCTCAAAGG  
CAAA 3ʼ 
pcDNA5-Fg-RAM WT 
Forward: 
5ʼ ACAGGATCCATGGACTACAAGGACGATGATGAC 
AAGCCCACTGACACTGCCGAAGC 3ʼ 
Reverse: 
5ʼ ACAGCGGCCGCTCAGTAGTAACCGTAAGG  
AGGC 3ʼ 
pcDNA5-HA-RAM WT 
Forward: 
5ʼ ACAGGATCCATGTACCCATACGATGTTCCAGAT 
TACGCTACTGACACTGCCGAAGC 3ʼ 
Reverse: 
5ʼ ACAGCGGCCGCTCAGTAGTAACCGTAAGG 
AGGC 3ʼ 
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Table 2.3: Oligonucleotide sequences employed for site-directed mutagenesis 
(purchased from Eurofins MWG). The construct that was prepared using each set of primers 
is indicated in the left column. 
pcDNA5-Fg-RAM WT 
(resistant to siRAM1) 
Forward: 
5ʼ TTTGAAGAGATGTTTGCGTCGCGCTTTACGGAG 
AATGACAAGGAGTATCAGGAATACC 3ʼ 
Reverse: 
5ʼ TTTCAGGTATTCCTGATACTCCTTGTCATTCTCC 
GTAAAGCGCGACGCAAACATCTCT 3ʼ 
pcDNA5-Fg-RAM K10N 
 
pcDNA5-RAM K10N GFP 
 
pGEX6P-1-RAM 1-90 K10N  
Forward: 
5ʼ GACACTGCCGAAGCTGTTCCAAATTTTGAAGAG 
ATGTTTGC 3ʼ 
Reverse: 
5ʼ CTAGCAAACATCTCTTCAAAATTTGGAACAGCT 
TCGGCAGT 3ʼ 
pcDNA5-Fg-RAM S36A 
 
Forward: 
5ʼ ACCTGAAACGCCCTCCTGAGGCTCCTCCAATTG 
TTGAGGAATGGA 3ʼ 
Reverse: 
5ʼ TCCATTCCTCAACAATTGGAGGAGCCTCAGGA 
GGGCGTTTCAGGT 3ʼ 
 
 
Table 2.4: Oligonucleotide sequences employed for qRT-PCR (purchased from Eurofins 
MWG). The transcript that was amplified using each set of primers is indicated in the left 
column. 
Gene Primer Set Sequence 
RAM 
Forward: 5ʼ CCTCAAACCTTTGGGATT 3ʼ 
Reverse: 5ʼ TTCTGTGGAACCTTGCTA 3ʼ 
RNMT 
Forward: 5ʼ GTACTGATATTGCCGATGT 3ʼ 
Reverse: 5ʼ ATTCACTATCACGACTCT 3ʼ 
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c-MYC 
Forward: 5ʼ TCTGAGGAGGAACAAGAA 3ʼ 
Reverse: 5ʼ GAAGGTGATCCAGACTCT 3ʼ 
Cyclin D1 
Forward: 5ʼ CATTGAACACTTCCTCTCC 3ʼ 
Reverse: 5ʼ ATGAACTTCACATCTGTGG 3ʼ 
RuvBL1 
Forward: 5ʼ CATTGGGCTGCGAATAAAG 3ʼ 
Reverse: 5ʼ TCTGTCTCACACGGAGTT 3ʼ 
GAPDH 
Forward: 5ʼ GGAGTCAACGGATTTGG 3ʼ 
Reverse: 5ʼ GTAGTTGAGGTCAATGAAGGG 3ʼ 
HA-RNMT 
Forward: 5ʼ CCATACGATGTGCCAGATTACGC 3ʼ 
Reverse: 5ʼ CAGAATTCACTGACGCTTTTGCC3ʼ 
Fg-RAM 
Forward: 5ʼ ACAAGGACGATGATGACAAGC 3ʼ 
Reverse: 5ʼ TTCTGTGGAACCTTGCTA 3ʼ 
 
Table 2.5: Oligonucleotide sequences employed for RNA interference (purchased from 
Dharmacon). 
Transcript targeted Targeted sequence 
Non-targeting siRNA - 
RAM (1st) GCUAGUAGAUUCACAGAAA 
RAM (2nd) CGAAGCUGUUCCAAAGUUU 
RNMT (1st) GUUCUAAACUUGUCUCUGA 
RNMT (2nd) GCAAAUAUGACUUCAACUU 
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2.1.8 Buffers and Solutions 
 
F buffer: 10 mM Tris (PH 7.05), 50 mM NaCl, 30 mM Na pyrophosphate, 50 mM NaF, 
10% Glycerol, 0.5% Triton        
A buffer: 10mM HEPES, 1.5 mM MgCl2, 10 mM KCl 
SDS running buffer: 25 mM Tris, 0.1% SDS, 250 mM glycine 
Transfer buffer: 25 mM Tris, 192 mM glycine, 20% methanol 
TBST: 25 mM Tris (pH 8.1), 155 mM NaCl, 0.1% tween 20 
4x Laemmli buffer: 242 mM, 10% SDS, 25% glycerol, 100 mM DTT, bromophenol 
blue 
MT assay buffer: 50 mM Tris (pH 8.0), 6 mM KCl, 1.25 mM MgCl2 
RB assay buffer: 20 mM Tris (pH 7.5), 50 mM KCl, 10 mM MgCl2, 0.1% triton X-100, 
5 mM DTT, 1 mg/ml BSA, 7.5% glycerol, 20 U RNasin and 50 μM S-adenosyl homo- 
cysteine (SAH) 
RB transfer buffer: 25 mM Tris, 190 mM glycine, 1 mM EDTA, 0.1% triton X-100  
2 x HEPES-buffered saline (HBS): 50 mM HEPES (pH 7.05), 1.5 mM Na2HPO4,  
275 mM NaCl 
TAE buffer: 40 mM Tris (pH 8.0), 40 mM acetic acid, 1 mM EDTA 
TBE buffer: 89 mM Tris (pH 8.0), 89 mM boric acid, 2.5 mM EDTA  
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2.2 Methods 
2.2.1 Cell Culture and Maintenance 
 
Table 2.6: Cell lines employed for the purpose of this study. Cell line origin and a short 
description of their maintenance are indicated. 
Cell line Origins Description-maintenance 
HEK-293 
Human embryonic kidney 
cells 
Adherent cells maintained in DMEM 
supplemented with 10% FCS and 2 mM 
L-glutamine 
HeLa 
Human cervical epithelial 
carcinoma 
Adherent cells maintained in DMEM 
supplemented with 10% FCS and 2 mM 
L-glutamine 
IMEC 
Human immortalised 
mammary epithelial cells 
Adherent cells maintained in DMEM 
nutrient mixture F-12 HAM 
supplemented with L-glutamine, 5 μg/ml 
insulin, 10 ng/ml EGF and 0.5 μg/ml 
hydrocortisone 
SAOS2 
Human osteosarcoma 
cells 
Adherent cells maintained in DMEM 
supplemented with 10% FCS and 2 mM 
L-glutamine 
U2OS 
Human osteosarcoma 
cells 
Adherent cells maintained in DMEM 
supplemented with 10% FCS and 2 mM 
L-glutamine 
Aʼ 
Human embryonic kidney 
cells 
Adherent cells maintained in DMEM 
supplemented with 10% FCS, 2 mM L-
glutamine and 1 mM Sodium Pyruvate 
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Cells were treated in γ-sterilised, tissue culture treated plasticware. Cells were 
maintained at 37ºC, under humidified atmosphere containing 5% CO2. Cells were 
grown to near confluence in 10 cm dishes and then sub-cultured by removing the old 
media, washing with PBS and treating with trypsin solution to disassociate them from 
the dish. Cells were diluted in fresh medium and seeded at 5 x 105 cells/10 cm dish. 
 
2.2.1.1 Transient plasmid and siRNA transfections  
2.2.1.1.1 DNA transfection using calcium phosphate method 
HEK-293 cells were transiently transfected with recombinant DNA vector using the 
classical calcium phosphate method. 5 μg of DNA vector were added to 500 μl of 2 
M CaCl2 and 500 μl of 2 x HBS was added to the mixture with continual mixing and 
incubated for 20 minutes to allow the formation of a fine co-precipitate of DNA-
Ca3(PO4)2. This mixture was added to 500,000 HEK-293 cells seeded into a 10 cm 
dish. Fresh media was added 4 hours post transfection. The cells were lysed 48 
hours post-transfection and the expression of the protein transfected was assessed 
by Western Blot (Figures: 3.8, 3.9, 4.7(a), 4.7(b), 6.4(a), 6.4(d), 6.5). 
 
2.2.1.1.2 DNA transfection using transfection reagents 
HeLa cells were transient transfected with recombinant DNA vector using GeneJuice 
according to manufactures instructions. For Western Blot, RT-PCR and cell 
proliferation analysis, 120,000 HeLa cells seeded in a 6-well plate were transfected 
with 1 μg DNA. For methyl-IPs and in vitro methyltransferase activity assays 600,000 
cells seeded in a 10 cm dish were transfected with 5 μg DNA [Figures: 3.5, 4.6 (d), 
4.7(e), 4.8, 4.10, 6.1, 6.2, 6.3, 6.8(b), 6.9(c), 6.10].  
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2.2.1.1.3 siRNA transfection 
HeLa cells were transfected with siRNAs (Table 2.5) using DharmaFECT 1 
transfection reagent according to manufactures instructions. For Western Blot, RT-
PCR and cell proliferation analysis, 120,000 HeLa cells seeded in a 6-well plate were 
transfected with 200 pmoles siRNAs. For methyl-IPs and in vitro methyltransferase 
activity assays 600,000 cells seeded in a 10 cm dish were transfected with 1 nmole 
siRNAs. Unless stated the 1st version of siRNAs presented in Table 2.5 were used. 
(Figures: 3.5, 4.5, 4.6, 4.8, 4.9, 4.10).  
 
2.2.1.2 Stable transfection procedures 
2.2.1.2.1 Retroviral infection method 
HEK-293 cells were stably transfected with DNA vectors expressing HA-RNMT or 
vector control using a retroviral infection method. 500,000 Aʼ phoenix packaging cells 
seeded into 10 cm dishes were transfected with 5 μg INI-HA-RNMT or vector control 
using the calcium phosphate method. 48 hours post-transfection the medium of the A’ 
cells was passed through a 0.45 µM filter and mixed 1:1 with the media of 600,000 
recipient HEK-293 cells seeded into 10 cm dishes. 5 µg/ml of polybrene was also 
added to the dishes to increase the infection efficiency of the recipient cells. 
Polybrene is a chemical that neutralises the charge repulsion between virons and the 
negative charges on the recipient cell surfaces. Stable pools were selected using 0.5 
mg/ml Geneticin [Figures: 3.1, 3.2(a)].  
 
2.2.1.2.2 Flp-In T-Rex system 
Flp-In T-REx U2OS cells (Invitrogen) stably expressing doxycycline-inducible GFP-
RAM or GFP alone were generated following manufacturer’s instructions. Flp-In T-
REx U2OS host cells generated by stably transfected pcDNA6/TR were kindly 
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provided by Prof. John Rouse’s lab, University of Dundee. 500,000 Flp-In T-REx 
U2OS host cells seeded into 10 cm plates were transfected with pcDNA5/FRT/TO 
vector expressing GFP-RAM WT, GFP-RAM S36A or GFP alone together with 
pOG44 plasmid (Invitrogen) encoding FLP-recombinase. 48 hrs later, the 
recombination of the pcDNA5-derived targeted sequence to the pcDNA6/TR target 
site was selected by supplementing 7.5 µg/ml blasticidin and 200 µg/ml hygromycin 
B in the cell media respectively. After selection cells were cultured in DMEM 
supplemented with 10% FBS, 7.5 µg/ml blasticidin and 200 µg/ml hygromycin B. 
Gene expression was induced for 16 hrs with 0.2 μg/ml Doxycycline [Figure: 6.4 (e)]. 
HeLa cells stably expressing doxycycline-inducible HA-RNMT were created by Dr. 
Rebecca Bounds in Dr. Cowling's lab using the T-Rex system (Invitrogen). These 
cells were collected and maintained in medium containing 0.5 mg/ml Geneticin and 
75 μg/ml Zeocin. HA-RNMT expression was induced with 0.2 μg/ml Doxycycline for 
the duration of time indicated (Figure: 4.9).    
HeLa cells stably expressing 6xHIS-Ubiquitin were generated and provided by Prof. 
Ron Hay’s lab, University of Dundee. Cells were maintained in DMEM supplemented 
with 10% FBS and 5 μg/ml Puromycin. 
 
2.2.1.3 Cell counting 
Cell number was determined by using a Neubauer chamber. Cells were trypsinised 
and diluted in DMEM containing 10% FBS. The cell sample was diluted 1:1 with 
Trypan Blue solution. The Neubauer chamber was filled with 20 μl of the cell sample. 
Cells were counted in four 1x1 mm squares of both Neubauer chambers and the 
average number of cells per square was determined. Non-viable cells were stained 
blue and were not counted. The actual number of cells per ml of DMEM was 
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determined by multiplying the average number of cells determined by counting with 
20,000.  
 
2.2.2 Mammalian Protein Extraction and Analysis 
2.2.2.1 Cell lysis 
Culture medium was removed and cells were washed twice in ice-cold PBS. F buffer 
supplemented with 1 mM DTT, 0.1 TIU (trypsin inhibitor unit) Aprotinin, 1 μM 
pepstatin and 10 μM leupeptin was used for cell lysis. Cell lysates were left on ice for 
15 min and centrifuged at 16,000 x g for 15 min at 4ºC to separate cell extracts from 
cellular debris (pellet). Supernatant was collected and transferred into a new tube. 
Protein concentration was estimated using the Bradford method. 
 
2.2.2.2 Protein concentration determination 
Protein concentration determination was performed using Bradford reagent and by 
reference to absorbance measurements obtained from a series of standard BSA 
(Bovine Serum Albumin) dilutions (for standard curve see Figure 1). 
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Figure 2.1: Standard curve based on BSA dilutions for the estimation of protein 
concentration. 
 
For the standard curve generation 4 μl of a series of BSA dilutions in F buffer were 
mixed with 200 μl of 1x Bio-rad protein assay reagent in a 96-well plate. The 
absorbance was measured at 595 nm with a plate reader. The measurement 
obtained from the blank was subtracted from all other samples measurements and 
the standard curve was prepared by plotting the absorbance of the protein versus the 
standard concentration (mg/ml). 
Cell extract protein concentration was estimated by combining 4 μl of cell extract with 
200 μl of 1x Bio-rad protein assay reagent in a 96-well plate. The absorbance was 
measured at 595 nm with a plate reader. The measurement obtained from the blank 
was subtracted from the sample measurement. The reading was plotted in the 
standard curve for estimating the protein concentration of the sample. 
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2.2.2.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
SDS-PAGE was performed to separate proteins according to molecular weight using 
a Mini-PROTEAN Tetra Electrophoresis System (Bio-Rad). The separating 
acrylamide gels were prepared in a final volume of 10 ml by combining 4 ml 1M Tris-
HCl, pH 8.8 (final concentration 400 mM), 100 μl 10% SDS (final concentration 0.1%), 
acrylamide : bisacrylamide solution and water. The composition of acrylamide : 
bisacrylamide and water is shown in the following table. 
 
Table 2.7: Amount of water and 40% Acrylamide : bisacrylamide used for preparation 
of different percentage acrylamide gel 
Final Acrylamide concentration 8% 12% 15% 
H2O (ml) 3.8 2.8 2 
40% Acrylamide : bisacrylamide (ml) 2 3 3.8 
 
The stacking gel (5% acrylamide) was made by combining 4 ml 1 M Tris base, pH 
6.8 (final concentration 400 mM), 100 μl 10% SDS (final concentration 0.1%), 1.2 ml 
acrylamide : bisacrylamide solution and 4.5 ml H2O. For the polymerization reaction 
APS and TEMED were added to a final concentration of 0.1% (v/v) and 0.01% (v/v) 
respectively.  
Protein samples were combined with 4x Laemmli buffer and F buffer to prepare a 1 
mg/ml protein sample in 1x Laemmli buffer. Samples were boiled for 5 min and 
centrifuged at 16,000 x g for 5 min at room temperature. Proteins were separated 
alongside molecular weight markers at 170 V. The amount of protein resolved and 
the percentage of acrylamide gel used for the detection of specific proteins is 
demonstrated in Table 2.8. 
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Table 2.8: List of the protein detected by western blot during this study. The amount of 
total protein extracts analysed and the percentage of SDS-PAGE used are indicated. 
Western blot against 
Amount of protein 
analysed (μg) 
% Acrylamide gel 
RAM endogenous 15 15 
Fg-RAM 12 15 
RNMT endogenous 5 8 
HA-RNMT 12 8 
Tubulin endogenous 5 8 
HSPA1 endogenous 5 8 
GFP 10 12 
GFP-RAM 10 12 
 
2.2.2.4 Western blot 
Resolved proteins were transferred onto polyvenylfluoride (PVDF) membranes in 
transfer buffer by wet blotting at 66 V for 90 min at 4ºC using Mini Trans-Blot Cell 
(Bio-Rad). For RAM western blots, transfer was performed using Trans-Blot Cell 
(Bio-Rad) at 60 V for 310 min at room temperature. The rest of the procedure was 
carried out at room temperature.  
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Table 2.9: List of antibodies used for western blot. The dilution of the antibody and the 
blocking reagent used are indicated. 
Antibody 
Wb working 
concentration 
Blocking 
RAM (0.18 mg/ml) 1/100 BSA 
RNMT (0.3 mg/ml) 1/1,000 Milk 
RAM P-S36 (0.15 mg/ml) 1/500 BSA 
Tubulin 1/1,000 Milk 
GST 1/10,000 Milk 
GFP 1/1,000 Milk 
HA 1/1,000 BSA 
HSPA1 1/1,000 Milk 
 
Membranes were blocked in TBST containing 5% Milk or 3% BSA depending on the 
primary antibody (Table 2.9) for 1 hr. Primary antibody was diluted in blocking buffer 
(Table 2.9) and incubated with the blot for 1 hr. Membranes were washed with TBST 
containing 5% Milk four times for 5 min. HRP-conjugated secondary antibody was 
diluted 1:2,000 in TBST containing 5% Milk and incubated with the membrane for 45 
min. The membrane was washed five times for 5 min with TBST. Immunoreactive 
proteins were visualized on X-ray film using enhanced chemiluminescence reagent 
according to manufacturerʼs instruction. 
 
2.2.2.5 Coomassie Briliant Blue SDS gel staining 
After SDS-PAGE the gel was washed two times for 2 min in water and stained in 
Coomassie Brilliant Blue R-250 stain (0.25% w/v) solution containing 40% methanol 
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and 10% acetic acid for 1 hr at room temperature. After staining, the gel was washed 
with destaining solution (40% methanol, 10% acetic acid) for 1 hr. The gel was 
washed in water until the background staining was removed.    
 
2.2.2.6 Immunoprecipitations 
Cell extracts were prepared as described previously. All immunoprecipitation steps 
were performed at 4ºC. For immunoprecipitations of endogenous and GFP-tagged 
proteins, extracts were pre-cleared by incubation with protein A/G beads for 1 hr. The 
indicated amount of antibody was incubated with cell extracts for 2 hrs. 25 μl protein 
A/G beads were added to the immunoprecipitation reaction for an additional 2 hrs. 
For immunoprecipitation of HA-tagged and Flag-tagged proteins, the indicated 
amount of anti-HA and anti-Flag antibodies conjugated to agarose were incubated 
with the cell extracts for 4 hrs respectively. Beads/agarose were pelleted and washed 
four times with F buffer. Proteins were eluted with 1x Laemmli buffer, boiled for 4 min 
and analysed by SDS-PAGE followed by western blot.  
 
2.2.2.7 Immunodepletions 
1 mg cell extracts were incubated with 1 μg antibody and 30 μl protein A/G beads for 
3 hrs at 4ºC. Beads were pelleted and supernatant was subjected to two more 
rounds of the same process. Supernatant was combined with Laemmli buffer, boiled 
for 5 min and analysed by SDS-PAGE followed by western blot (Figure: 3.6).   
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2.2.2.8 Large scale immunoprecipitation coupled with mass 
spectrometry analysis 
HEK-293 cell extracts were prepared as described previously. 50 mg of HEK-293 cell 
extracts were pre-cleared with 50 μl protein A/G beads for 1 hr at 4ºC. 50 μg anti-HA 
antibodies conjugated to agarose were incubated with the supernatant for 4 hrs. The 
agarose was pelleted, washed five times with F buffer and resuspended in 1x 
Laemmli buffer. The sample was boiled for 5 min and analysed by SDS-PAGE 
followed by Coomassie staining [Figures: 3.2 (a), 5.4(a)].  
Mass spectrometry analysis was performed by the FingerPrints Proteomics Facility 
located in the College of Life Sciences at the University of Dundee. Briefly, 
Coomassie stained gel bands were excised, washed, and incubated overnight with 
trypsin. Peptides were extracted and separated on a nanoLC system, which was 
attached to a mass spectrometer with a nano flow ionization source attached. MS/MS 
Ion Search was performed for peptide identification. 
 
2.2.2.9 RNase A treatment 
HeLa cell extracts were subjected to immunoprecipitation of endogenous RNMT and 
RAM as described previously. After washing the beads 100 μg/ml RNAse A in 400 μl 
NEB2 buffer were added to the beads for 60 min at 4ºC. Beads were subsequently 
washed three more times with F buffer and resuspended in 1x Laemmli buffer. The 
sample was boiled for 5 min and analysed by SDS-PAGE followed by western blot. 
To control for RNAse A activity 10 μg total RNA was digested with 100 μg/ml RNAse 
A in 40 μl NEB2 buffer for 60 min at 4ºC. The reaction products were analysed by 1% 
denaturing agarose gel stained by ethidium bromide [Figure: 3.6(b)].  
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2.2.2.10 Gel filtration of mammalian extracts 
HeLa cells were resuspended in buffer A and passed through a 20G needle 20 times, 
subjected to three freeze-thaw cycles in a dry ice/isopropanol bath, and centrifuged 
at 14,000 g for 10 min at 4ºC. The supernatant was centrifuged at 100,000 g for a 
further 60 min at 4ºC. 1 mg cell extract was resolved on a Superdex s200 10/30 HR 
column (Pharmacia) in 50 mM Tris-HCl (pH 8.0), 6 mM KCl, and 1.25 mM MgCl2, 
using an AKTA FPLC (Pharmacia). 1 μg of recombinant monomeric RNMT and RAM 
as well as 1:2 mixture of recombinant RNMT and RAM were also analysed by 
Superdex s200 in the same buffer in order to compare the migration of cellular with 
recombinant proteins. Following void volume, 0.5 ml fractions were collected, 
combined with Laemmli buffer and analysed by SDS-PAGE followed by western blot 
(Figure: 3.7). 
 
2.2.2.11 Immunofluorescence 
Cells were grown on coverslips prior to treatment. All incubations were performed in 
0.2% BSA/PBS at room temperature unless stated. Cells were fixed in 4% 
paraformaldehyde for 10 min, blocked with 10% donkey serum for 20 min, and 
incubated in 20 μg/ml polyclonal sheep anti-RAM or 0.3 μg/ml polyclonal sheep 
RNMT antibodies for 1 hr, then washed and incubated with 4 mg/ml Alexa Fluor 488-
conjugated Donkey Anti-Sheep antibodies for 45 min. Cells were counterstained with 
1 mg/ml DAPI (4ʼ,6-diamidino-2-phenylindole), mounted in 2.5% hydromount, and 
visualized by fluorescence microscopy (Zeiss LSM 700) (Figure: 4.5). 
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2.2.2.12 Proteasome inhibitor treatment 
10 μM MG132 and 20 μM clasto-Lactacystin β-Lactone were added to the cell media 
10 hrs prior lysis. Cells were lysed and analysed by SDS-PAGE followed by western 
blot. 
 
2.2.2.13 Orthophosphate labelling 
HEK-293 cells were transiently transfected with pcDNA5-Fg-RAM and pcDNA5-HA-
RNMT using calcium phosphate. 45 hrs later the cells were washed twice with PBS 
and starved with sodium-phosphate-deficient DMEM for 4 hrs and labelled with 0.15 
mCi orthophosphate for 2 hrs at 37 oC. Cells were lysed with F buffer and 5 mg cell 
extracts were subjected to immunoprecipitation with 5 μg anti-Flag antibodies 
conjugated to agarose for 4 hrs at 4ºC. Immunoprecipitates were washed 3 times 
with F buffer and resuspended in 1x Laemmli buffer. The sample was boiled for 5 min 
and analysed by SDS-PAGE followed by western blot (5% of the sample) or 
autoradiography (50% of the sample) visualized by phosphoimaging (Molecular 
Dynamics) [Figure: 6.4(d)]. 
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2.2.3 RNA Extraction and Analysis 
2.2.3.1 RNA extraction 
RNA was isolated with Qiagen RNeasy Mini Kit following manufacturerʼs instructions.  
 
2.2.3.2 RT-qPCR 
Complementary DNA (cDNA) was synthesized using 500 ng total RNA and qScript 
cDNA Synthesis Kit (Quanta Bioscience) following manufacturerʼs instruction in a 
final reaction volume of 20 μl using random hexamer primers.  
The cDNA was diluted 100 times in water and 3 μl were subjected to qPCR using 
SYBR GREEN fastmix according to manufacturerʼs instruction. The primers used are 
demonstrated in Table 2.4. qPCR assays were performed on a iQ5 Multicolor Real-
Time PCR Detection System (Bio-Rad). The critical threshold (Ct) values were 
determined and expression values were normalised against the reference gene, 
GAPDH. Melting curves were determined to ensure primer specificity. PCR products 
were sequence verified by University of Dundee Sequencing Service.  
 
2.2.3.3 Immunoprecipitation of methyl-capped mRNAs 
Total RNA was extracted from around 2,000,000 HeLa cells grown in 10 cm plates 
using 1 ml TRIzol reagent. The lysate was left at room temperature for 5 min and 
mixed vigorously with 0.2 ml chloroform. The sample was centrifuged at 14,000 g for 
10 min at 4ºC to allow RNA, DNA and proteins to separate into the aqueous, inter- 
and organic phase respectively. The aqueous phase was transferred to a new tube, 
combined with 0.5 ml isopropanol and incubated at room temperature for 10 min to 
precipitate RNA, which was pelleted by centrifugation at 14,000 g for 10 min at 4ºC. 
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The RNA pellet was washed with 1 ml 70% ethanol, allowed to dry at room 
temperature for 10 min and resuspended in 50 μl DEPC-treated water.  
mRNA was purified from 100 μg of total RNA using standard laboratory protocol. 10 
μl purified anti-m7G antibody or control antibody was pre-bound to 25 μl Protein A/G 
agarose in PBS, 0.01% Triton, 0.1 mg/ml BSA, 0.1 mg/ml polyU and 1 mM DTT for 
30 min at room temperature followed by two washes. Immunoprecipitations (IPs) 
were carried out using 2 μg oligo dT-purified RNA in 200 μl of the same buffer 
complemented with 5 U RNasin for 1 hr at room temperature followed by three 
washes. Input RNA was incubated under the same conditions as the 
immunoprecipitations. RNA was purified from the IPs and inputs by 
phenol/chloroform extraction and precipitated using 1/10th volume of 5 M sodium 
acetate and 4 μg tRNA as a carrier. RNA was resuspended in 50 μl DEPC-treated 
water. RT-qPCR was performed to detect the methyl-cap transcript levels of c-Myc, 
GAPDH, Cyclin D1 and RuvBL1 relative to input levels [Figure: 4.8(c), 4.9(c)].  
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2.2.4 Biochemical Assays 
2.2.4.1 Phenol/chloroform extraction 
Phenol/chloroform extraction was performed to remove any contaminating proteins 
from RNA samples. An equal volume of phenol/chloroform was added to the nucleic 
acid solution and mixed by vortexing until an emulsion formed. The aqueous and 
organic layers were separated by centrifugation at 14,000 g for 10 min at 4ºC. The 
aqueous phase was transferred to a new tube and combined with 1/10 volume of 5 M 
ammonium acetate and two volumes of 100 % ethanol. The solution was incubated 
at -20oC overnight. The precipitate was pelleted by centrifugation at 16,000 g for 60 
min at 4ºC. The pellet was washed with 70 % ethanol to remove excess salt and 
allowed to dry for 10 min before resuspending in 50 μl distilled water.  
 
2.2.4.2 RNA band-shift assay 
55 nt transcripts were in vitro transcribed using 20 U T7 RNA polymerase according 
to manufacturerʼs instructions. Briefly, 500 ng EcoRI linearized pGEM-CEM4 DNA 
was used as a template in a 50 μl transcription reaction containing DEPC water, 250 
μM rATP, rCTP, rUTP, 12.5 μM rGTP, 1 mM cap analogue, 10 mM DTT, 20 U 
RNAsin and labeled with [α-32P]-GTP (3000 Ci/mmol) for 2 hrs at 37ºC. Radiolabelled 
transcripts were purified by phenol/chloroform extraction and resuspended in 50 μl 
DEPC-treated water. 
1/50 purified transcripts were incubated with 0.5–2 pmol recombinant RAM and/or 2 
pmol RNMT in RB assay buffer for 1 hr at 4ºC in 10 μl reaction. Complexes were 
resolved at 4ºC by native PAGE [4.5% acrylamide, 25 mM Tris (pH 8.3), 190 mM 
glycine, 1 mM EDTA, and 0.1% Triton X-100]. The gel was dried and visualized by 
phosphoimaging (Molecular Dynamics). When relevant, 700 ng affinity-purified anti-
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RAM, RNMT, and GST sheep antibodies were incubated with complexes 15 min prior 
to PAGE resolution. 
 
2.2.4.3 In vitro cap methyltransferase activity assay 
55 nucleotide long transcripts were in vitro transcribed using 20 U T7 RNA 
polymerase according to manufacturerʼs instructions. Briefly, 500 ng EcoRI linearized 
pGEM-CEM4 were in vitro transcribed in the presence of Promega transcription 
buffer, 250 μM rNTPs, 20 U RNasin, for 2 hrs at 37ºC. Transcripts were purified by 
phenol/chloroform extraction. 
200 ng in vitro transcribed RNA were capped in 20 μl volume with 10 μCi [α-32P]-GTP 
in the prescence of 2 μg recombinant RNGTT (capping enzyme) and 40 U RNasin in 
Promega buffer for 1 hr at 37ºC. In vitro capped RNA was purified by 
phenol/chloroform extraction. The pelleted RNA was resuspended in 50 μl DEPC-
treated water. 
For the in vitro cap methylation assay the indicated amount of recombinant RNMT 
and RAM proteins or 1 μg total cell extracts were combined with 200 μM S-adenosyl-
methionine and 1/50 purified capped transcripts in MT assay buffer in a final volume 
of 10 μl and incubated at 37ºC for 10 min unless indicated differently. Following the 
reaction, RNA was purified by phenol/chloroform extraction. The pelleted RNA was 
resuspended in 4 μl of 50 mM sodium acetate (pH 5.5) and incubated with 1 U P1 
nuclease for 60 min at 37ºC to release free GpppG or m7GpppG. Cap structures 
were resolved by thin layer chromatography using PEI (polyethylenimine) cellulose 
plates and 0.4 M ammonium sulfate as solvent. Labelled GpppG and m7GpppG 
spots were visualized and quantified by autoradiography [Figures: 4.2, 4.3(b), 4.8(b), 
4.9(b)].  
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2.2.4.4 In vitro pull down assays 
For RNMT precipitation, 10 μg of either recombinant GST-RAM or GST bound to 
glutathione-sepharose was rotated with 1 μg recombinant RNMT in 500 μl F buffer 
for 2 hrs at 4ºC. Glutathione-sepharose was recovered by centrifugation and washed 
four times in F buffer. Proteins were eluted using Laemmli buffer, boiled for 5 min and 
analysed by SDS-PAGE followed by Western blot. 
For RAM precipitation, 10 μg recombinant GST-RNMT bound to glutathione-
sepharose were combined with 500 μl F buffer and a titration of recombinant RAM 
WT or K10N mutant protein (10 ng, 100 ng or 1 μg). Samples were incubated for 1 
min, 10 min, 1 hr or 4 hrs at 4ºC. Sepharose was pelleted, washed four times with F 
buffer and resuspended in 1x Laemmli buffer. The samples were boiled for 5 min and 
analysed by SDS-PAGE followed by western blot (Figures: 3.4, 6.9).  
 
2.2.4.5 In vitro sumoylation 
Recombinant SUMO1, SUMO2, E1-SAE1/2 and Ubc9 proteins were kindly provided 
by Ron Hayʼs lab, University of Dundee. In a total final volume of 10 μl, 3 μg protein 
substrate (recombinant RNMT, RAM WT, RAM K10N or RNMT/RAM complex) were 
incubated with 0.1 μg E1-SAE enzyme, 0.75 μg Ubc9 and 3 μg SUMO1 or SUMO2 
in the presence of 50 mM Tris (pH 7.5), 5 mM MgCl2, 5 mM ATP and water. The 
samples were incubated at 37ºC for the time points indicated in the figures, combined 
with Laemmli buffer, boiled for 2 min and analysed by SDS-PAGE followed by 
Coomassie staining or western blot (Figures: 6.7, 6.8).   
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2.2.5 Recombinant Protein Production 
2.2.5.1 Preparation of RAM truncation mutants fused N-terminally to 
GST 
pGEX-6P1-based vectors, expressing truncated RAM proteins (RAM WT, RAM 1-55, 
RAM 56-118, RAM 1-90, RAM 91-118) fused N-terminally to a GST tag, were 
transduced into BL21 (DE3) E. coli. Single transformants were expanded to a 1 L 
culture. When culture absorbance at 600 nm was 0.6, expression of recombinant 
protein was induced with 0.5 M IPTG (isopropyl-β-D-thiogalactopyranoside) at 25ºC 
for 16 hrs.  Cells were harvested by centrifugation, resuspended in 15 ml lysis buffer 
[50 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 
0.1% beta-mercaptoethanol, 0.2 mM PMSF, 1 mM benzamidine, 100 μg/ml leupeptin, 
1mg/ml lysozyme] and sonicated on ice six times for 30 sec. Insoluble material was 
removed by centrifugation for 20 min at 40,000 g. 1 ml glutathione-sepharose resin 
was incubated with the soluble material for 1 hr, washed five times in wash buffer [50 
mM Tris (pH 7.5), 150 mM NaCl, 0.01% Triton X-100, 0.1% beta-mercaptoethanol, 
0.2 mM PMSF, 1 mM benzamidine, 100 μg/ml Leupeptin] and protein was eluted in 
5ml wash buffer supplemented with 50 mM glutathione. The recombinant proteins 
were resolved by SDS-PAGE and exploited for RNA band shift assays and in vitro 
cap methylation assays (Figures: 4.3, 4.4).  
 
2.2.5.2 Preparation of recombinant GST-RAM and GST-RNMT bound 
to glutathione-sepharose 
pGEX-6P1-based vectors, expressing RAM or RNMT fused N-terminally to a GST 
tag, were transduced into BL21 (DE3) E. coli. Single transformants were expanded to 
a 1 L culture. When culture absorbance at 600 nm was 0.6, expression of 
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recombinant protein was induced with 1 M IPTG (isopropyl-β-D-
thiogalactopyranoside) for 18 hrs at 15ºC.  Cells were harvested by centrifugation, 
resuspended in 15 ml lysis buffer [50 mM Hepes (pH 7.5), 250 mM NaCl, 0.1% beta-
mercaptoethanol, 1 mM benzamidine, 100 μg/ml leupeptin, 1 mg/ml lysozyme] and 
sonicated six times on ice for 30 sec. Insoluble material was removed by 
centrifugation for 20 min at 60,000 g. 1 ml glutathione-sepharose resin was incubated 
with the soluble material for 1 hr and washed in 25 ml wash buffer [50 mM Hepes (pH 
7.5), 250 mM NaCl, 0.1% beta-mercaptoethanol]. GST-RNMT (Figure 6.4a) or GST-
RAM (Figure 3.4a) fused to glutathione-sepharose was used for in vitro pull down 
assays (Figures: 3.4, 6.5).  
 
2.2.5.3 Preparation of recombinant RNMT/RAM complex for 
biochemical assays 
pOPC bicistronic vector, expressing RAM 1-90 fused N-terminally to a GST tag and 
untagged full length RNMT, were transduced into BL21 (DE3) E. coli. Single 
transformants were expanded to a 1 L culture. When culture absorbance at 600 nm 
was 0.6, expression of recombinant protein was induced with 1 M IPTG (isopropyl-β-
D-thiogalactopyranoside) for 18 hrs at 15ºC.  Cells were harvested by centrifugation, 
resuspended in 25 ml lysis buffer [50 mM Hepes (pH 7.5), 250 mM NaCl, 0.1% beta-
mercaptoethanol, 1 mM benzamidine, 100 μg/ml leupeptin, 1 mg/ml lysozyme] and 
sonicated six times on ice for 30 sec. Insoluble material was removed by 
centrifugation for 20 min at 60,000 g. 1 ml glutathione-sepharose resin was incubated 
with the soluble material for 2 hrs and washed five times in wash buffer [50 mM 
Hepes (pH 7.5), 250 mM NaCl, 0.1% beta-mercaptoethanol]. GST tag was removed 
by incubating glutathione-sepharose overnight in wash buffer containing 200 μg of 
prescission protease. The flow-through was collected and analysed by SDS-PAGE 
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followed by Coomassie staining (Figure 6.4b). The recombinant complex was used 
for in vitro sumoylation assay (Figures: 6.9).  
 
2.2.5.4 Preparation of recombinant RAM WT and RAM K10N  
pGEX-6P1-based vectors, expressing RAM 1-90 WT and RAM 1-90 K10N  fused N-
terminally to a GST-tag, were transduced into BL21 (DE3) E. coli. Single 
transformants were expanded to a 2 L Luria Bertani broth culture. When culture 
optical absorbance at 600 nm was 0.6, expression of recombinant proteins were 
induced with 0.5 M IPTG (isopropyl-β-D-thiogalactopyranoside) for 18 hrs at 15ºC. 
Cells were harvested by centrifugation at 4,000 g for 20 min, resuspended in 25 ml 
lysis buffer [50 mM Hepes (pH 7.5), 250 mM NaCl, 0.1% beta-mercaptoethanol, 1 
mM benzamidine, 100 μg/ml leupeptin, 1 mg/ml lysozyme] and sonicated six times 
on ice for 30 sec. Insoluble material was removed by centrifugation for 30 min at 
60,000 g. 1 ml glutathione-sepharose resin was incubated with the soluble material 
for 90 min. The sepharose was subsequently washed in 50 ml wash buffer [50 mM 
Hepes (pH 7.5), 250 mM NaCl, 0.1% beta-mercaptoethanol].  
For RAM 1-90 WT and RAM 1-90 K10N elutions, the glutathione-sepharose was 
incubated for 16 hrs at 4ºC in 5 ml of a buffer containing 25 mM Hepes (pH 7.5), 250 
mM NaCl, 0.1% beta-mercaptoethanol and 0.2 mg PreScission protease. The 
PreScission protease cleaved GST-tag, which remained on the beads, while RAM 1-
90 WT or K10N were eluted in the buffer. The protein samples were cleared by 
centrifugation at 4,000 g for 15 min. The protein yield obtain from the GST-
purification was 10 mg for both RAM 1-90 WT and K10N. Analysis of the cell lysates 
before and after the affinity purification as well as the cleaved purified RAM 1-90 WT 
and K10N is demonstrated in a coomassie stained SDS-PAGE (Figure 6.4c). 
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RAM 1-90 WT and RAM 1-90 K10N were further purified by size exclusion 
chromatography. 1 ml of the purified samples was injected onto a gel filtration 
Superdex 200 10/30 column (GE Healthcare) operating in an AKTA FPLC 
(Pharmacia) with a flow rate of 0.4 ml/min and equilibrated in 25 mM Tris (pH 7.5), 
150 mM NaCl buffer. 0.5 ml fractions were collected. The elution profiles are 
demonstrated in Figure 6.4d and analysis of the peak fractions by coomassie stained 
SDS-PAGE is presented in Figure 6.4e. Fractions C5-C7 were combined and 
concentrated to a final concentration 1 mg/ml.  
 
2.2.5.5 Preparation of recombinant RAM for crystallographic studies 
See chapter 5 pages; Figure 5.1  
 
2.2.5.6 Preparation of recombinant RNMT / RAM complex for 
crystallographic studies 
See chapter 5 pages; Figure 5.2  
 
2.2.5.7 Preparation of recombinant HIS-RNMT / GST-RAM complex  
See chapter 5 pages; Figure 5.3  
 
2.2.5.8 Preparation of recombinant RNMT for biochemical assays 
See chapter 5; Figure 5.4  
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2.2.6 Cloning Methodology 
 
All constructs prepared for this study are presented in Table 2.11. 
 
2.2.6.1 Polymerase chain reaction (PCR) 
DNA was amplified using polymerase chain reaction (PCR) from cDNA or vector 
templates using Expand High Fidelity PCR System (Roche) according to 
manufacturerʼs instruction. Briefly, 100 ng vector or 1 μg cDNA template DNA was 
combined with a 100 μl reaction mixture containing 1x High Fidelity PCR System 
buffer supplemented with 1.5 mM MgCl2, 200 μM dNTPs, 0.5 μM of each primer 
(Table 2.2) and 5 U of high fidelity DNA polymerase. Reactions were performed in a 
DNA Engine Dyad Peltier Thermal Cycler (Bio-Rad) PCR machine. DNA was first 
denatured at 95ºC for 2 min before entering a cycle of denaturation at 95ºC for 30 
sec, annealing at 52ºC for 30 sec and extension at 72ºC for 40 sec (for RAM cloning) 
or 90 sec (for RNMT cloning). After a total of 30 cycles the reaction entered a final 
extension phase at 72ºC for 2 min. Products were purified with a PCR purification kit. 
 
2.2.6.2 Site-directed mutagenesis 
DNA vectors were subjected to site directed mutagenesis using QuickChange site-
directed mutagenesis kit (Stratagene) according to manufacturerʼs instruction. Briefly, 
20 ng plasmid DNA was combined with a 50 μl reaction mixture containing 1x site-
direceted mutagenesis buffer, 200 μM dNTPs, 0.5 μM of each primer (Table 2.3) and 
5 U of high fidelity DNA polymerase. Reactions were performed in a DNA Engine 
Dyad Peltier Thermal Cycler (Bio-Rad) PCR machine. DNA was first denatured at 
95ºC for 2 min before entering a cycle of denaturation at 95ºC for 30 sec, annealing 
at 52ºC for 30 sec and extension at 72ºC for 7 min. After a total of 18 cycles the 
reaction entered a final extension phase at 72ºC for 5 min. The original plasmid 
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derived from bacteria source was digested by the addition of 2 U DpnI to the PCR 
products and incubation for 1 hr at 37ºC. Products were purified with a PCR 
purification kit and used for E. coli cell transformation. 
 
2.2.6.3 PCR purification  
PCR products were purified using QIAquick PCR Purification Kit (Qiagen) according 
to manufacturerʼs instruction. DNA was eluted in 50 μl distilled water. 
 
2.2.6.4 Restriction enzymes digestion 
Restriction digests of DNA were performed with restriction enzymes using the buffers 
recommended by the manufacturer (NEB). Typically, 50 μl reaction volume 
containing two different restriction enzymes and 1x NEB buffer compatible for both 
enzymes was incubated for 4 hrs at 37ºC. For the backbone vector DNA digestion, 
after 3 hrs digestion, 1 μl CIP alkaline phosphatase was added to the reaction 
mixture in order to dephosphorylate 5ʼ-phosphate ends created by the restriction 
digestion and reduce “self-ligation” of vector during cloning. Digestion products were 
analysed by agarose gel electrophoresis and purified using gel extraction kit.  
 
2.2.6.5 Agarose gel electrophoresis 
Linear double stranded DNA molecules were separated according to their molecular 
weight by agarose gel electrophoresis. Typically, 1% (w/v) agarose was melted in 1x 
TAE buffer and cast in a gel tray after addition of 0.1% gel red. DNA samples were 
combined with 5x Green GoTaq reaction buffer as loading dye. Electrophoresis was 
performed in Mini-Sub Cell GT Cell (Bio-Rad) in 1x TAE buffer at 120 V for 
approximately 40 min. DNA was visualised with a UV transilluminator, extracted and 
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purified by QIAquick Gel Extraction Kit (Qiagen) according to manufacturerʼs 
instructions. DNA was typically eluted in 40 μl distilled water. 
 
2.2.6.6 Ligation 
After restriction enzyme digestion and gel extraction of the DNA, vector and insert 
DNA were ligated using T4 DNA ligase according to manufacturerʼs instruction. In 
general, 10 μl ligation reaction containing 1x T4 ligase buffer and 1 U T4 DNA ligase 
were incubated for 1 hr at room temperature. 5 μl of the reaction were used to 
transform competent DH5α E. coli cells.  
 
2.2.6.7 Transformation of E. coli cells with plasmids 
30 μl competent E. coli cells (Table 2.10) were incubated with 200 ng DNA or 5 μl 
ligation reaction mixture for 20 min on ice. The cells were heated for 1 at 45ºC min 
and incubated for 2 min on ice. The bacteria were plated on selective LB agar plates 
containing the appropriate antibiotic (50 μg/ml ampicillin, 50 μg/ml kanamycin, 50 
μg/ml chloramphenicol) and incubated overnight at 37ºC. In case of kanamycin 
selection the bacteria were incubated in SOC media for 1 hr at 37ºC before plating. 
 
Table 2.10: E. coli strains and their genotype used in this study. 
Bacterial Strain Genotype 
DH5α 
Fʼ φ80dlacZΔΜ15 Δ(lacZYA-argF) U169 deoR recA1 
endA1 hsdR17 phoA supE44 λ- thi-1 gyrA96 reA1 
BL21 (DE3) B F- ompT hsdS(rB-mB-) dcm+ Tetr gal endA 
BL21 CodonPlus (DE3)-RIL 
B F- ompT hsdS(rB-mB-) dcm+ Tetr gal endA Hte [argU 
ileY leuW Camr] 
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2.2.6.8 Plasmid preparation 
Plasmid DNA was purified from DH5α E. coli cells growing overnight at 37ºC. DNA 
QIAprep Miniprep Kit (Qiagen) was used to purify 5-10 μg DNA eluted in 50 μl 
distilled water according to manufacturerʼs instructions.  
To produce large amount of plasmids DNA Maxi Kit (Qiagen) was used according to 
manufacturerʼs instructions. Typically 500-1000 μg DNA were resuspended in 1 ml 
distilled water. 
 
Table 2.11: Constructs generated for the purpose of this study. A short description of the 
generation method is indicated.  
Construct 
Generated 
Vector 
Backbone 
Generation Method 
RAM WT pGEX-6P-1 
RAM was amplified from cDNA derived from 
HeLa cells by PCR using primers described in 
Table 2.2. BamHI and XhoI restriction enzymes 
in NEB 2 buffer were used for double digestion of 
vector and insert. 
RAM 1-90 pGEX-6P-1 
RAM 1-90 was amplified from pGEX-6p-1-RAM 
WT construct by PCR using primers described in 
Table 2.2. BamHI and XhoI restriction enzymes 
in NEB 2 buffer were used for double digestion of 
vector and insert. 
RAM 1-90 
K10N 
pGEX-6P-1 
Site-directed mutagenesis (see primers at Table 
2.3) using pGEX-6P-1-RAM 1-90 as template. 
RAM 1-55 pGEX-6P-1 
RAM 1-55 was amplified from pGEX-6p-1-RAM 
WT construct by PCR using primers described in 
Table 2.2. BamHI and XhoI restriction enzymes 
in NEB 2 buffer were used for double digestion of 
vector and insert. 
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RAM 91-118 pGEX-6P-1 
RAM 91-118 was amplified from pGEX-6p-1-
RAM WT construct by PCR using primers 
described in Table 2.2. BamHI and XhoI 
restriction enzymes in NEB 2 buffer were used 
for double digestion of vector and insert. 
RAM 56-118 pGEX-6P-1 
RAM 56-118 was amplified from pGEX-6p-1-
RAM WT construct by PCR using primers 
described in Table 2.2. BamHI and XhoI 
restriction enzymes in NEB 2 buffer were used 
for double digestion of vector and insert. 
6xHIS-RNMT 
165-476 / RAM 1-
90 
pOPC 
bicistronic 
RNMT 165-476 and RAM 1-90 were amplified 
from pGEX-6p-1-RNMT and pGEX-6p-1-RAM 
WT constructs respectively by PCR using 
primers described in Table 2.2. NdeI and BamHI 
restriction enzymes in NEB 2 buffer were used 
for double digestion of inserts and intermediate 
vectors (pOPT for RAM and pOPH for RNMT). 
RAM and RNMT were subsequently double 
digested from pOPT and pOPH with XbaI/BamHI 
or SacI/KpnI respectively and ligated to pOPC 
that was digested with the same enzymes. 
GST-RAM 1-90 / 
6xHIS-RNMT full 
lenght  
pOPC 
bicistronic 
RAM 1-90 and RNMT were amplified from 
pGEX-6p-1-RAM WT and pGEX-6p-1-RNMT 
constructs respectively by PCR using primers 
described in Table 2.2. NdeI and BamHI 
restriction enzymes in NEB 2 buffer were used 
for double digestion of inserts and intermediate 
vectors (pOPG for RAM and pOPH for RNMT). 
RAM and RNMT were subsequently double 
digested from pOPG and pOPH with XbaI/BamHI 
or SacI/KpnI respectively and ligated to pOPC 
that was digested with the same enzymes. 
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RAM WT pEGFP-N3 
RAM was amplified from pGEX-6p-1-RAM WT 
construct by PCR using primers described in 
Table 2.2. XhoI and BamHI restriction enzymes 
in NEB 2 buffer were used for double digestion of 
vector and insert. 
RAM 1-90 pEGFP-N3 
RAM 1-90 was amplified from pGEX-6p-1-RAM 
WT construct by PCR using primers described in 
Table 2.2. XhoI and BamHI restriction enzymes 
in NEB 2 buffer were used for double digestion of 
vector and insert. 
RAM 1-55 pEGFP-N3 
RAM 1-55 was amplified from pGEX-6p-1-RAM 
WT construct by PCR using primers described in 
Table 2.2. XhoI and BamHI restriction enzymes 
in NEB 2 buffer were used for double digestion of 
vector and insert. 
RAM 91-118 pEGFP-N3 
RAM 91-118 was amplified from pGEX-6p-1-
RAM WT construct by PCR using primers 
described in Table 2.2. XhoI and BamHI 
restriction enzymes in NEB 2 buffer were used 
for double digestion of vector and insert. 
RAM 56-118 pEGFP-N3 
RAM 56-118 was amplified from pGEX-6p-1-
RAM WT construct by PCR using primers 
described at Table 2.2. XhoI and BamHI 
restriction enzymes in NEB 2 buffer were used 
for double digestion of vector and insert. 
HA-RNMT 1-120 pcDNA5 
HA-RNMT was amplified from pGEX-6p-1-RNMT 
construct by PCR using primers described at 
Table 2.2. BamHI and XhoI restriction enzymes 
in NEB 2 buffer were used for double digestion of 
vector and insert. 
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HA-RNMT 121-
476 
pcDNA5 
HA-RNMT 121-476 was amplified from pGEX-
6p-1-RNMT construct by PCR using primers 
described at Table 2.2. BamHI and XhoI 
restriction enzymes in NEB 2 buffer were used 
for double digestion of vector and insert. 
Fg-RAM WT pcDNA5 
Fg-RAM was amplified from cDNA derived from 
HeLa cells by PCR using primers described at 
Table 2.2. BamHI and NotI restriction enzymes 
in NEB 3 buffer were used for double digestion of 
vector and insert. 
HA-RAM WT pcDNA5 
HA-RAM was amplified from cDNA derived from 
HeLa cells by PCR using primers described at 
Table 2.2. BamHI and NotI restriction enzymes 
in NEB 3 buffer were used for double digestion of 
vector and insert. 
Fg-RAM K10N pcDNA5 
Fg-RAM K10N was amplified from cDNA derived 
from HeLa cells by PCR using primers described 
in Table 2.2. BamHI and NotI restriction 
enzymes in NEB 3 buffer were used for double 
digestion of vector and insert. 
Fg-RAM S36A pcDNA5 
Site-directed mutagenesis (see primers at Table 
2.3) using pcDNA5-Fg-RAM WT as template. 
Fg-RAM WT 
WBL 
pcDNA5 
Site-directed mutagenesis (see primers at Table 
2.3) using pcDNA5-Fg-RAM WT as template. 
Fg-RAM K10N 
WBL 
pcDNA5 
Site-directed mutagenesis (see primers at Table 
2.3) using pcDNA5-Fg-RAM WT as template. 
GFP pcDNA5 
GFP was digested out from pEGPN3 with EcoRI 
and NotI in NEB 3 and ligated to pcDNA4 
digested with the same enzymes. Subsequently, 
pcDNA4-GFP was digested with BamHI and 
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EcoRI in NEB 3 and GFP was ligated to pcDNA5 
digested with the same enzymes. 
RAM WT GFP pcDNA5 
RAM was digested out from pEGPN3 with EcoRI 
and BamHI in NEB 3 and ligated to pcDNA4-
GFP that was digested with the same enzymes.  
Subsequently, pcDNA4-RAM GFP was digested 
with BamHI and NotI in NEB 3 and RAM GFP 
was ligated to pcDNA5 digested with the same 
enzymes. 
RAM K10N GFP pcDNA5 
Site-directed mutagenesis (see primers at Table 
2.3) using pcDNA5- RAM WT GFP as template. 
RAM S36A GFP pcDNA5 
Site-directed mutagenesis (see primers at Table 
2.3) using pcDNA5- RAM WT GFP as template. 
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Chapter 3:  Identification of FAM103A1/ RAM 
as an RNMT Binding Protein 
3.1 Introduction 
The RNA N-7 methylguanosine cap is a modification of the 5ʼ end of all functional 
eukaryotic mRNAs with implications in all steps of gene expression including 
transcription, splicing, nuclear export of the mRNA, mRNA decay and silencing as 
well as mRNA translation. Two essential enzymes are responsible for N-7 
methylguanosine cap formation in mammalian cells, the capping enzyme, RNGTT, 
that adds the reverse guanosine group (also called cap) to the nascent pre-mRNA 
and the RNA guanine-7 methyltransferase, RNMT, that methylates the cap at the N-7 
position (Cowling, 2010c). 
Several groups have demonstrated recently that methyl-cap formation is a regulated 
process within cells. Recent studies have demonstrated that a subpopulation of 
mRNA possesses unmethylated guanosine cap at its 5ʼ end (Chang et al., 2012). 
Furthermore, glucose starvation and amino acids deprivation reduces the synthesis 
of methyl-cap transcript levels in budding yeasts (Jiao et al., 2010). In addition, over-
expression of transcription factors such as E2F1 and c-Myc, induce synthesis of N-7 
methylguanosine capped transcript levels in human cells (Cowling and Cole, 2007; 
Cole and Cowling, 2009; Fernandez-Sanchez et al., 2009). Interestingly, inhibition of 
cap-methylation is synthetic lethal with elevated c-Myc expression and abolishes 
Myc-induced protein synthesis, cell proliferation and cell transformation (Fernandez-
Sanchez et al., 2009). Although methyl-cap formation is a critical step for gene 
expression and has been associated with Myc-induced tumourigenic activity, the 
exact molecular details of its formation in mammalian cells are yet to be determined.  
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RNMT has been demonstrated to interact with the Importin-α (Wen and Shatkin, 
2000), the RNA polymerase II and the capping enzyme (Pillutla et al., 1998b; Shafer 
et al., 2005) but none of the above interactions have been validated by endogenous 
proteins. In order to gain better understanding of the mechanistic details of RNA 
guanine-7 methylation we decided to investigate RNMT interactome attempting to 
identify the RNMT binding proteins. In addition, identification of RNMT interactome 
could provide information of how RNA cap methyltransferase activity is regulated 
within cells.  
  
 126 
3.2 Results 
3.2.1 Optimisation of RNMT immunoprecipitation 
In order to purify RNMT complexes from human cells and identify novel RNMT 
binding proteins an unbiased biochemical approach was used. HEK-293 (Human 
Embryonic Kidney) cells, stably expressing Haemagglutinin tagged RNMT (HA-
RNMT) or vector control, were generated using a retroviral infection method (Figure 
3.1a). Briefly, HEK-293 cells were transduced with retroviruses derived from virus 
packaging cells transfected with a retrovirus construct expressing HA-RNMT or 
vector control. The reasons HEK-293 cells were chosen was their rapid proliferation 
rates and the high yield of protein production they exhibit. The expression level of 
HA-RNMT was equivalent with endogenous RNMT as indicated by western blot 
analysis for RNMT detection (Figure 3.1a). This was desirable considering that 
overexpression of proteins can lead to identification of false-positive binding partners.  
Firstly, the conditions of RNMT immunoprecipitation were optimised. Endogenous 
and HA-RNMT were immunoprecipitated from HEK-293 cells stably expressing HA-
RNMT or vector control. The conditions for exogenous and endogenous RNMT 
immunoprecipitation were determined using either polyclonal antibodies raised in 
house against RNMT or a monoclonal antibody that recognises the HA-tag of the 
fusion protein. Previous studies had shown that the α-RNMT antibodies were specific 
for RNMT (Cowling, 2010a), (see also Figure 4.5). HA-RNMT was 
immunoprecipitated equivalently either by α-RNMT or by α-HA antibodies but not 
when negative control α-Tubilin antibodies were used (Figure 3.1b). 
As shown in Figure 3.1b both α-RNMT and α-HA antibodies are able to yield similar 
amount of immunoprecipitated RNMT. Therefore, α-HA antibody was employed for 
 127 
the immunoprecipitation experiments so that cells stably expressing vector control 
could be used as a negative control to detect non-specific binding proteins.  
The immunoprecipitation conditions were further optimised, by determining the 
amount of HA-RNMT remaining in the immunodepleted extracts after α-HA 
immunoprecipitation. As Figure 3.1c illustrates most of the HA-RNMT present in cell 
extracts was efficiently immunoprecipitated and consequently not detected in the 
immunodepleted extracts suggesting that the amount of α-HA antibody used was 
sufficient for efficient HA-RNMT immunoprecipitation.  
In order to identify novel RNMT binding proteins a large scale immunoprecipitation of 
HA-RNMT was performed (Figure 3.2a). RNMT was purified from HEK-293 lysates in 
non-denaturing conditions using α-HA antibody. Immunoprecipitates were analysed 
by Coomassie stained SDS-polyacrylamide gel. Together with HA-RNMT, two 
additional polypeptides were co-purified with molecular masses of around 70,000 and 
15,000 Daltons. These bands together with the equivalent parts of the gel in the 
vector control lane were excised and subjected to mass spectrometry analysis. 
HSPA1 and FAM103A1 were identified as proteins co-purified with RNMT, which 
were not detected in the vector control sample. The peptides of HSPA1 and 
FAM103A1 identified by mass spectrometry are presented in Figure 3.2b.  
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Figure 3.1: Optimisation of RNMT immunoprecipitation.  
(a) RNMT was detected by western blot in extracts from HEK-293 cell lines stably 
expressing HA-RNMT or vector control (Vec). The migration of endogenous RNMT 
and HA-RNMT is indicated. Western blots with anti-HA antibodies (HA) were 
performed to detect HA-RNMT. β-Tubulin (Tub) was detected as loading control.  
(b-c) Western blot analysis of immunoprecipitates from HEK-293 cells stably 
expressing HA-RNMT or vector control (Vec).  
(b) Immunoprecipitations were performed with 1.5 mg of cell extracts using 1 µg of 
the indicated antibodies. Western blot analysis was performed to detect RNMT 
and HA-tag in inputs (Inp) and immunoprecipitates (IP).  
(c) Immunoprecipitations were performed with 5 mg of cell extracts using 5 µg 
monoclonal anti-HA antibody conjugated to agarose. Western blot analysis was 
performed in inputs (Inp), immunodepleted extracts (F.T), and immunoprecipitates 
(HA IP) to detect HA-tag.  
The asterisk (*) indicates the cross-reacting heavy chain. 
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RAM Peptides Identified 
by Mass Spectrometry 
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Figure 3.2: HSPA1 and FAM103A1/RAM are found in a complex with RNMT.  
(a) HA-RNMT complexes were isolated from HEK-293 cells stably expressing HA-
RNMT or vector control (Vec). 50 mg of cell extracts were immunoprecipitated with 50 
µg anti-HA antibodies conjugated to agarose. Immunoprecipitates were resolved by 
gradient 4-12% SDS-PAGE and stained by Coomassie blue. Migration of FAM103A1/
RAM, HA-RNMT, HSPA1 as well as antibody heavy chain (HC) and light chain (LC) 
are indicated. 
(b) The excised Coomassie stained gel bands were subjected to mass spectrometry 
analysis. The peptides were analysed by MS/MS Ion search and the indicated 
peptides were identified by Mascot software.  
(c-d) Endogenous RNMT and HSPA1 co-immunoprecipitations. 1 mg of HEK-293 (c) 
and IMEC (d) cell extracts were subjected to immunoprecipitations with 1 µg of the 
indicated antibodies. Western blots were performed to detect RNMT and HSPA1 in 
inputs (Inp) and immunoprecipitates (IP). The asterisk (*) indicates the cross-reacting 
heavy chain. 
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3.2.2 Validation of the interaction between HSPA1 and 
RNMT  
During times of cellular stress like heat shock, HSPA1 expression is induced. HSPA1 
is mainly a cytoplasmic protein but reports have also demonstrated nuclear 
localisation and function of HSPA1 (Maheswaran et al., 1998). During stress HSPA1 
binds to its protein substrates and stabilises them against denaturation and 
aggregation while during normal growth HSPA1 assists the folding of newly 
synthesised proteins, the formation and dissociation of complexes as well as the 
degradation of unwanted proteins (Evans et al., 2010).  
We validated the interaction between RNMT and HSPA1 by immunoprecipitation of 
both endogenous RNMT and HSPA1 followed by western blot. To validate the 
interaction between RNMT and HSPA1 immunoprecipitations of endogenous proteins 
were performed with both HEK-293 and immortalized mammary epithelial (IMEC) cell 
lysates. Antibodies raised in the same species as α-RNMT and α-HSPA1 were used 
for negative control for non-specific binding. As shown in Figure 3.2(c), when RNMT 
was immunoprecipitated HSPA1 was detected in the immunoprecipitates and vice 
versa (Figure 3.2c).  
Although the interaction between RNMT and HSPA1 was validated in two 
independent human cell lines we decided not to pursue the investigation of HSPA1 
effect upon RNMT mainly because of time constraints. Instead, we decided to focus 
on FAM103A1, a protein of unknown function. We designated FAM103A1 as RAM 
(RNMT-activating mini-protein) and for the rest of this thesis FAM103A1 will be 
referred as RAM. 
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3.2.3 Validation of RAM and RNMT interaction 
Homo sapiens RAM consists of 118 amino acids and has molecular mass of 14.3 
kDa. RAM is only present in vertebrates and it is well-conserved in higher eukaryotes, 
having 87% identical amino acid sequence with Mus musculus and 52% with 
Xenopus tropicalis according to BLAST (Basic Local Alignment Search Tool) 
algorithm. Although RAM amino acid sequence has no annotated functional domain 
three distinct domains in H. sapiens RAM were identified according to its amino acid 
sequence (Figure 3.9a). The N-terminal domain of RAM (amino acids 1-55) is 
extremely well conserved among vertebrates as Figure 3.3 indicates. The C-terminal 
domain of RAM (amino acids 91-118) although not as well conserved is highly 
enriched in Glutamine, Tyrosine and Proline amino acids (19 out of the 28 residues in 
H. sapiens). The intermediate domain of RAM (55-90) is enriched in positively 
charged Arginine residues (7 out of 36 residues).  
Firstly, we validated the interaction between RNMT and RAM with recombinant 
proteins. Recombinant untagged RNMT was incubated with recombinant GST-
tagged RAM or GST alone (Figure 3.4a). Complexes were purified by glutathione-
sepharose and analysed by SDS-PAGE followed by western blot (Figure 3.4b). 
RNMT was purified by GST-tagged RAM but not by GST alone suggesting that 
RNMT and RAM interact directly and in the absence of RNA.  
Extensive literature review indicated that RAM had not been investigated previously 
and therefore, there were no available antibodies raised against RAM. The lack of α-
RAM antibodies prevented us from validating the interaction between RAM and 
RNMT with endogenous proteins. Therefore, we raised α-RAM antibodies using 
University of Dundee DSTT (Division of Signal Transduction Therapy) service. Briefly, 
recombinant GST-RAM was injected into a sheep and 20 weeks later blood serum 
was collected and α-RAM antibodies were affinity purified. 
 132 
The specificity of the generated α-RAM antibodies was determined by depleting RAM 
from HeLa cells using siRNA or overexpressing RAM fused N-terminally either to 
FLAG (Fg) or HA-tag. As Figure 3.5 illustrates α-RAM antibodies detected both 
endogenous and overexpressed Fg-RAM and HA-RAM in cell lysates analysed by 
western blot. The quantity of endogenous RAM detected after RAM depletion from 
cells suggests that the protein recognised by α-RAM antibodies corresponds to 
endogenous and overexpressed RAM. This was further demonstrated by 
immunofluorescence analysis as will be described later in chapter 4 (Figure 4.5). 
  
Figure 3.3: Amino acid sequence alignment of the Homo sapiens RAM protein 
and homologs in Mus musculus, Monodelphis domestica, Ornithorhynchus 
anatinus, Tangara guttata, and Xenopus tropicalis.  
The EMBL-EBI ClustalW2 Multiple Alignment software was used for the alignment, 
selecting the default parameters. Amino acids identical in H. sapiens RAM protein 
and at least another species are highlighted in grey, and those identical in all 
species investigated are indicated (*). 
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Figure 3.4: RNMT and RAM interact directly.  
(a) 10 µg of purified recombinant GST-RAM and RNMT were resolved in a 15% 
SDS-PAGE and stained by Coomassie blue. GST-RAM and RNMT are indicated. 
(b) 1 µg recombinant RNMT (input) was mixed with 10 µg GST or GST-RAM and 
affinity purified with glutathione-sepharose. Proteins eluted were separated by 
SDS-PAGE and detected by western blotting for RNMT, RAM, and GST.  
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Figure 3.5: Characterisation of α-RAM antibodies specificity. 
HeLa cells were transfected with RAM siRNA (si RAM1), non-targeting control (si 
con), or transfected with pcDNA5-Fg-RAM, pcDNA5-HA-RAM or vector control 
(Vec). Total cell lysates were analysed by western blot to detect RAM or β-Tubulin 
(Tub) as loading control. 
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3.2.4 Investigation of RAM and RNMT interaction 
The interaction between RNMT and RAM was further validated with endogenous 
proteins in HeLa cells, primary T lymphocytes and SAOS2 cells. After RNMT 
immunoprecipitation RAM was detected in the immunoprecipitates as was 
demonstrated by western blot (Figure 3.6, left panel). In addition, after RAM 
immunoprecipitation, using α-RAM antibodies, RNMT was co-immunoprecipitated 
(Figure 3.6, left panel). When control α-GST antibodies were used neither RAM nor 
RNMT could be detected in the immunoprecipitates.  
It was next investigated whether RNA could mediate the interaction between RAM 
and RNMT. After immunoprecipitation of both RAM and RNMT from HeLa cells the 
immunoprecipitates were treated with RNase with no effect in RAM/RNMT co-
immunoprecipitation (Figure 3.6b) suggesting, that RNA is not mediating the 
interaction between RAM and RNMT. To ensure that the RNase A was working, total 
RNA was digested side by side with the immunoprecipitates. The RNA was 
subsequently analysed by ethidium stained agarose gel. As Figure 3.6c indicates the 
RNase successfully digested the predominant ribosomal RNA species present in the 
total RNA sample.  
In order to determine the relative amount of RAM and RNMT that interact with each 
other we performed immunodepletion studies (Figure 3.6, right panel). α-RNMT 
antibodies were used to deplete RNMT from HeLa, primary T lymphocytes and 
SAOS2 cell extracts that were subsequently analysed by western blot to detect RAM 
and RNMT. As Figure 3.6(a) demonstrates, RAM was depleted from the cell extracts 
together with RNMT. In addition, when α-RAM antibodies were used to deplete RAM 
from the cell extracts RNMT was depleted together with RAM. This was not true 
when α-GST antibodies were used as a negative control.  
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To further validate this finding we performed gel filtration analysis with HeLa cell 
extracts followed by western blot to detect RAM and RNMT. Gel filtration is a 
technique that separates native complexes according to their size. In Figure 3.7, 
upper panels indicate that cellular RAM and RNMT can be detected in the same 
fractions with a peak at fraction number 7 that corresponds complexes with molecular 
mass of 200 kDa. In addition, we analysed recombinant monomeric RNMT and RAM 
(Figure 3.7, middle panel) and recombinant RNMT and RAM in a complex (Figure 3.7, 
lower panel). Monomeric recombinant RNMT has a peak elution at fraction number 
10 that corresponds to 100 kDa molecular mass approximately. Monomeric RAM is 
eluted at fraction 21-22 that corresponds to 10 kDa molecular mass (Figure 3.7, 
middle panel). There is no evidence of any detectable monomeric RNMT or RAM in 
HeLa cell extracts according to the gel filtration analysis (Figure 3.7, upper panel).  
Recombinant RNMT was combined with an excess of recombinant RAM, in order to 
form a complex, prior to gel filtration analysis. The complex had a peak elution at 
fraction number 8 corresponding to 150 kDa molecular mass (Figure 3.7, lower 
panel). Cellular RAM/RNMT complexes migrate in larger molecular mass fractions 
than the recombinant one, indicating that cellular RNMT and RAM complex may 
contain additional proteins. The gel filtration results together with the 
immunodepletion studies suggest that RAM and RNMT exist in the same complexes 
within cells.  
Although the recombinant RAM/RNMT complex migrates at 150 kDa, that is more 
than the addition of the molecular mass of RNMT (that is 55 kDa) and RAM (that is 
14 kDa), we believe that only one RNMT and one RAM protein is present in each 
complex within cells. This is based on the observation that exogenously expressed 
HA-RNMT fails to immunoprecipitate endogenous RNMT (Figure 3.1c, 3.2a), 
suggesting that RNMT complexes consist of one RNMT protein. The same is true for 
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RAM. Endogenous RAM was not detected after immunoprecipitation of Fg-RAM 
(Figure 6.5), suggesting that cap methyltransferase complexes contain one RAM 
protein. 
  
Figure 3.6: Validation of RAM and RNMT interaction with endogenous proteins. 
(a) Immunoprecipitations were performed with 1 mg of extracts from HeLa cells, 
human primary T cells and SAOS2 cells using 1 µg of α-RNMT, α-RAM, or α-GST 
antibodies. Western blots were used to detect RAM and RNMT in inputs, 
immunoprecipitates (IP), and immunodepleted extracts (F.T). 5 µg cell extracts were 
loaded in the input lane.  
(b) HeLa cell extracts were subjected to immunprecipitations as described in (a) and 
additionally the immunoprecipitates were treated with RNAse A. RAM and RNMT 
were detected in the immunoprecipitates by western blot. 20 µg cell extracts were 
loaded in the input lane. 
(c) 1 µg of cellular RNA was incubated with (+) or without (-) RNAse A. RNA was 
purified and resolved in 1% denaturing agarose gel electrophoresis. Markers (Mar.) 
are indicated. The 28S, 18S and 5S ribosomal subunits present in the RNAse A 
untreated sample are indicated. 
The asterisk (*) indicates the cross-reacting heavy chain. 
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Figure 3.7: There is no evidence of any monomeric RNMT or RAM in HeLa 
cell extracts.  
Gel filtration analysis was performed on a Superdex 200 10/30 column to resolve 
1 mg HeLa cell extracts (upper panel), 1 µg recombinant RNMT and 1 µg 
recombinant RAM (middle panel), or 1 µg recombinant RNMT combined with an 
excess of RAM (lower panel). 0.5 ml fractions (frac) were collected following the 
void volume and analysed. Western blots were performed to detect RAM and 
RNMT. The migration of standards is indicated.  
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3.2.5 Mapping RAM and RNMT interaction domains 
In order to identify the interacting regions of RNMT and RAM, mammalian expression 
vectors were designed to express truncated mutants of these proteins. The decision 
about which RNMT truncated mutants to generate was based on previous 
publications (Saha et al., 1999; Shafer et al., 2005). RNMT 1-120 is not required for 
RNMT cap methyltransferase activity but contains two nuclear localisation signals 
(NLS). In addition, RNMT 1-120 is required for the recruitment of RNMT to chromatin 
and has a regulatory role upon RNMT activity (Aregger et al., in submission). On the 
other hand, RNMT 121-479 contains the cap methyltransferase domain and an 
additional NLS (Figure 3.8a). RAM mutants were designed based on the nature of 
their constituent amino acids, as discussed earlier (Figure 3.9a).  
In HEK-293 cells, RAM was expressed fused to Green Fluorescent Protein on the C-
terminus (RAM-GFP), and RNMT was fused to the HA epitope on the N-terminus 
(HA-RNMT). RAM-GFP, HA-RNMT, and their truncated mutants, were 
immunoprecipitated via their GFP and HA tags respectively. A series of expression 
constructs were generated to express RNMT truncated mutants containing amino 
acids 1-120 and 121-479 fused N-terminally with an HA-tag and RAM truncated 
versions expressing amino acids 1-55, 56-118, 1-90 and 91-118 fused C-terminally 
with GFP. 
HA-RNMT was co-immunoprecipitated with RAM-GFP but not GFP alone (Figure 3.8, 
3.9, upper panels). Conversely, RAM-GFP but not GFP alone was co-
immunoprecipitated with HA-RNMT (Figure 3.8, 3.9, middle panels). This confirms 
the interaction of RAM and RNMT observed in Figure 3.6a using an alternative set of 
antibodies. 
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RAM-GFP and GFP were co-expressed with HA fusions of full length RNMT (FL), 
RNMT 1-120, RNMT 121-476 and vector control. After immunoprecipitations using α-
HA or α-GFP antibodies, followed by western blot analysis, RAM-GFP was observed 
to interact with RNMT FL and RNMT 121-476 but not with RNMT 1-120 (Figure 3.8). 
Full length RNMT or truncated versions did not interact with GFP alone. The 
expression levels of full length RNMT and its truncated mutants were comparable as 
indicated by western blot analysis of the inputs (Figure 3.8, lower panel).  
HA-RNMT and vector control were co-expressed with GFP fusions of RAM FL, RAM 
1-55, RAM 56-118, RAM 1-90, RAM 91-118 and GFP alone. After 
immunoprecipitations using α-HA or α-GFP antibodies, followed by western blot 
analysis, HA-RNMT was observed to interact with RAM FL and RAM 1-55 but not 
with RAM 56-118 (Figure 3.9, right panel). HA-RNMT was also observed to interact 
with RAM 1-90 but not with RAM 91-118 (Figure 3.9, left panel). The expression 
levels of full length RAM-GFP and its truncated mutants were comparable as 
indicated by western blot analysis of the inputs (Figure 3.9, lower panel). 
  
Figure 3.8: RAM interacts with the catalytically active domain of RNMT. 
(a) Diagram depicting RNMT C-terminus catalytic domain and N-terminus 
regulatory domain (N-term.). 
(b) HEK-293 cells were transfected with pEGFPN3-RAM or vector control (GFP) 
and pcDNA5 vector control (Vec) or truncated mutants of HA-RNMT expressing 
full length RNMT, the amino acids 1-120, or the amino acids 121-476 fused to a 
HA-tag as indicated above the panel. Immunoprecipitations were performed with 
2 mg cell extracts using 2 µg α-HA or α-GFP antibodies. Western blots were 
performed to detect RAM and RNMT, using α-GFP and α-HA antibodies 
respect ively, in α -GFP immunoprecip i tates (upper panel) , α -HA 
immunoprecipitates (middle panel) and inputs (lower panel). (*) indicates a cross-
reacting band.   
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Figure 3.9: RNMT interacts with the RAM N-terminus. 
(a) Diagram depicting RAM domains as identified according to the nature of its 
constituent amino acids.   
(b) HEK-293 cells were transfected with pcDNA5-HA-RNMT or vector control 
(Vec) and pEGFPN3 vector control (GFP) or truncated mutants of RAM-GFP 
expressing full length RAM, the amino acids 1-55, the amino acids 56-118 (left 
panel), the amino acids 1-90, or the amino acids 91-118 (right panel) fused to a 
GFP-tag as indicated above the panels. Immunoprecipitations were performed 
with 2 mg cell extracts using 2 µg α-HA or α-GFP antibodies. Western blots were 
performed to detect RAM and RNMT, using α-GFP and α-HA antibodies 
respect ively, in α -GFP immunoprecip i tates (upper panel) , α -HA 
immunoprecipitates (middle panel) and inputs (lower panel).  
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3.3 Discussion 
RNA guanine-7 methylation is a regulated process and its inhibition is synthetic lethal 
with elevated c-MYC expression levels (Jiao et al., 2010; Fernandez-Sanchez et al., 
2009). Nonetheless, the mechanistic details of RNA guanine-7 methylation in 
mammalian cells are yet to be determined. We reasoned that novel components of 
the RNA cap methylation machinery are missing and in order to identify them we 
decided to perform an unbiased biochemical approach purifying RNA guanine-7 
methyltransferase (RNMT) complexes from the cells.  
HSPA1 and a protein of unknown function with the code name FAM103A1 was found 
to interact with RNMT. FAM103A1 was designated as RAM. The interactions of 
RNMT with HSPA1 and RAM were validated using endogenous proteins. These are 
the first proteins having shown to interact with endogenous mammalian RNMT.  
Mammalian RNMT has been demonstrated to interact with the phosphorylated 
carboxyl-terminal domain of RNA polymerase II (Pillutla et al., 1998b), capping 
enzyme (Pillutla et al., 1998b) and Importin-α (Wen and Shatkin, 2000) after in vitro 
pull down assays. The interaction between RNMT and RNA pol II has also been 
demonstrated after overexpression of RNMT and cross-linking treatment (Shafer et 
al., 2005). Previous attempts to demonstrate the interaction between RNMT and 
capping enzyme or RNA polymerase II in vivo performing co-immunoprecipitation or 
SILAC (Stable Isotope Labelling by Amino acids in Cell culture) proteomic analysis, 
were unsuccessful (Dunn; Bounds; Fu; unpublished data). This suggests that the 
affinity of these interactions is low and this may explain the reasons we did not detect 
these proteins after RNMT purification. 
Importin-α was detected in a SILAC based RNMT purification performed by Sianadh 
Dunn in Victoria Cowlingʼs Lab. In addition, when Michael Aregger in Cowlingʼs lab 
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performed RNMT purification for mass spectrometry analysis to detect RNMT post-
translational modifications following the same preparation as we did, Importin-α was 
detected to co-migrate with RNMT in the Coomassie stained gel. Since RNMT and 
Importin-α have simillar molecular mass it is possible that Importin-α may have co-
purified with RNMT in our RNMT complex purification but failed to be observed in the 
Coomassie stained gel because of its co-migration with RNMT.  
HSPA1 is a heat shock protein being highly up-regulated during heat shock 
conditions predominantly at the transcriptional level. Heat shock is responsible for 
translation repression of most mRNA transcripts apart from the heat-shock mRNAs 
(Storti et al., 1980). Although the phosphorylation of several translation factors has 
been implicated in translation repression, the exact mechanistic details of this 
inhibition are not clear (Sonenberg et al., 2001). It is a possibility that HSPA1, by 
interacting with RNMT, can modulate the methyl-cap levels of mRNA transcripts and 
alter their translation efficiency. However, HSPA1 is a common contaminant in 
proteomic studies. We never investigated the possibility of HSPA1 altering RNMT 
activity due to time constraints. 
RAM was the second protein that was found to interact with RNMT after mass 
spectrometry analysis. More interestingly, under the conditions we investigated, we 
could not detect any monomeric RNMT or RAM within cells. This suggests, that at 
least under physiological conditions, all RAM and RNMT exist in the same complexes. 
The observaton that purified recombinant RAM and RNMT can interact with each 
other suugests that RAM and RNMT interact directly.  
Recombinant RAM/RNMT migrate at smaller molecular weight complexes after gel 
filtration analysis than cellular RAM/RNMT complexes. That suggests that additional 
proteins are interacting with RAM/RNMT complex in the cells. HSPA1 and Importin-α 
interaction with RNMT may be responsible for the shift observed in the cellular 
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complexes. In addition, as will be described later, hnRNPA1 amongst other RNA 
binding proteins was found to interact with the cap methyltransferase complex 
(Figure 6.4). Whether these interactions are RNA mediated remains to be determined. 
However, these interactions may explain the increased molecular mass of the cellular 
cap methyltransferase complex observed after gel filtration.  
Finally, the domains responsible for the interaction between RAM and RNMT were 
analysed. RAM N-terminus, which is highly conserved in vertebrates, was 
responsible for binding to the catalytically active RNMT domain. This observation 
raised the possibility that RAM can modulate RNMT activity, a hypothesis that will be 
investigated in the following chapter. 
To summarise, a novel protein designated as RAM was identified to interact with 
RNMT in several human cell lines. RAM and RNMT interaction is direct and it is not 
mediated by RNA. Interestingly, RAM was isolated from cell extracts as heterodimer 
with RNMT and there was no evidence of any monomeric RNMT or RAM under the 
conditions it was investigated. These findings suggest an important biological 
function of RAM upon RNMT, something that will be investigated in the following 
chapter.  
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Chapter 4:  Functional Investigation of RAM 
4.1 Introduction 
In the previous chapter it was demonstrated that RAM and RNMT exist in the same 
complex within cells. In all cell lines investigated, including epithelial, T and 
osteogenic cells, there was no evidence of any monomeric RNMT or RAM. Since the 
interaction between RAM and RNMT was novel its biological significance remained 
unknown. Therefore, this chapter focuses on addressing what is the effect of RAM 
upon RNMT and elucidating the biological relevance of RAM. 
 
4.2 Results 
As described previously, the protein domains responsible for RAM/RNMT interaction 
were analysed by co-immunoprecipitation of exogenously expressed cellular proteins 
(Figures 3.8, 3.9). The evolutionary conserved RAM N-terminus was found to interact 
with the catalytically active RNMT domain. Although no previously established 
functional domains were identified in the RAM amino acid sequence, the RAM C-
terminus has an enrichment of amino acids similar to the C-terminal domain of 
hnRNPU protein (Figure 4.1a), known to posses RNA-binding activity (Kiledjian and 
Dreyfuss, 1992). Furthermore, the assigned intermediate domain of RAM is Arginine-
rich, a characteristic of RNA-binding domains (Bayer et al., 2005). This observation 
raised the possibility that RAM is an RNA binding protein.  
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4.2.1 Investigation of RAM biochemical functions 
In order to determine whether RAM can bind RNA we performed in vitro RNA band-
shift assays. In vitro synthesised 32P-labelled transcript were incubated with 
recombinant purified RNMT and/or RAM (Figure 4.1b). The complexes formed were 
resolved by native PAGE and the RNA/protein complexes were visualised by 
autoradiography. “Free” RNA was detected at the bottom of the gel whereas the 
migration of RNA bound to protein was retarded through the gel. The assay 
demonstrated that monomeric RNMT is not able to bind RNA (Figure 4.1b lane 2), 
however, monomeric RAM binds RNA in a dose-dependent manner (Figure 4.1b 
lanes 6-8). Interestingly, RAM/RNMT complex can bind RNA with higher affinity than 
RAM alone (Figure 4.1b lanes 3-5). The fact that although RNMT does not bind RNA, 
RAM/RNMT complex binds RNA efficiently suggests that RAM function may be to 
recruit RNA to RNMT.  
To validate that the band-shift observed in Figure 4.1b was due to RAM and RNMT 
binding and not any co-purified contaminants, the assay was repeated in the 
presence of antibodies specific for RAM, RNMT or GST as negative control. The 
labelled transcripts were analysed by native PAGE and visualised by 
autoradiography (Figure 4.1c). The presence of RAM in the complexes was 
confirmed since α-RAM antibodies super-shifted the complex and inhibited its 
visualisation (Figure 4.1c, compare lanes 3,4,11,12 with lanes 15,16). In addition, 
RNMT presence in the complexes was confirmed after incubation with α-RNMT 
antibodies, which inhibited the complex detection (Figure 4.1c, compare lanes 
2,4,10,12 with lanes 6,8). To summarise, the experiments presented in Figure 4.1 
demonstrate that RAM is an RNA-binding protein that can recruit RNA to RNMT in 
vitro.  
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To investigate whether the increased RNA-binding activity observed when RAM and 
RNMT form a complex equates to an increase in RNMT enzymatic activity, in vitro 
cap methylation assays were performed. The in vitro cap methylation assays were 
performed by Dr. Victoria Cowling. Briefly, in vitro synthesised 32P-capped-labelled 
transcripts were incubated with recombinant RNMT and the methyl donor S-
adenosyl-methionine (Figure 4.2a). The reaction transcripts were purified, digested 
with P1 nuclease to release the cap structure, and analysed by thin layer 
chromatography. The conversion of cap (GpppG) to methyl-cap (m7GpppG) structure 
was visualised by autoradiography and the relative RNMT activity was determined. 
As Figure 4.2a indicates RNMT can methylate the cap of transcripts in vitro in a 
dose-dependent manner. The addition of RAM to the in vitro cap methylation reaction 
increased RNMT activity up to five-fold, whilst monomeric RAM had no detectable 
cap methyltransferase activity. 
Interestingly, RAM had the greatest effect upon RNMT activity when RAM and RNMT 
were combined in 1:1 molar ratio and excess of RAM resulted in a decrease in cap 
methylation (Figure 4.2c). A possible explanation of this observation is that excessive 
RAM titrates RNA away from the cap methyltransferase complex. This finding 
supports the idea that RAM and RNMT form a 1:1 equimolar complex. To summarise, 
the in vitro cap methylation assays demonstrated that RAM can increase RNMT 
activity up to five-fold.  
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Figure 4.1: RAM is an RNA binding protein and recruits RNA to RNMT. 
(a) Amino acid sequence alignment of the H. sapiens RAM and hnRNPU. The EMBL-
EBI ClustalW2 Multiple Alignment software was used for the alignment, selecting the 
default parameters. Amino acids identical in H. sapiens RAM and hnRNPU are 
indicated by asterisk (*). Colon (:) and period (.) indicate conservation between 
strongly and weakly similar amino acid properties respectively. 
(b-c) RNA band shift assays were used to investigate the interaction of RNA with 
RAM and RNMT. (b) 2 pmol RNMT and/or 0.5-2 pmol RAM were incubated with an 
excess of 32P-capped transcript, and complexes were resolved by native PAGE. (c) 2 
pmol RNMT and/or 2 pmol RAM were incubated with an excess of 32P-capped 
transcript. Prior to gel electrophoresis the complexes were incubated with no 
antibodies (left panel), 700 ng α-RNMT antibodies (middle-left panel), 700 ng α-GST 
antibodies (middle-right panel), or 700 ng α-RAM antibodies (right panel).  
RNA and RNA/protein complexes are indicated. 
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Figure 4.2: RAM increases RNMT cap methyltransferase activity in vitro. 
(a) The in vitro cap methylation assay was performed using a titration of 
recombinant RNMT, molarity indicated, or no protein (c), in the presence of 32P-
capped transcript and S-adenosyl methionine. The conversion of GpppG to 
m7GpppG was measured by resolving the P1 digested purified reaction transcripts 
by thin layer chromatography. GpppG and m7GpppG migration is indicated right of 
the panel.  
(b) Cap methylation assay was performed with 20 nM RNMT and/or 20 nM RAM. 
Mean relative cap methylation of four independent experiments and standard 
deviation is depicted (left panel).  
(c) As in (b), except a RAM titration was used as indicated bellow the panel. Mean 
relative cap methylation of four independent experiments and standard deviation is 
depicted. 
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4.2.2 RAM domain analysis 
The domains of RAM responsible for RNA binding and RNMT activation were further 
investigated by generating a series of recombinant truncated RAM proteins based on 
the nature of RAM constituent amino acids as described in Chapter 3. Recombinant 
full length RAM and RAM truncated mutants expressing RAM 1-55, RAM 56-118, 
RAM 1-90 and RAM 91-118 fused N-terminally to GST (Glutathione S-transferase)-
tag were purified from bacteria cells and employed for in vitro RNA band-shift assays 
and cap methyltransferase activity assays. The recombinant RAM proteins used for 
the in vitro assays were analysed by Coomassie stained SDS polyacrylamide gel 
(Figure 4.4a). Production of recombinant GST-RAM 56-118 resulted in the 
purification of multiple bands, which are either contaminants or GST-RAM 56-118 
degradation products. 
As demonstrated previously, full length RAM could bind to RNA (Figure 4.3a lanes 
3,8). RAM 1-55 did not bind to RNA but RAM 56-118 did bind (Figure 4.3a lanes 4,5). 
RAM 1-90 exhibited RNA-binding activity whereas RAM 91-118 did not (Figure 4.3a 
lanes 9,10). These results collectively suggest that the Arginine-rich middle domain 
of RAM, corresponding to amino acids 56-90, is responsible for RNA-binding.  
Cap methylation assays were performed by Dr. Cowling to determine the effect of the 
RAM truncated mutants on RNMT cap methyltransferase activity (Figure 4.3b). 
Interestingly, RAM 1-55 activated RNMT equivalently to full length RAM, whereas 
RAM 56-118 did not (Figure 4.3b lanes 4,5,6). RAM 1-90 also activated cap 
methylation whereas RAM 91-118 did not (Figure 4.3b lanes 10,11,12). Therefore, 
RAM truncated mutants able to bind to RNMT can also increase RNMT activity 
independently of their ability to bind RNA. This finding together with the fact that RAM 
binds to the catalytically active domain of RNMT suggests that RAM may activate 
RNMT by changing RNMT active site conformation. Crystallographic studies need to 
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be performed to investigate this hypothesis further. In addition, RAM may increase 
the RNMT affinity for the methyl donor, S-adenosyl-methionine (SAM), or the N7-
methylguanosine-cap structure. Biophysical studies need to be performed for 
elucidating this possibility. Chapter 5 is focusing on addressing all the above 
possibilities.  
The functional analysis of different RAM domains regarding their ability to interact 
with RNMT, to bind RNA and to activate RNMT is depicted in Figure 4.4b.  
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Figure 4.3: RAM can activate RNMT in vitro independently of its ability to 
bind RNA. 
(a) RNA band shift assays of 2 pmol GST-RAM or GST truncated RAM fragments, 
as indicated below the panel, were incubated with an excess of 32P-capped 
transcript, and complexes were resolved by native PAGE.  
(b) Cap methylation assay was performed using 20 nM RNMT and/or GST-RAM 
truncated fragments as indicated bellow the panel. Mean relative cap methylation 
of four independent experiments and standard deviation is depicted. 
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Figure 4.4: Summary of RAM domain analysis. 
(a) 10 µg recombinant GST-RAM and GST-RAM truncated fragments were 
resolved in a 15% SDS-PAGE (left panel) or 10% SDS-PAGE (right panel), as 
indicated above the panel. The gels were stained by Coomassie blue. 
(b) Diagram depicting RAM deletion mutants and their capability of RNMT binding, 
RNA binding, and RNMT activation.   
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4.2.3 Investigation of the biological significance of RAM  
The in vitro assays described previously were constructive for elucidating RAM 
biochemical function, however, the primary focus of our research was to investigate 
the function and biological significance of RAM within cells. Prior to investigating the 
effect of RAM upon cellular cap methyltransferase activity, it was important to 
determine whether RAM was regulating RNMT expression levels or localisation. 
RNMT is a nuclear protein (Wen and Shatkin, 2000) and its correct localisation is 
essential for cell viability (Shafer et al., 2005).  
Immunofluorescence analysis was performed to determine the effect of RAM upon 
RNMT localisation. HeLa cells were depleted of RAM or RNMT using two 
independent siRNAs (Table 2.5) or non-targeting siRNA control (Figure 4.5, left 
panel). Consistent with previous findings based on exogenously overexpressed 
RNMT (Wen and Shatkin, 2000; Shafer et al., 2005), endogenous RNMT is also a 
nuclear protein (Figure 4.5, left panel). Depletion of endogenous RAM expression by 
siRNA did not result in a change of RNMT localisation but instead resulted in a loss 
of RNMT expression (Figure 4.5, left panel). RNMT expression was also diminished 
after treating the cells with siRNAs directed against RNMT suggesting that the α-
RNMT antibodies that were used for the immunofluorescence analysis are specific.  
RAM localisation was investigated by immunofluorescence analysis of endogenous 
RAM (Figure 4.5, right panel). Immunofluorescence staining depicted that RAM is a 
nuclear protein since RAM staining correlated with the nuclear staining observed by 
DAPI. This is not a surprise considering that it has been demonstrated that RAM and 
RNMT exist in the same complexes and RNMT is a nuclear protein. HeLa cells were 
depleted of RAM or RNMT using two independent siRNAs (Table 2.5) or non-
targeting siRNA control. As expected, depletion of RAM, using siRNAs directed 
against RAM mRNA, resulted in reduction of endogenous RAM expression as 
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demonstrated by immunofluorescence. Interestingly, RNMT depletion resulted in 
decreased expression of RAM (Figure 4.5, right panel). To summarise, 
immunofluorescence analysis demonstrated that both RAM and RNMT are localised 
in the nucleus. In addition, although RAM did not have an effect upon RNMT 
localisation, it appeared to be required for RNMT expression levels and vice versa. 
RNMT was essential for RAM expression according to immunofluorescence analysis 
and this result was further validated by western blot. When RAM was depleted using 
two independent siRNAs against RAM for 48 and 72 hrs, RNMT expression was 
diminished as well (Figure 4.6a). RT-qPCR demonstrated that RAM depletion did not 
affect RNMT transcript levels suggesting that RAM can regulate RNMT expression at 
a post-transcriptional level (Figure 4.6c). Furthermore, when RNMT was depleted 
from HeLa cells employing two independent siRNAs, RAM expression levels were 
depleted together with RNMT (Figure 4.6b). RT-qPCR analysis performed by 
Sianadh Dunn in the Cowling Lab demonstrated that depletion of RNMT does not 
decrease RAM transcript levels suggesting that RNMT can regulate RAM expression 
at a post-transcriptional level.  
To confirm that the reduced RNMT expression observed after RAM depletion was not 
due to “off-target” effects of siRNAs, cells were transfected with a siRNA-resistant 
RAM expression vector, which enabled the reintroduction of RAM back into cells. As 
Figure 4.6d demonstrates, expression of RAM from the RAM siRNA-resistant vector 
was sufficient to restore endogenous RNMT expression levels. The above results 
collectively suggest that RAM and RNMT can regulate each otherʼs expression at a 
post-transcriptional level.  
This was further validated by exogenously expressing both RAM and RNMT in HEK-
293 cells. When expressed alone, HA-RNMT expression was relatively low, however 
when co-expressed with Fg-RAM, a significant increase in HA-RNMT expression was 
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observed (Figure 4.7a). The effect of RAM on RNMT was again independent of 
transcript levels (Figure 4.7c). This effect was also independent of cap 
methyltransferase activity since overexpression of RAM enhanced the expression of 
a methyltransferase dead RNMT mutant (MTD) equivalent to wild-type RNMT (Figure 
4.7b,d). Moreover, the same was true for Fg-RAM. When expressed alone, Fg-RAM 
expression was relatively low, however, when co-expressed with HA-RNMT, a 
significant increase in Fg-RAM expression was observed (Figure 4.7a). The effect of 
RNMT on RAM was again independent of transcript levels (Figure 4.7c). This effect 
was also independent of RNMT cap methyltransferase activity since expression of 
RNMT mutant (MTD) could also enhance Fg-RAM expression (Figure 4.7b,d).  
Messenger RNA cap methylation is required for efficient mRNA translation (Both et 
al., 1975; Muthukrishnan et al., 1975). However, the experiments with the 
methyltransferase dead (MTD) RNMT mutant suggested that the defects in 
expression levels of RAM and RNMT in the absence of each other were not due to 
reduced translation of RAM and RNMT transcripts. In other words, cellular cap 
methyltransferase activity is not required in order RAM and RNMT to stimulate the 
expression of each other suggesting that the stimulatory effect of RAM and RNMT 
upon each other expression is not translational but rather that RAM and RNMT 
proteins can stabilise each other.  
In order to confirm that RAM and RNMT stabilise each other, we inhibited 
proteasomal degradation. Fg-RAM and HA-RNMT were exogenously expressed in 
HeLa cells in the presence or absence of MG132 proteasomal inhibitor (Figure 4.7e, 
left panel). Similarly with what was observed in HEK-293, Fg-RAM could enhance 
expression of HA-RNMT and vice versa. MG132 could rescue the defect in 
expression of both Fg-RAM and HA-RNMT when transfected alone suggesting that 
RNMT and RAM protect each other from proteasomal degradation (Figure 4.7e, right 
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panel). Because MG132 can also inhibit the activities of some lysosomal cysteine 
proteases (Tatham et al., 2011) we validated this result with another proteasomal 
inhibitor, clasto-Lactacystin β-Lactone. Similarly to MG132, clasto-Lactacystin β-
Lactone could also rescue the expression defects of both Fg-RAM and HA-RNMT 
when transfected without each other (Figure 4.7e, right panel). 
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Figure 4.5: RAM and RNMT are nuclear proteins. 
Immunofluorescence microscopy was used to detect endogenous RAM and 
RNMT in HeLa cells. Cells were transfected with two independent siRNAs directed 
against RAM or RNMT and a non-targeting control (si control) for 48 hrs prior to 
fixation. RNMT antibody was diluted 1/1000 (left panel) and RAM antibody 1/100 
(right panel) for RNMT and RAM detection respectively. DAPI stain was used to 
detect nuclei and bright field for cell visualisation.  
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Figure 4.6: RAM is required for cellular RNMT expression and vice versa. 
(a) Expression of RAM was reduced in HeLa cells by transfection of two 
independent siRNAs (1 or 2) directed against RAM in comparison with non-
targeting siRNAs (c) for 48 and 72 hrs. Western blots were performed to detect 
RAM, RNMT and β-Tubulin (Tub) as loading control.  
(b) Expression of RAM and RNMT was reduced in HeLa cells by transfection of 
two independent siRNAs (1 or 2) directed against RAM or RNMT in comparison 
with non-targeting siRNAs (c) for 48 hrs. Western blots were performed to detect 
RAM, RNMT and β-Tubulin (Tub) as loading control.  
(c) RNA was isolated and RAM and RNMT transcript levels were determined by 
qRT-PCR from HeLa cells transfected with two independent siRNAs (1 or 2) 
directed against RAM or control siRNAs (c) for 48 and 72 hrs.  
(d) HeLa cells were transfected with pcDNA5-Fg-RAM (+) or vector control (-), 48 
hrs later cells were transfected with siRNA directed against RAM (1) or control (c), 
and 48 hrs later cells were lysed. Western blots were performed to detect RAM, 
RNMT and β-Tubulin (Tub) as loading control. 
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Figure 4.7: RAM and RNMT protect each other from proteasomal degradation. 
HEK-293 cells were transfected with pcDNA5-Fg-RAM (Fg-RAM) and pcDNA5-HA-
RNMT (HA-RNMT) (a,c), pcDNA5-HA-RNMT-MTD (HA-RNMT-MTD) (b,d) or empty 
vector control for 48 hrs.  
(a-b) Western blots were performed to detect RAM (* indicates FLAG-RAM), RNMT 
(HA-tag) and β-Tubulin (Tub) as loading control.  
(c-d) RNA was isolated and qRT-PCR was performed to detect FLAG-RAM and HA-
RNMT transcript levels.  
(e) HeLa cells were transfected with pcDNA5-Fg-RAM (Fg-RAM), pcDNA5-HA-
RNMT (HA-RNMT) as indicated above the panel. MG132 and clasto-Lactacystin β-
Lactone proteasome inhibitors or vehicle were added to the cell media prior lysis. 
Western blots were performed to detect RAM, RNMT (HA-tag) and β-Tubulin (Tub) 
as loading control. 
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4.2.4 Investigation of the effect of RAM on cellular cap 
methylation 
To determine the role of RAM in cellular cap methylation, endogenous RAM was 
depleted from HeLa cells using siRNA against RAM or a non-targeting siRNA control. 
In order to determine that any effect observed in RNMT activity is due to RAM 
depletion and not due to siRNA “off-target” effects, we restored RAM and RNMT 
expression levels similarly to endogenous levels by transfection of siRNA-resistant 
expression vectors 24 hrs following RAM depletion. Western blot analysis of the cell 
lysates is presented in the Figure 4.8a.  
HeLa cell extracts depleted of RAM were subjected to in vitro cap methylation assay 
as described previously. As expected, RAM depletion, and concurrent reduction of 
RNMT expression, resulted in a loss of cellular cap methyltransferase activity (Figure 
4.8b, siRAM -RAM) as measured by the conversion of the labelled cap to methyl cap 
over a time-course of 15 min. Restoration of RAM and RNMT expression to 
endogenous levels rescued the reduction of cap methyltransferase activity (Figure 
4.8b, siRAM +RAM). 
Although the previous experiment clearly demonstrated that cellular RAM is required 
for cellular cap methyltransferase activity in vitro, we wanted to determine whether 
RAM was also required for cellular methyl-cap levels of endogenous transcripts. In 
order to investigate this hypothesis, antibodies that specifically recognise methyl-
capped transcripts were utilised (Cole and Cowling, 2009). mRNA was purified from 
HeLa cells treated with non-targeting siRNA, siRNA against RAM and also siRNA 
against RAM followed by restoration of RAM and RNMT expression similarly to 
endogenous levels by transfection of expression vectors. The methyl-cap transcripts 
were immunoprecipitated using antibodies raised against the N7-methylguanosine 
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cap moiety, purified and converted to cDNA. Gene-specific qRT-PCR was performed 
to determine the relative methyl-cap levels after normalisation to inputs. As Figure 
4.8c demonstrates, depletion of RAM resulted in a reduction of the endogenous 
methyl-cap transcript levels of c-MYC, RuvBL1, GAPDH and cyclin D1. When RAM 
and RNMT levels were restored, the methyl-cap levels of c-MYC, RuvBL1, GAPDH 
and cyclin D1 endogenous transcripts were restored as well. The above experiments 
demonstrate that RAM is required for mRNA cap methylation within cells (Figure 
4.8c) and this is partially because RAM protects RNMT from proteasomal 
degradation (Figure 4.7e).  
The in vitro assays presented in the beginning of the chapter have demonstrated that 
RAM is required for efficient RNMT activity. In order to determine whether, in addition 
to stabilising RNMT, RAM could also increase RNMT activity within cells, an RNMT 
doxycycline-inducible system was employed. Endogenous RAM was depleted from 
HeLa cells using siRNA directed against RAM mRNA, at the same time that 
exogenous RNMT expression was induced by doxycycline (Figure 4.9a). Using this 
system we managed to express HA-RNMT similar to endogenous levels, in the 
absence of RAM. In vitro cap methylation assay were performed with HeLa cell 
extracts and cellular RNMT activity was determined. Expression of monomeric RNMT 
demonstrated low activity after incubating HeLa cell extracts in the in vitro cap 
methylation reaction (Figure 4.9b). More interestingly, monomeric RNMT was not 
able to restore methyl-cap transcript levels after RAM depletion as exhibited by gene-
specific qRT-PCR following methyl-cap immunoprecipitation (Figure 4.9c), 
suggesting that RAM is required for RNMT activity within cells.  
We have demonstrated that RAM is required for RNMT stability but also for RNMT 
activity in HeLa cells. RNMT is an essential gene and it is required for cell viability 
(Chu and Shatkin, 2008; Shafer et al., 2005). Since RAM plays such a pivotal role in 
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RNMT function it was not a surprise that inhibition of RAM expression, by using two 
independent siRNAs against RAM, resulted in loss of cell accumulation (Figure 4.10), 
as determined by cell counting. This effect was partially due to an induction of 
apoptosis as determined by the cleavage of the apoptotic marker PARP 
(Gonatopoulos-Pournatzis et al., 2011). When a RAM siRNA resistant expression 
vector was used to restore RAM expression, the reduction in cell accumulation was 
rescued. Therefore, RAM, like RNMT, appears to be an essential gene for cell 
viability.  
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Figure 4.8: RAM is required for cellular cap methyltransferase activity. 
HeLa cells were transfected with RAM siRNA (1) or control siRNA (c), 24 hrs later 
cells were transfected with pcDNA5-Fg-RAM and pcDNA5-HA-RNMT + (RAM + 
RNMT) or vector control - (RAM + RNMT) and 24 hrs later cells were lysed.  
(a) Western blots were performed to detect RAM, RNMT and β-Tubulin (Tub) as 
loading control.  
(b) Relative cap methyltransferase activity was detected in cell extracts using the 
in vitro cap methyltransferase assay. 1 µg cell extracts were subjected to the 
assay over 5, 10, and 15 min. The reaction products were analysed by thin layer 
chromatography followed by autoradiography.  
(c) Methyl cap levels of four endogenous transcripts indicated were determined 
relative to total transcript levels using qRT-PCR following 7-methyl guanosine 
immunoprecipitations.  
Bar charts depicts the average values and mean relative standard deviation of 
three independent experiments.  
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Figure 4.9: RAM is essential for cellular cap methyltransferase activity. 
HeLa cells stably transfected with doxycycline (Dox) inducible HA-RNMT were 
transfected with RAM siRNA (1) or control siRNA (c) for 48 hrs whilst HA-RNMT 
expression was induced for the time point indicated.  
(a) Western blots were performed to detect RAM, RNMT and β-Tubulin (Tub) as 
loading control.  
(b) Relative cap methyltransferase activity was determined in cells induced for 2 
hrs with doxycycline, using the in vitro cap methyltransferase assay. 1 µg cell 
extracts were subjected to the assay over 10 min. A representative autoradiogram 
of a thin layer chromatography plate is presented.  
(c) Methyl cap levels of four endogenous transcripts indicated was determined 
relative to total transcript levels using qRT-PCR following 7-methyl guanosine-
immunoprecipitations. Cells were induced for 6 hrs with doxycycline prior to RNA 
isolation. Bar charts depict the average value and mean relative standard 
deviation of three independent experiments.  
Functional Investigation of RAM 
168!
C
el
l n
um
be
r x
10
5  24hrs 48hrs 
0 
2 
4 
6 48hrs 
RAM si: c 1 2 1 2 c c 1 1 
RAM: - - + 
Figure 4.10: RAM depletion inhibits cell proliferation rates. 
HeLa cells were transfected with two independent siRNAs (1 or 2) directed against 
RAM or control siRNAs (c). 24 hrs later they were transfected with pcDNA5-Fg-
RAM and pcDNA5-HA-RNMT (+) or vector control (-) (right panel). Cell counts 
were determined 24 and 48 hrs post-transfection using a Neubauer chamber. Bar 
charts depicts the average cell number and mean relative standard deviation of 
three independent experiments.  
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4.3 Discussion 
In the previous chapter RAM was identified as an RNMT-interacting protein and 
further studies demonstrated that RAM and RNMT exist in the same complexes in 
vivo. The function of RAM was uncharacterised, therefore, the amino acid sequence 
of RAM was analysed to identify functional motifs and similarities to other proteins. 
RAM C-terminal domain is rich in Glutamine, Tyrosine and Proline amino acids and 
exhibits some conservation with the C-terminal domain of hnRNPU protein (Kiledjian 
and Dreyfuss, 1992), which is an RNA-binding protein. Furthermore, RAM contains 
Arginine-rich motifs which are commonly present in RNA-binding proteins (Bayer et 
al., 2005). In order to investigate whether RAM is an RNA-binding protein we 
performed RNA band-shift assays. We demonstrated that RAM amino acids 56-90 
are responsible for RNA binding and recruitment of RNA to RNMT. RAM can bind 
uncapped, capped and methyl-capped RNA equally well (Gonatopoulos-Pournatzis 
et al., 2011). This is not a surprise considering that the cap-binding pocket resides 
within the RNMT active site.   
In addition, RAM can increase RNMT methyltransferase activity in vitro up to five-fold. 
Surprisingly, the RNA-binding domain of RAM is not required for RAM to increase 
RNMT activity in vitro. The RNMT-binding domain of RAM alone is sufficient to 
stimulate RNMT methyltransferase activity possibly by altering RNMT conformation. 
To further investigate this hypothesis crystallographic studies of RAM/RNMT complex 
were performed as described in the following chapter (Chapter 5). Although the RNA-
binding domain of RAM appears not to be required for the in vitro activation of RNMT, 
its biological function is intriguing. The in vitro studies in this chapter were performed 
with the same in vitro synthesised 55-nucleotide transcript. However, the possibility 
that RAM binds to specific RNA transcrips in vivo, where the transcriptome is far 
more complex, cannot be excluded. Thus, RAM may have evolved in order to recruit 
 171 
specific transcripts to the cap methyltransferase complex. In order to investigate this 
hypothesis further experiments are required to be performed.  
Within cells, RAM is essential for mRNA cap methylation. This is partially because it 
is required for efficient RNMT methyltransferase activity but also because RAM 
protects RNMT from proteasomal degradation. Depletion of RAM results in reduction 
of N7-methylguanosine capped endogenous transcripts as demonstrated after 
methyl-cap immunoprecipitations. Moreover, RAM is required for the maintenance of 
RNA poll II transcripts in a gene-specific manner (Gonatopoulos-Pournatzis et al., 
2011). Not surprisingly, RAM is required for efficient protein synthesis within cells 
(Gonatopoulos-Pournatzis et al., 2011) partially because N7-methylguanosine cap 
formation is required for protein synthesis (Both et al., 1975; Muthukrishnan et al., 
1975), but also because RAM is required for RNA poll II transcript maintenance. 
Since RAM is required for gene expression, RAM depletion is deleterious for cells. 
Cell accumulation is drastically decreased after RAM depletion, partially due to an 
increase in apoptosis. 
In summary, we have identified and functionally characterised RAM, a novel 
component of the cap methylation machinery. RAM is required for efficient gene 
expression and cell viability. Future studies will be focused on determining the 
mechanism by which RAM activates RNMT. Crystallographic and biophysical studies 
will be performed, as will be described in the following chapter. Furthermore, the final 
chapter (Chapter 6) will be focused on how RAM function is regulated within cells.  
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Chapter 5:  Purification of Recombinant RAM, 
RNMT and RAM/RNMT complex for 
Crystallographic and Biophysical Studies 
5.1 Introduction 
In the previous chapters, the identification of a novel protein, RAM, which is an 
essential component of the RNA guanine-7 methylation machinery, was described. 
RAM was isolated from mammalian cell extracts as an obligate heterodimer with 
RNMT. RAM is an RNA-binding protein and can increase RNMT activity both in vitro 
and within cells. In addition, RAM can stabilise RNMT by protecting it from 
proteasomal degradation. Although RAM recruits RNA to RNMT in vitro, RAM 
mutants unable to bind RNA stimulate RNMT activity similarly with wild-type RAM 
suggesting that RAM RNA-binding domain is not required for RNMT activation.  
This chapter is focused on investigating the mechanisms by which RAM activates 
RNMT. RAM binds to RNMT catalytic domain and this interaction may be able to 
alter the conformation of RNMT and influence its activity. In order to investigate this 
hypothesis we pursued crystallographic studies in collaboration with the van Aalten 
Laboratory in the College of Life Sciences at the University of Dundee. The crystal 
structure of the human monomeric RNMT catalytic domain (amino acids 165-476) 
has been resolved by the Structural Genomics Consortium (PDB code 3EPP, 3BGV). 
Consequently, our aim was to determine the structure of monomeric RAM and 
RAM/RNMT complex. Structural studies will decipher whether RAM can alter RNMT 
conformation and vice versa. In addition, the crystal structure of the complex will 
provide information about which RAM and RNMT amino acids are involved in their 
interaction. As regards RAM, solving its structure will be informative for determining 
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whether the RAM RNA-binding domain is integrated with the RNMT-binding domain 
or whether these two domains form distinct structures.  
Additionally to the crystal structure approach, in order to determine the effect of RAM 
upon the affinity of RNMT for SAM and capped transcripts we decided to undertake a 
biophysical approach. The first step for this approach is the purification of 
recombinant RNMT and RAM. The exact biophysical techniques that will be used for 
answering the above questions are explored in the discussion of this chapter.  
Finally, in collaboration with the Drug Discovery Unit at the University of Dundee, we 
aim to perform a screen for developing inhibitors of the interaction between RAM and 
RNMT. Sinefugin, a S-adenosyl-methionine analogue, has been reported to inhibit 
RNA guanine-N7 methyltransferases, however its specificity for mammalian RNMT is 
10-fold lower in comparison with S. cerevisiae Abd1p (Chrebet et al., 2005). 
Conversely, tubercidin inhibits mammalian RNMT but can also inhibit all cellular 
methyltransferases including DNA and protein methyltransferases (Fernandez-
Sanchez et al., 2009). The low specificity of tubercidin for RNMT prompted the 
pursuit of novel and more specific RNMT inhibitors. The identification of an inhibitor 
of RAM/RNMT interaction, apart from being a useful tool for performing biochemical 
studies, may also have potential therapeutic effects. Therefore, recombinant 
RAM/RNMT complex was purified with the aim to perform inhibitor screening. The 
RAM/RNMT complex purification procedure is described in this chapter. 
The discussion of this chapter explores all the methodology that will be used in the 
future for the biophysical studies and for the identification of a RAM/RNMT interaction 
inhibitor. Furthermore, the discussion analyses all the applications that a cap 
methylation inhibitor will have in biochemical research and the putative effects that it 
may have in cancer treatment.  
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5.2 Results 
5.2.1 Purification of recombinant RAM for crystallographic 
studies 
RAM contains 118 amino acids; however, recombinant RAM 1-90 was purified from 
bacteria for crystallographic studies. The reason the purification was performed with 
RAM 1-90 truncated mutant was that the initial protein purification yield obtained with 
the full length RAM was not adequate for crystallographic studies and therefore a 
truncated construct encoding amino acids 1-90 was used. Since RAM 1-90 can both 
activate RNMT and bind to RNA (Figure 4.3) it was reasoned that RAM 1-90 
truncated mutant is comparable with WT and can obtain the proper conformation.  
The steps followed for RAM 1-90 purification are presented in Figure 5.1a. Briefly, 
pGEX-6P1-based vector, expressing RAM 1-90 fused N-terminally to a GST-tag, 
were transduced into BL21 (DE3) E. coli. Single transformants were expanded to a 4 
L Luria Bertani broth culture. When culture optical absorbance at 600 nm reached 0.6, 
expression of recombinant protein was induced with 0.5 M IPTG (isopropyl-β-D-
thiogalactopyranoside) for 18 hrs at 15ºC. Cells were harvested by centrifugation at 
4,000 g for 20 min, resuspended in 25 ml lysis buffer [50 mM Hepes (pH 7.5), 250 
mM NaCl, 0.1% beta-mercaptoethanol, 1 mM benzamidine, 100 μg/ml leupeptin, 1 
mg/ml lysozyme] and sonicated six times on ice for 30 sec. Insoluble material was 
removed by centrifugation for 30 min at 60,000 g. The soluble material was incubated 
with 2 ml glutathione-sepharose resin for 90 min. Glutathione-sepharose specifically 
binds to glutathione S-transferase (GST) and consequently to the GST-tagged 
proteins. The sepharose was subsequently washed in 50 ml wash buffer [50 mM 
Hepes (pH 7.5), 250 mM NaCl, 0.1% beta-mercaptoethanol].  
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For RAM 1-90 elution, the glutathione-sepharose was incubated for 16 hrs at 4ºC in 
10 ml of a buffer containing 25 mM Hepes (pH 7.5), 250 mM NaCl, 0.1% beta-
mercaptoethanol and 0.2 mg PreScission protease. RAM 1-90 and GST-tag were 
linked with a PreScission protease targeted amino acid sequence. Addition of the 
PreScission protease, cleaved the GST-tag, which remained bound on glutathione-
sepharose, and eluted RAM 1-90. The protein sample was cleared by centrifugation 
at 4,000 g for 15 min. The protein yield obtain from the GST-purification was 20 mg. 
Analysis of the cell lysates before and after the affinity purification as well as the 
cleaved purified RAM 1-90 is demonstrated in a Coomassie stained SDS-
polyacrylamide gel (Figure 5.1b). 
In order to further purify RAM, the protein sample was diluted in a final volume of 250 
ml in a buffer containing 25 mM Hepes (pH 7.5), 10 mM NaCl and was loaded on a 
HiTrap SP cation exchange 5 ml column (GE Healthcare) operating in an AKTA 
FPLC (Pharmacia) at a flow rate of 1 ml/min. Cation exchange chromatography 
separates molecules in the basis of differences in their net surface charge. At pH 7.5 
SP sepharose is negatively charged and therefore binds RAM 1-90 that, at the same 
pH, has a positively charged net surface (RAM 1-90 PI: 8.2).  
After the protein was loaded onto the SP column, the column was washed with 50 ml 
of a buffer containing 25 mM Hepes (pH 7.5), 10 mM NaCl. The protein was eluted in 
25 mM Hepes (pH 7.5) and a salt gradient between 10 to 1000 mM NaCl over 50 ml. 
1.5 ml fractions were collected. The elution profile of RAM 1-90 is presented in Figure 
5.1c. The fractions were analysed in a Coomassie stained SDS-PAGE in Figure 5.1d. 
Fractions B3-B6 were combined and concentrated to 6 mg/ml. Further concentration 
resulted in protein precipitation. The concentrated sample was analysed by 
Coomassie stained SDS-polyacrylamide gel (Figure 5.1e). RAM 1-90 had been 
purified to 99% homogeneity. 
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Sitting drop vapour diffusion method was used for crystal formation. Crystallographic 
trays were set up using purified RAM 1-90 at the concentration of 6 mg/ml. 
Crystallisation screens Crystal Screens I/II, Index (Hampton Research) and JCSG+ 
(Qiagen) containing a matrix of buffers were used for protein crystallisation. Briefly, 
70 μl of mother liquor was deposited to the reservoir well of sitting drop plates 
(Douglas Instruments). 0.5 μl of protein solution was combined with 0.5 μl of mother 
liquor in the protein well. The tray was sealed with Crystal Clear sealing tape 
(Douglas Instruments), allowing easy visualization of the drops, and stored at 20ºC. 
Once per week the trays were examined for crystals formation. Until present no 
protein crystals have been formed.  
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Figure 5.1: Purification of recombinant RAM for crystallographic studies. 
pGEX6p-1 vector expressing RAM 1-90 truncated protein fused N-terminally to a 
GST-tag was transformed into competent E. coli bacteria BL21(DE3) cells. GST-
RAM expression was induced with IPTG and purified from cell lysates with 
glutathione-sepharose. RAM was eluted by cleaving off the GST-tag on the 
sepharose by GST-tagged PreScission protease. RAM was subsequently purified 
by cation exchange chromatography.  
(a) Purification steps followed for recombinant RAM purification.  
(b) 5 µg of cell lysates before (Inp) and after (F.T) affinity purification of GST-RAM 
and 30 µg of eluted (Eluate) GST-tag cleaved RAM were resolved in a 15% SDS-
PAGE and stained by Coomassie blue. RAM is indicated. 
(c) Elution profile of cation-exchange chromatography. A Linear gradient of NaCl 
was employed for the elution. The blue line represents the UV absorbance at 280 
nm. The green line represents the percentage of 1M NaCl over 10mM NaCl. The 
brown line represents the ionic conductivity.  
(d) The eluted fractions from the cation-exchange chromatography, as indicated 
above the gel, were separated by electrophoresis through a 15% polyacrylamide 
gel and stained by Coomassie blue. RAM is indicated. Fractions B3-B7 were 
combined and concentrated to 6 mg/ml. 
(e) 20 µg, 60 µg and 150 µg of the concentrated sample were resolved in a 15% 
SDS-polyacrylamide gel and stained by Coomassie blue. RAM is indicated. 
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5.2.2 Purification of recombinant RAM/RNMT complex for 
crystallographic studies 
In parallel with the attempt to crystallise monomeric RAM we also attempted to 
crystallise RAM/RNMT complex. As explained before we focused on RAM 1-90. 
Since monomeric truncated RNMT 165-476 had been successfully crystallised in the 
past (PDB code 3EPP, 3BGV) we decided to use this RNMT version in our 
crystallisation trials.  
The steps followed for RAM 1-90/RNMT 165-476 complex purification are presented 
in Figure 5.2a. Briefly, pOPC-based bicistronic vector expressing RNMT 165-476 
fused N-terminally with a 6xHIS-tag and untagged RAM 1-90 were transduced into 
BL21 CodonPlus (DE3)-RIL E. coli cells. Single transformants were expanded to a 6 
L Terrific broth culture. When culture optical absorbance at 600 nm reached 1.3, 
expression of recombinant proteins was induced with 1 M IPTG (isopropyl-β-D-
thiogalactopyranoside) for 18 hrs at 15ºC. Cells were harvested by centrifugation at 
4,000 g for 20 min, resuspended in 200 ml lysis buffer [50 mM Hepes (pH 7.0), 500 
mM NaCl, 0.1% beta-mercaptoethanol, 1 mM benzamidine, 100 μg/ml leupeptin, 1 
mg/ml lysozyme] and passed five times through a constant-flow cell disruptor 
(Constant Systems) at operating pressure of 20,000 psi. Insoluble material was 
removed by centrifugation for 60 min at 60,000 g at 4ºC.  
The soluble material was incubated for 90 min with 3 ml IMAC-sepharose charged 
with Nickel chloride that had been equilibrated with lysis buffer. Nickel-charged 
IMAC-sepharose specifically binds and purifies HIS-tagged proteins allowing their 
purification from cell lysates. The sepharose was subsequently washed in 50 ml 
wash buffer [25 mM Hepes (pH 7.0), 500 mM NaCl, 0.1% beta-mercaptoethanol]. 
RAM 1-90/RNMT 165-476 complex was eluted in 15 ml elution buffer [25 mM Hepes 
(pH 7.0), 500 mM NaCl, 250 mM imidazole, 0.1% beta-mercaptoethanol]. Although 
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RAM 1-90 was untagged, it was successfully purified from the lysates together with 
6xHIS-RNMT 165-476. The protein yield was 40 mg. Analysis of the cell lysates 
before and after the affinity purification as well as 40 μg RAM 1-90/RNMT 165-476 is 
demonstrated in a Coomassie stained SDS-polyacrylamide gel (Figure 5.2b).  
RAM 1-90/RNMT 165-476 was further purified by Heparin chromatography. Heparin 
is a sulfated glycosaminoglycan that carries a highly negative charge that is often 
employed for the purification of RNA-binding proteins, like RNMT (Thillier et al., 2012). 
The elution sample was diluted in 500 ml with a buffer containing 25 mM Hepes 
(pH7.0), 0.1% beta-mercaptoethanol and loaded on a HiTrap Heparin 5 ml column 
(GE Healthcare) operating in an AKTA FPLC (Pharmacia) with a flow rate of 1 ml/min. 
The column was washed with 50 ml 25 mM Hepes (pH 7.0), 10 mM NaCl, 0.1% beta-
mercaptoethanol. The protein was eluted in 25 mM Hepes (pH 7.0) and a salt 
gradient between 10 to 1000 mM NaCl in 10 column volumes. 1.5 ml fractions were 
collected. The elution profile of RAM 1-90/RNMT 165-476 complex is presented in 
Figure 5.2c. The fractions were analysed in a Coomassie stained SDS-
polyacrylamide gel (Figure 5.2d). 
Fractions B8-B13 were combined to a final volume of 10 ml. The sample was 
concentrated to 3 ml and injected to a gel filtration s75 26/60 column (GE Healthcare). 
Gel filtration separates complexes according to their molecular weight. The column 
was operating in an AKTA FPLC (Pharmacia) with a flow rate of 1 ml/min and 
equilibrated in 20 mM PIPES, pH 6.5, 150 mM NaCl buffer. 2.5 ml fractions were 
collected. The elution profile is demonstrated in Figure 5.2e and analysis of the peak 
fractions by Coomassie stained SDS-polyacrylamide gel is presented in Figure 5.2f. 
Fractions C13-D1 were combined and concentrated to approximately 45 mg/ml. 
Analysis of the purified sample by SDS-PAGE followed by Coomassie blue staining 
demonstrated that the proteins had been purified to homogeneity (Figure 5.2g). The 
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presence of both RAM and RNMT in the sample was confirmed by MALDI-TOF mass 
spectrometry analysis performed by the FingerPrints Proteomics facility at the 
University of Dundee.  
Crystallographic trays were set up as described previously. The crystallographic 
screens Crystal Screen I/II, Index, MembFac, PegIon (Hampton Research) and 
ProPlex (Molecular Dimensions Ltd) were utilised. In addition to purified RAM/RNMT 
complex sample, ternary complexes of RAM/RNMT and SAH (S-adenosyl 
homocysteine) were screened for crystal formation. As previously RNMT had been 
crystallised in a complex with SAH (Structural Genomics Consortium; PDB code 
3BGV), ternary complexes were generated by combining RAM/RNMT with SAH in 
1:2 molar ratio. Until present no protein crystals have been formed. 
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Figure 5.2: Purification of RAM/RNMT complex for crystallographic studies.  
pOPC bicistronic vector expressing RNMT 165-476 truncated protein fused N-
terminally to a 6xHIS-tag and untagged RAM 1-90 truncated protein was transformed 
into competent E. coli bacteria BL21(DE3) +RIL codon cells. 6xHIS-RNMT and RAM 
expression was induced with IPTG and purified from cell lysates with Nickel-charged 
IMAC-sepharose. The complex was eluted from the sepharose with imidazole and 
subsequently purified by heparin and size-exclusion chromatography (Superdex 75 
column).  
(a) Purification steps followed for recombinant RAM/RNMT complex purification.  
(b) 3 µg of cell lysates before (Inp) and after (F.T) affinity purification of RAM/RNMT 
complex and 40 µg of eluted (Eluate) GST-tag cleaved RAM were resolved in a 15% 
SDS-polyacrylamide gel and stained by Coomassie blue. RAM and RNMT are 
indicated. RAM and RNMT are indicated.  
(c) Elution profile of heparin chromatography. A linear gradient of NaCl was employed 
for the elution. The blue line represents the UV absorbance at 280 nm. The green line 
represents the percentage of 1M NaCl over 10mM NaCl. The brown line represents the 
ionic conductivity.  
(d) The eluate from affinity purification (Eluate) was diluted and loaded onto a heparin 
column (Inp). The flow-through (F.T) was collected and analysed. The eluted fractions 
from the heparin column, as indicated above the gel, were separated by 
electrophoresis through a 15% polyacrylamide gel and stained by Coomassie. RAM 
and RNMT are indicated. Fractions B8-B13 were combined and loaded onto a size-
exclusion chromatography column. RAM and RNMT are indicated.  
(e) Elution profile of size-exclusion chromatography. The blue line represents the UV 
absorbance at 280 nm. The brown line represents the ionic conductivity.  
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Figure 5.2: Purification of RAM/RNMT complex for crystallographic studies.  
(f) Fractions C10-D6 of size-exclusion chromatography, as indicated above the 
gel, were separated by electrophoresis through a 15% polyacrylamide gel and 
stained by Coomassie blue. The original eluate from affinity purification (Eluate) 
as well as the combined fractions eluted from heparin chromatography (Heparin) 
and the concentrated sample injected into size-exclusion chromatography (Inp) 
were analysed in the first lanes of the gel. RAM and RNMT are indicated. 
Fractions C12-C15 of size-exclusion chromatography were combined and 
concentrated to 19 mg/ml. RAM and RNMT are indicated.  
(g) 57 µg and 190 µg of the concentrated sample were resolved in a 15% SDS-
polyacrylamide gel and stained by Coomassie blue. RAM and RNMT are 
indicated.  
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5.2.3 Purification of recombinant RAM/RNMT complex for 
inhibitor screening 
Recombinant RAM/RNMT complexes were purified for performing biophysical 
screens for the identification of an inhibitor of RAM/RNMT interaction. The steps 
followed for RAM/RNMT complex purification are presented in Figure 5.3a. Briefly, 
pOPC-based bicistronic vector expressing full length RNMT fused N-terminally with a 
6xHIS-tag and RAM 1-90 fused N-terminally with a GST-tag were transduced into 
BL21 (DE3) E. coli cells. Single transformants were expanded to a 4 L Luria Bertani 
broth culture. When culture optical absorbance at 600 nm reached 0.6, expression of 
recombinant protein was induced with 0.5 M IPTG (isopropyl-β-D-
thiogalactopyranoside) for 18 hrs at 15ºC. Cells were harvested by centrifugation at 
4,000 g for 20 min, resuspended in 50 ml lysis buffer [50 mM Tris (pH 7.5), 250 mM 
NaCl, 0.1% beta-mercaptoethanol, 1 mM benzamidine, 100 μg/ml leupeptin, 1 mg/ml 
lysozyme] and sonicated six times on ice for 30 sec. Insoluble material was removed 
by centrifugation for 30 min at 60,000 g. The soluble material was incubated for 90 
min with 2 ml glutathione-sepharose resin and then washed in 50 ml wash buffer [50 
mM Tris (pH 7.5), 250 mM NaCl, 0.1% beta-mercaptoethanol].  
RAM/RNMT complex was eluted in 10 ml elution buffer [25 mM Tris (pH 7.5), 250 
mM NaCl, 50 mM glutathione, 0.1% beta-mercaptoethanol]. The protein yield was 20 
mg. Analysis of the cell lysates before and after the affinity purification as well as 40 
μg purified RAM/RNMT complex is demonstrated in a Coomassie stained SDS-
polyacrylamide gel (Figure 5.3b).  
The sample was concentrated to 3 ml and injected into a gel filtration s200 16/60 
column (GE Healthcare) operating in an AKTA FPLC (Pharmacia) with a flow rate of 
1 ml/min and equilibrated in 25 mM Tris (pH 7.5), 150 mM NaCl buffer. Fractions of 
1.5 ml were collected. The elution profile is demonstrated in Figure 5.3c and analysis 
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of the peak fractions by Coomassie stained SDS-PAGE is presented in Figure 5.2d. 
Fractions C2-C8 were combined and concentrated to 2.5 mg/ml. Analysis of the 
purified sample was performed by SDS-PAGE followed by Coomassie staining as 
demonstrated in Figure 5.3e.  
The purified GST-RAM/6xHIS-RNMT complex apart from being used for inhibitor 
screening has been also used for in vitro phosphorylation assays performed by 
Michael Aregger in Victoria Cowlingʼs lab. Western blot analysis and in vitro 
methylation assays of the purified complex, performed by Aregger, demonstrated the 
presence of RAM/RNMT in the purified sample and that it was retaining functional 
conformation after purification.  
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Figure 5.3: Purification of recombinant RAM/RNMT complex for inhibitor 
screening. 
pOPC bicistronic vector expressing RNMT fused N-terminally to a 6xHIS-tag and 
RAM 1-90 truncated protein fused N-terminally to a GST-tag was transformed into 
competent E. coli BL21(DE3) cells. 6xHIS-RNMT and GST-RAM expression was 
induced with IPTG and purified from cell lysates with glutathione-sepharose. The 
complex was eluted from the sepharose with glutathione and subsequently purified 
by size-exclusion chromatography (Superdex 200 10/30 column). 
(a) Purification steps followed for recombinant GST-RAM/6xHIS-RNMT complex 
purification.  
(b) 40 µg of eluted (Eluate) RAM/RNMT complex was resolved in a 10% SDS-
polyacrylamide gel and stained by Coomassie blue. GST-RAM and HIS-RNMT are 
indicated. 
(c) Elution profile of size exclusion chromatography. The blue line represents the 
UV absorbance at 280 nm. The brown line represents the ionic conductivity.  
(d) The affinity purification eluate (Inp) was loaded onto a size-exclusion 
chromatography column and the indicated eluted fractions were separated by 
electrophoresis through a 10% polyacrylamide gel stained by Coomassie blue. 
Fractions C3-C6 were combined and concentrated to 10 mg/ml. 
(e) 60 µg of the concentrated sample were resolved in a 15% SDS-polyacrylamide 
gel and stained by Coomassie blue. GST-RAM and HIS-RNMT are indicated. 
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5.2.4 Purification of recombinant RNMT complex for 
biophysical studies 
Finally, recombinant full length RNMT was purified for biophysical assays. The steps 
followed for HIS-RNMT purification are presented in Figure 5.4a. Briefly, pNifty-based 
vector, expressing full length RNMT fused N-terminally with a 6xHIS-tag were 
transduced into BL21 CodonPlus (DE3)-RIL E. coli cells. Single transformants were 
expanded to a 2 L Terrific broth culture. When culture optical absorbance at 600 nm 
reached 1.3, expression of recombinant protein was induced with 1 M IPTG 
(isopropyl-β-D-thiogalactopyranoside) for 18 hrs at 15ºC. Cells were harvested by 
centrifugation at 4,000 g for 20 min, resuspended in 50 ml lysis buffer [50 mM Hepes 
(pH 7.5), 500 mM NaCl, 0.1% beta-mercaptoethanol, 1 mM benzamidine, 100 μg/ml 
leupeptin, 1 mg/ml lysozyme] and sonicated six times on ice for 30 sec. Insoluble 
material was removed by centrifugation for 30 min at 60,000 g.  
The soluble material was incubated for 90 min with 1 ml IMAC-sepharose charged 
with Nickel chloride and washed in 20 ml wash buffer [25 mM Hepes (pH 7.5), 500 
mM NaCl, 0.1% beta-mercaptoethanol]. HIS-RNMT was eluted in 5 ml elution buffer 
[25 mM Hepes (pH 7.5), 500 mM NaCl, 250 mM imidazole, 0.1% beta-
mercaptoethanol]. The protein yield was 5 mg. Analysis of the cell lysates before and 
after the affinity purification as well as 40 μg purified RNMT is demonstrated in a 
Coomassie stained SDS-polyacrylamide gel (Figure 5.4b). 
HIS-RNMT was further purified by Heparin chromatography. The elution sample was 
diluted in 50 ml with a buffer containing 25 mM Hepes (pH7.5), 0.1% beta-
mercaptoethanol and loaded on HiTrap Heparin 5 ml column (GE Healthcare) 
operating in an AKTA FPLC (Pharmacia) in a flow rate of 1 ml/min. The column was 
washed with 50 ml of a buffer containing 25 mM Hepes (pH 7.5), 10 mM NaCl, 0.1% 
beta-mercaptoethanol. The protein was eluted in 25 mM Hepes pH 7.5 and a salt 
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gradient between 10 to 1000 mM NaCl in 10 column volumes. Fractions of 1 ml were 
collected. The elution profile of HIS-RNMT is depicted in Figure 5.4c. The proteins 
were visualised after separating by SDS-PAGE followed by Coomassie staining 
(Figure 5.4d). 
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Figure 5.4: Purification of recombinant RNMT for biophysical assays. 
pNIFTY vector expressing RNMT fused N-terminally to a HIS-tag was 
transformed into competent E. coli bacteria BL21(DE3) +RIL codon cells. HIS-
RNMT expression was induced with IPTG and purified from cell lysates with 
Nickel-charged IMAC-sepharose. RNMT was eluted from the sepharose with 
imidazole and subsequently purified by heparin chromatography.  
(a) Purification steps followed for recombinant HIS-RNMT purification.  
(b) 4 µg of cell lysates before (Inp) and after (F.T) affinity purification of RNMT 
and 40 µg of eluted (Eluate) HIS-RNMT were separated by electrophoresis 
through a 8% polyacrylamide gel and stained by Coomassie blue. HIS-RNMT is 
indicated. 
(c) Elution profile of heparin chromatography. A linear gradient of NaCl was 
employed for the elution. The blue line represents the UV absorbance at 280 nm. 
The green line represents the percentage of 1M NaCl over 10mM NaCl. The 
brown line represents the ionic conductivity.  
(d) The eluate of affinity purification was diluted and loaded onto a heparin 
column (Inp). The flow-through (F.T) was collected and analysed. The eluted 
fractions from the heparin column, as indicated above the gel, were analysed in 
a 10% SDS-polyacrylamide gel and stained by Coomassie blue. HIS-RNMT is 
indicated. 
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5.3 Discussion  
This chapter describes the purification of monomeric RAM, RNMT as well as the 
purification of RAM/RNMT complex from bacteria cells. Monomeric RAM 1-90 and 
RAM 1-90/RNMT 165-476 complex were screened for crystal formation.  
In the past, the structure of human monomeric RNMT (Structural Genomics 
Consortium; PDB code 3BGV, 3EPP), the mRNA cap methyltransferase of the 
microsporidian parasite Encephalitozoon cuniculi (Fabrega et al., 2004) and the 
Vaccinia virus methyltransferase complex composed of D1 and D12 subunits (De la 
Peña et al., 2007) had been crystallised. In all the above cases, the RNA guanine-N7 
methyltransferase was crystallised in the presence of a ligand, usually SAH (De la 
Peña et al., 2007; Fabrega et al., 2004), (Structural Genomics Consortium; PDB code 
3BGV), which is a by-product of the methylation reaction. Therefore, RAM/RNMT 
complex was attempted to be crystallised in the presence of SAH as well.  
Unfortunately, until present neither RAM nor RAM/RNMT complex crystallisation was 
successful. At the moment more crystallisation conditions are being screened both in 
the presence and in the absence of SAH. In the future, RAM and RAM/RNMT 
complex crystallisation will be attempted in the presence of a short RNA molecule 
that can possibly facilitate the crystallisation of the proteins. Furthermore, the 
crystallisation of RNMT 165-476 with different RAM truncated versions will be 
attempted since often in crystallographic studies removal of a few amino acids is 
required for the production of a “crystallisable” protein. 
In addition to crystallographic studies, the recombinant proteins can also be used for 
biophysical studies. Therefore, as described in the result section, recombinant full 
length RNMT, RAM 1-90 and RAM/RNMT complex were prepared. The recombinant 
proteins that were prepared for the biophysical assays were not purified to 
homogeneity since the biophysical assays we are planning to use do not require 
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absolute protein purity. Our research interests were to address whether and how 
RAM can alter RNMT affinity for SAM, RNA and GpppG. In order to address the 
above questions we decided to perform biolayer interferometry in collaboration with 
the Drug Discovery Unit at the University of Dundee. Biolayer interferometry is a 
technique that measures changes in the interference pattern generated from visible 
light reflected from a biolayer containing biotinylated-targeted proteins (Wartchow et 
al., 2011). Additional proteins, small molecules and fragments that bind to the 
targeted-protein can change the interference pattern and the interaction details can 
be characterised. Biolayer interferometry is a label-free interaction technology with 
many advantages including more prompt set up in comparison with traditional 
methods, avoiding the common problem of the label itself interfering with the assay 
and most importantly avoiding washing steps that perturb with reaction equilibrium 
and diminish weak or transient interactions (Rich and Myszka, 2007).  
Biolayer interferometry can be also used for screening and identifying small 
molecules that bind to RNMT. This may prove useful for identifying inhibitors of 
RNMT active site or RAM/RNMT interaction. RNMT active site can bind to many 
molecules like SAM, SAH, sinefugin and tubercidin suggesting that RNMT is 
“ligandable”. The first step for the identification of an inhibitor is to detect molecules 
that bind to the targeted protein. In subsequent steps, expanded libraries derived 
from the initial hits can be screened for inhibitory effects. Having a crystal structure of 
the targeted protein can facilitate the design of an inhibitor. This is an additional 
reason why the crystal structure of RAM/RNMT complex would be highly informative.  
An inhibitor of the mRNA cap methyltransferase apart from being useful for 
biochemical studies may also have therapeutic effects. At present, our research is 
based on siRNA and cDNA transfections that come with disadvantages such as the 
toxicity of transfection reagents, the incomplete depletion of targeted proteins (70-
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90% depletion) but also the extended time period that they require to function (at 
least 24 hrs). A specific mRNA cap methyltransferase inhibitor would bypass all the 
above problems and would be useful for research purposes. Recently it was 
demonstrated that inhibition of cap-methylation is synthetic lethal with elevated Myc 
expression and abolishes Myc-induced protein synthesis, cell proliferation and cell 
transformation (Fernandez-Sanchez et al., 2009). Considering that Myc deregulation 
is found in 70% of human tumours (Cole and Cowling, 2008), these findings indicate 
that cap-methylation inhibitors can be tested as putative drugs for cancer treatment. 
The uniqueness of RAM/RNMT interface promises the development of relatively 
specific inhibitors with putative therapeutic effects in cancer treatment. At the 
moment there are no specific inhibitors for human RNA guanine-N7 
methyltransferase.  
In order to develop an inhibitor we decided to use the Alpha screen assay in 
collaboration with the Drug Discovery Unit. For this purpose recombinant GST-RAM 
/HIS-RNMT complex was generated. The complex will be screened for the 
identification of an inhibitor that can disrupt the interaction (Sehr et al., 2007). The 
principle of the Alpha screen assay is based on energy transfer producing a 
luminescent/fluorescent signal. Briefly, GST-RAM and HIS-RNMT will bind to two 
different kinds of beads (donor and acceptor beads) via the two different tags they 
express at their N-terminus. Donor beads are excited with 680 nm light and produce 
singlet O2 which can diffuse 200 nm distance in solution. As long as RAM and RNMT 
interact with each other acceptor beads will be in close proximity and the transferred 
energy from the singlet O2 to the acceptor beads will produce detectable light at 580 
nm (Barbeau A, Banks P, 2002). The advantages of Alpha screen assay are that it 
has high sensitivity, low background, and that it can be performed in as small volume 
as 10 μl (Illy et al., 2002). Following succesful identification of putative inhibitors able 
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to disrupt RAM/RNMT interaction by Alpha screen assay, biolayer interferometry will 
be used for validating the positive hits. The disruption of RAM/RNMT interaction will 
change the interference pattern of the targeted RNMT disposing biolayer 
interferometry as an orthogonal assay for validating Alpha screen assay positive hits.  
To summarise, this chapter describes the production of recombinant monomeric 
RAM and RAM/RNMT in a complex that are being used for crystallographic studies. 
In addition, the recombinant proteins will be employed in a variety of biophysical 
assays like biolayer interferometry and Alpha screen assay that will be used to 
investigate the effect of RAM upon RNMT as well as to develop inhibitors of the 
mammalian RNA guanine-N7 methyltransferase complex.  
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Chapter 6:  Investigation of the mechanisms 
that regulate the RNA guanine-7 
methyltransferase complex 
6.1 Introduction 
The final chapter focuses on the mechanisms that regulate the RNA guanine-7 
methyltransferase complex. While studying RAM function, a single nucleotide 
polymorphism (SNP) responsible for an amino acid substitution was identified in 
RAM coding sequence. SNPs have the potential to modulate protein functions 
between individuals. As will be analysed in the first part of this chapter the RAM SNP 
mutation that was identified can modulate RAM stability.  
The second part of chapter 6 describes the identification of two novel post-
translational modifications of the RNA guanine-7 methyltransferase complex and 
discusses the significance of these findings. 
 
6.1.1 Single nucleotide polymorphisms (SNPs) 
SNP is defined as a DNA sequence variation at one specific position in the genome 
that occurs in at least 1% of the human population (Heinrichs and Look, 2007). SNPs 
are the most common mode of genetic variation in vertebrates (Feuk et al., 2006). 
The SNP consortium, together with the Human Genome Project, identified 1.5 million 
SNPs in the human genome, 60,000 of which are located within exons 
(Sachidanandam et al., 2001).  
SNPs can be divided into the following categories: synonymous, which do not result 
in an amino acid alteration and non-synonymous, which result in an amino acid 
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change that frequently cause structural changes to the protein and are retained by 
natural selection (Cohuet et al., 2008). Therefore, SNPs can provide the material for 
the natural selection to occur (Shastry, 2002); information that can be employed for 
the study of the evolutionary history of human populations (Stoneking, 2001). In 
addition, SNPs can provide insight into the pathogenesis of various diseases with the 
optimal goal to promote personalised medicine (Gadow, 2012). 
One of the most significant developments to date in the molecular study of disease 
genetics has emerged from the availability of SNPs information that enable 
association studies directed at identifying genetic determinants for common disease 
(Cardon and Bell, 2001). Genome wide association studies have linked specific 
SNPs with several diseases including several forms of cancer (Ghoussaini et al., 
2012; Macgregor et al., 2012; Gudmundsson et al., 2012), diabetes (Cho et al., 2012; 
Shea et al., 2011) and cardiovascular disease (Ehret et al., 2011; Ozaki et al., 2009). 
 
6.1.2 Post-translational modification 
During our studies novel post-translational modifications of both RAM and RNMT 
were identified. Post-translational modifications are a common feature of gene 
expression altering protein characteristics and function. In higher eukaryotes a 
plethora of post-translational modifications, including phosphorylation, ubiquitination, 
sumoylation, neddylation, acetylation, methylation, glycosylation and many more, 
have been reported (Walsh, 2006). Post-translational modification of proteins can 
regulate protein function by causing changes in protein activity, stability, cellular 
localisation and dynamic interactions with other proteins (Seo and Lee, 2004). During 
this study it was identified that RNMT can be sumoylated and RAM phosphorylated. 
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Thus, the rest of the introduction is specifically focused on sumoylation and 
phosphorylation post-translational modifications. 
SUMO (Small ubiquitin-like modifiers) is a protein family that is covalently linked to a 
variety of proteins modifying their biological properties (Hay, 2005). In vertebrates 
there are three expressed SUMO paralogs designated as SUMO1, SUMO2 and 
SUMO3 with 11 kDa molecular mass. SUMO2 and SUMO3 differ from each other by 
three amino acid in the N-terminus while SUMO1 is only 50% identical with SUMO2 
and SUMO3. The SUMO2 and SUMO3 pool is more abundant than SUMO1 and is 
utilised when cells are exposed to a variety of cellular stresses like heat and oxidative 
stress (Saitoh and Hinchey, 2000).  
SUMO is conjugated to Lysine residues of substrate proteins often within a 
consensus motif ψKχE (where ψ is a large hydrophobic residue and χ any amino 
acid). SUMO conjugation to substrate proteins involves a heterodimeric SUMO-
activating enzyme (SAE) containing SAE1 and SAE2, the Ubc9 SUMO-conjugating 
enzyme and the SUMO E3 ligases. Ubc9 has the ability to recognise and directly 
sumoylate many substrates but often SUMO E3 ligases are utilised for sumoylation 
of proteins ʻʼoutsideʼʼ the consensus motif (Wilkinson and Henley, 2010).  
SUMO2 and SUMO3 have the ability to form polySUMO chains, by covalently 
binding to themselves via the Lysine residue at the N-terminus consensus motif 
ψKχE. Conversly, SUMO1 lacks the consensus site and is therefore unable to form 
polychains (Hannoun et al., 2010).  
Sumoylation is an essential process for cell viability. Ubc9 knock-out mice die at an 
early embryonic stage (Nacerddine et al., 2005). Sumoylation of a protein can modify 
its function. Often, SUMO conjugation promotes or inhibits the interaction of the 
substrate with other proteins. In addition, sumoylation may alter the conformation of 
the substrate protein, regulating its function directly. Finally, there is often an 
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interplay between sumoylation and other post-translational modification like 
ubiquitination, phosphorylation or acetylation (Wilkinson and Henley, 2010). 
Sumoylation is a highly dynamic process that can be readily reversed by 
desumoylation enzymes.  
By using mass spectrometry analysis we identified that RAM can be phosphorylated 
at Serine-36. Protein phosphorylation is the most widespread type of post-
translational modification used in signal transduction affecting growth, division, 
motility and other cellular processes (Ubersax and Ferrell, 2007). Protein kinases 
catalyse the transfer of a γ-phosphate from ATP to a serine, threonine or tyrosine 
residue of the protein substrate. The human kinome consists of 518 proteins 
(Johnson, 2009). Phosphorylation is a dynamic modification that can have profound 
effects on the function of the substrate protein like altering its conformation, 
subcellular localization, activity or binding partners in response to signal transduction 
pathways (Johnson, 2009). 
 
6.2 Results 
6.2.1 Identification of RAM K10N single nucleotide 
polymorphism (SNP)  
After the identification of RAM, a novel RNMT binding protein, the coding sequence 
was cloned into a mammalian expression vector from complementary DNA (cDNA) 
synthesised from HEK-293 total RNA. Four independently produced constructs were 
sequenced and all were found to carry a mutation at position 215 of the mRNA 
sequence converting a Guanosine to Thymidine (GT), which introduced an amino 
acid substitution from Lysine (K) to Asparagine (N). In the rest of this thesis this 
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mutation will be referred to as RAM K10N. Since RAM WT cloning was unsuccessful 
from HEK-293 cells, the cloning was repeated from cDNA derived from HeLa cells. 
Additional clones derived from HeLa cDNA contained the K10N mutation at 1:1 ratio 
with WT, suggesting that HeLa cells possess at least one RAM WT and one RAM 
K10N allele. It should be stated that we think that HEK-293 cells are also expressing 
both RAM WT and K10N since the RAM protein peptides originally detected by mass 
spectrometry (Figure 3.2b), were trypsinised after the 10th amino acid indicating that 
this amino acid was Lysine and not Asparagine.  
According to the NCBI database out of 4418 individuals that have been sequenced 
91% were homozygous for RAM WT, 8.6% were heterozygous RAM WT/RAM K10N 
and 0.2% were homozygous for RAM K10N 
(http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=61738562 at 01/08/12). Taking into 
account that 8.6% of the population is heterozygous, the predicted RAM K10N 
homozygous occurrence would be 0.19%, which is similar to the percentage 
observed in the population. This suggests that RAM K10N mutation homogeneity 
does not have any deleterious effects for the organism. RAM K10N single nucleotide 
polymorphism has not been associated with any disease. 
 
6.2.2 Investigation of RAM K10N biochemical function 
The biochemical function of RAM K10N mutation was further investigated. The fact 
that HeLa cells are heterozygous for RAM K10N mutation suggests that RAM K10N 
mutation does not affect RAM nuclear localisation since endogenous RAM 
expression in HeLa cells is restricted in the nucleus (Figure 4.5, right panel).  
The effect of K10N mutation on RAM expression levels was subsequently 
investigated. Fg-RAM WT and Fg-RAM K10N were transfected into HeLa and IMEC 
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cells. Cell extracts were analysed by western blot to detect RAM and β-Tubulin as 
loading control. The Fg-RAM K10N mutant was expressed less efficiently in 
comparison to Fg-RAM WT in both HeLa and IMEC cells (Figure 6.1a,c). qRT-PCR 
demonstrated that the expression levels of Fg-RAM WT and K10N transcripts were 
similar suggesting that RAM K10N mutation affects RAM expression at a post-
transcriptional level. Therefore, Fg-RAM K10N could either be translated less 
efficiently or it could be less stable than Fg-RAM WT. The most direct way to address 
this question would be to perform a pulse-chase experiment with 35S labelled amino 
acids. However, RAM amino acid sequence contains only two Methionine and no 
Cysteine. Thus, radiolabelled amino acid incorporation would be low.  
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Figure 6.1: RAM K10N is expressed less efficiently than RAM WT. 
HeLa cell were transfected with pcDNA5-Fg-RAM WT, pcDNA5-Fg-RAM K10N or 
vector control (Vec).  
(a) Cell extracts were analysed by western blot to detect RAM, RNMT and β-
Tubulin (Tub). 
(b) qRT-PCR was performed to detect Fg-RAM transcripts levels.   
IMEC cells were transfected with pcDNA5-Fg-RAM WT, pcDNA5-Fg-RAM K10N 
or vector control (Vec).  
(c) Cell extracts were analysed by western blot to detect RAM, RNMT and β-
Tubulin (Tub). 
(d) qRT-PCR was performed to detect Fg-RAM transcripts levels.   
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6.2.3 Determining the mechanism that affects RAM K10N 
expression 
Due to the previous finding that RNMT can stabilise RAM expression (Figure 4.6, 
4.7) the effect of endogenous RNMT, but also RAM, upon Fg-RAM WT and K10N 
expression was investigated. HeLa cells were depleted of endogenous RAM and 
RNMT using siRNA directed against RAM or RNMT (siRAM1 and siRNMT1 
respectively). Fg-RAM WT or K10N resistant to siRAM1 were introduced by 
transfection to restore RAM expression levels when siRAM1 was used. Cell extracts 
were analysed by western blot to detect RAM, RNMT or β-Tubulin (Tub) as loading 
control (Figure 6.2a). As demonstrated previously (Figure 4.6c), siRNA-mediated 
RAM depletion does not affect RNMT transcript levels and vice versa. In the absence 
of endogenous RNMT, the overexpression of Fg-RAM is decreased, which may 
indicate that endogenous RNMT is required for the stability of both Fg-RAM WT and 
K10N (Figure 6.2a; siRNMT1). When endogenous RAM was depleted, the 
expression levels of both Fg-RAM WT and K10N were increased suggesting that 
possibly, endogenously and exogenously expressed RAM compete for RNMT in 
order to be stabilised and expressed efficiently (Figure 6.2a; siRAM1). This was 
further supported by the observation that exogenous RAM reduces the expression of 
endogenous RAM, which migrates just below the Fg-RAM on western blots (Figure 
6.2a; compare lane 1 with 2 and 3).  
An interesting observation is that despite the enhanced expression of Fg-RAM WT 
compared to K10N, both Fg-RAM WT and K10N can rescue endogenous RNMT 
expression to the same extent when endogenous RAM is depleted (Figure 6.2a; 
siRAM1). The fact that RAM WT and K10N expression is different despite equal 
RNMT levels is intriguing and may suggest that the defect in Fg-RAM K10N 
expression is RNMT independent. 
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HA-RNMT overexpression resulted in similar observations. HeLa cells were 
transfected with Fg-RAM WT or Fg-RAM K10N and a titration of HA-RNMT. As 
expected, HA-RNMT stabilised both Fg-RAM WT and Fg-RAM K10N protein levels. 
Moreover, HA-RNMT could rescue the expression defect of Fg-RAM K10N (Figure 
6.2b, left panel; 0.5 μg, 0.1 μg).  
Conversely, when the amount of transfected HA-RNMT was below detection by 
western blotting (Figure 6.2b, left panel; 20 ng), RAM K10N mutant expression 
defects could not be rescued. The same pattern was observed when a 
methyltransferase dead (MTD) HA-RNMT mutant was transfected (Figure 6.2b, right 
panel). This suggests that HA-RNMT can rescue RAM K10N expression defects 
independently of its RNA guanine-7 methyltransferase activity probably via protecting 
it from proteasome degradation.  
In order to directly demonstrate that Fg-RAM K10N mutant is less stable than Fg-
RAM WT, the proteasomal degradation was inhibited by using proteasomal inhibitors. 
HeLa cells were transfected with constructs expressing Fg-RAM WT or K10N and 
subsequently the cells were treated with proteasome inhibitors MG132, clasto-
Lactacystin β-Lactone or vehicle control. A titration of the cell lysates transfected with 
Fg-RAM WT was analysed by western blot (Figure 6.3a). In the absence of 
proteasome inhibitor Fg-RAM K10N appeared to be expressed four-fold less 
efficiently in comparison with Fg-RAM WT (Figure 6.3a; left panel). When cells were 
treated with MG132 or clasto-Lactacystin β-Lactone proteasome inhibitors, the 
expression of Fg-RAM K10N became equivalent with the expression of Fg-RAM WT 
suggesting that Fg-RAM K10N is more susceptible to proteasomal degradation and 
thus less stable than Fg-RAM WT. 
Inhibition of protein synthesis by using the drug cycloheximide (CHX), which targets 
translation elongation, allowed the determination of protein half life by detecting the 
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level of protein remaining over time. HeLa cells were transfected with constructs 
expressing Fg-RAM WT or K10N and subsequently the cells were subjected to a 
time-course treatment with cycloheximide (Figure 6.3b). Fg-RAM K10N appeared to 
be less stable than Fg-RAM WT as demonstrated by western blot (Figure 6.3b; 
compare 0 and 2 hrs in the left and right panel). To summarise, the above result 
indicate that Fg-RAM K10N is degraded by the proteasome more efficiently than Fg-
RAM WT.  
  
Figure 6.2: RAM expression is dependent on RNMT. 
(a) The expression of endogenous RAM and RNMT was reduced in HeLa cells by 
transfection of siRNAs directed against RAM or RNMT in comparison with the 
non-targeting siRNAs (c), as indicated above the panel, for 75 hrs. HeLa cells 
were subsequently transfected with pcDNA5-Fg-RAM WT, pcDNA5-Fg-RAM 
K10N or vector control (Vec) 24 hrs post-siRNA transfections. Cell extracts were 
analysed by western blot to detect RAM, RNMT and β-Tubulin (Tub) as loading 
control.  
(b) HeLa cells were transfected with 0.5 µg pcDNA5-Fg-RAM WT, pcDNA5-Fg-
RAM K10N or vector control (Vec) and a titration of pcDNA5-HA-RNMT WT (left 
panel) or pcDNA5-HA-RNMT methyltransferase dead (MTD) (right panel) as 
indicated above the panels. Western blots were performed to detect RAM, RNMT 
and β-Tubulin (Tub). 
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Figure 6.3: RAM K10N mutant is less stable than RAM WT. 
(a) HeLa cells were transfected with pcDNA5-Fg-RAM WT, pcDNA5-Fg-RAM K10N 
or vector control (Vec). Cells were treated with the proteasome inhibitors MG132 
and clasto-Lactacystin β-Lactone or vehicle as indicated above the panels. Western 
blot analysis was performed to detect RAM, RNMT and β-Tubulin (Tub). A half 
(RAM WT 6 µg) and a quarter (RAM WT 3 µg) of the amount of extracts from cell 
transfected with pcDNA5-Fg-RAM WT were analysed. 
(b) HeLa cells were transfected with pcDNA5-Fg-RAM WT (left panel), pcDNA5-Fg-
RAM K10N (right panel) or vector control (Vec). Cells were treated with 50 µg/ml 
Cycloheximide (CHX) for the time points indicated above the panels. Western blot 
analysis was performed to detect RAM, RNMT and β-Tubulin (Tub).  
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6.2.4 Investigating whether RAM K10N mutation affects 
RAM/RNMT interaction 
In chapter 4 it was demonstrated that RNMT protects RAM from proteasomal 
degradation, which suggests that RAM degradation and interaction with RNMT are 
two interconnected processes. In order to investigate whether K10N mutation affects 
the interaction between RAM and RNMT, in vitro pull-down assays with recombinant 
proteins were performed. The production of the recombinant GST-RNMT, RAM 1-90 
WT and K10N is described in the Material and Methods section. SDS-polyacrylamide 
Coomassie stained gels of the purified proteins utilised in the in vitro pull-down 
experiments are presented in Figure 6.4a,c-e.  
Recombinant GST-RNMT was incubated with recombinant RAM 1-90 WT and RAM 
1-90 K10N for a time course and the complexes were purified with glutathione-
sepharose and analysed by western blot (Figure 6.5a). It should be noted that α-
RAM antibodies recognise equally recombinant RAM WT and RAM K10N as the 
input lanes of Figure 6.5a,b indicate. With elevated incubation time more RAM was 
detected to bound to RNMT. RAM K10N mutation did not affect the interaction 
between RAM and RNMT. A similar pull-down experiment was performed with a 
titration of RAM WT or K10N (Figure 6.5b) and resulted in increased detection of 
both RAM WT and K10N indicating that this mutation does not affect the interaction 
between recombinant RAM and RNMT.  
In order to investigate whether the interaction between cellular RNMT and RAM WT 
or K10N is also equivalent within cells, where post-translational modifications can 
modify the interactome, GFP-tagged expression vectors were utilised. GFP-tag often 
stabilises cellular proteins (Kaba et al., 2002; Stevens et al., 2010) and that was the 
case with RAM. As Figure 6.5c indicates the expression of RAM WT-GFP was similar 
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with RAM K10N-GFP enabling us to investigate the effect of K10N mutation without 
taking into account the defect of RAM K10N expression. HeLa cells were transfected 
with RAM WT-GFP, RAM K10N-GFP or GFP control and α-GFP antibodies were 
utilised for immunoprecipitating RAM from the HeLa cell lysates. The amount of 
RNMT detected in the immunoprecipitates was similar when RAM WT-GFP or K10N-
GFP were immunoprecipitated suggesting that also within cells RAM K10N mutation 
does not interfere with RAM/RNMT interaction.  
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Figure 6.4: Purification of recombinant monomeric GST-RNMT, RNMT/RAM 
complex, monomeric RAM WT and monomeric RAM K10N. 
(a) 30 µg recombinant GST-RNMT were resolved in a 8% SDS-polyacrylamide gel 
and stained by Coomassie blue. GST-RNMT is indicated.  
(b) 12 µg recombinant RNMT/RAM complex were resolved in a 15% SDS-
polyacrylamide gel and stained by Coomassie blue. RNMT and RAM are indicated.  
(c) 6 µg of the cell lysates before (Inp) and after (F.T) the affinity purification of GST-
RAM WT (RAM WT) and GST-RAM K10N (RAM K10N) and 30 µg of the eluted 
GST-tag cleaved RAM WT and RAM K10N were resolved in a 15% SDS-PAGE 
stained by Coomassie blue. RAM is indicated. 
(d) Elution profile of size-exclusion chromatography (Superdex S200) of RAM WT 
(left) and RAM K10N (right) recombinant proteins. The blue line represents the UV 
absorbance at 280 nm and the brown line represents the ionic conductivity.  
(e) Fractions C2-C10 after size-exclusion chromatography of RAM WT (left) or RAM 
K10N (right) were resolved in a 15% SDS-PAGE and stained by Coomassie blue. 
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Figure 6.5: The interaction of RNMT and RAM is not affected by RAM K10N 
mutation. 
(a) 10 µg GST-RNMT or GST alone conjugated to glutathione-sepharose was 
incubated with 100 ng of recombinant RAM WT or RAM K10N for the time points 
indicated above the panels. Inputs (Inp WT, Inp K10N) and RAM WT and RAM 
K10N purified with GST-RNMT glutathione-sepharose were analysed by western 
blot to detect RNMT and RAM.  
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Figure 6.5: The interaction of RNMT and RAM is not affected by RAM K10N 
mutation. 
(b) 4 µg GST-RNMT was incubated with a titration of recombinant RAM WT and 
RAM K10N (10 ng, 100 ng or 1 µg). Inputs (Inp WT, Inp K10N) and RAM WT and 
RAM K10N purified by GST-RNMT glutathione-sepharose were analysed by 
western blot to detect RNMT and RAM.  
(c) HeLa cells were transfected with pcDNA5-RAM WT-GFP, pcDNA5-RAM 
K10N-GFP or vector control (GFP). RAM GFP complexes were purified from cell 
extracts with anti-GFP antibodies. Inputs and immunoprecipitates were analysed 
by western blot to detect GFP, RAM and RNMT.  
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6.2.5 Identification and validation of RAM Serine-36 
phosphorylation site 
Previous experiments indicated that RAM K10N mutation destabilises the protein 
without affecting its interaction with RNMT. The reason why the RAM K10N mutant is 
less stable than the RAM WT was further investigated. Lysine is one of the most 
commonly post-translationally modified amino acids. Methylation, acetylation, 
ubiquitination, sumoylation and neddylation are some post-translational modifications 
that can modify Lysine residues of a substrate protein. To determine whether K10 
was linked with any post-translational modification (PTM), RAM complexes were 
purified from human cells and then analysed for PTM using mass spectrometry. 
Expression vectors encoding HA-RAM and HA-RNMT were transiently transfected 
into HEK-293 cells and RAM/RNMT complexes were affinity purified from cell lysates 
using α-HA antibody. The immunoprecipitates were resolved by SDS-PAGE and 
visualized by Coomassie staining. The RAM band was excised, trypsinised and 
analysed by mass spectrometry to detect PTMs (Figure 6.6a). LTQ orbitrap VELOS 
was used for the identification of the peptides. Mascot search was used for the 
mapping of the identified peptides with the corresponding protein.  
RAM amino acid coverage after mass spectrometry analysis was 66% including 
Lysine-10. However, mass spectrometry analysis identified no modification linked 
with Lysine-10. The only post-translational modification identified in RAM was a 
phosphorylation at residue Serine-36 (Figure 6.6b). Several phosphoproteomics 
studies have identified RAM phosphorylation at Serine-36 previously (Chen et al., 
2009; Dephoure et al., 2008; Olsen et al., 2010; Weber et al., 2012).  
Surprisingly, in addition to RAM, two other polypeptides co-purified with the cap 
methyltransferase complex as demonstrated in the SDS-PAGE (Figure 6.6a; 
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indicated by *). The corresponding proteins were excised, trypsinised and analysed 
by mass spectrometry to identify their identity. The proteins that co-purified with the 
cap methyltransferase complex are listed in Figure 6.6c. All the proteins identified are 
RNA-binding proteins raising the possibility of being indirect interactors of the RNA 
guanine-7 methyltransferase complex via RNA. Due to time constraints, the effect of 
the above proteins on RNA guanine-7 methylation was not investigated. However, it 
should be noted here that the interaction of RAM and RNMT with some of these 
proteins may be responsible for the shift after size exclusion chromatography that is 
observed when cellular RAM/RNMT is compared with the recombinant complex 
(Figure 3.7). 
The phosphorylation at Serine-36 residue was validated by orthophosphate labelling. 
HEK-293 cells were transfected with Fg-RAM WT or an Fg-RAM S36A mutant in the 
presence of HA-RNMT. The Fg-RAM S36A mutant has an Alanine substitution 
instead of a Serine at position 36. Cells were pulsed labelled with radiolabelled 
orthophosphate and RAM complexes were immunoprecipitated from the cell extracts 
using α-FLAG antibody. The complexes were resolved by SDS-PAGE followed by 
autoradiography or western blot (Figure 6.6d). The amount of Fg-RAM WT and S36A 
immunoprecipitated was equivalent as the western blots indicate (Figure 6.6d; upper 
panels). The autoradiography demonstrated that Fg-RAM WT is phosphorylated, 
whereas Fg-RAM S36A is not. This indicates that Serine-36 is the predominant RAM 
phosphorylation site in HeLa cells under the conditions we examined. 
Having validated that RAM is phosphorylated, antibodies specific for the 
phosphorylated RAM S36 site were raised by DSTT (Division of Signal Transduction 
Therapy) service at the University of Dundee.  
The specificity of the antibodies was investigated in cell extracts from U2OS cells 
stably expressing GFP, RAM-GFP WT and RAM-GFP S36A under the control of a 
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doxycycline inducible system. RAM-GFP expression was induced with doxycycline 
and the cell extracts were subjected to α-GFP immunoprecipitations. The 
immunoprecipitates were analysed by western blot for the detection of RAM and 
phosphorylated RAM at Serine-36 (Figure 6.6e). Although the expression of both 
RAM-GFP WT and RAM-GFP S36A was equivalent as demonstrated by RAM 
western blot (Figure 6.6e; lower panel), only RAM-GFP WT was detected by the 
phospho-specific RAM S36 antibodies (Figure 6.6e; upper panel).  
Next, the effect of K10N mutation on RAM S36 phosphorylation was investigated. 
HEK-293 cells were transiently transfected with Fg-RAM WT, Fg-RAM K10N or Fg-
RAM S36A in the presence of HA-RNMT. Cell extracts were subjected to α-Flag 
immunoprecipitations and the immunoprecipitates were analysed by western blot to 
detect RNMT (Figure 6.7; upper panel), RAM (Figure 6.7; middle panel) and RAM 
phosphorylation at Serine-36 (Figure 6.7; lower panel). The amount of RAM 
immunoprecipitation was equivalent in all conditions. RAM K10N mutation did not 
affect RAM Serine-36 phosphorylation as western blot with the phospho-specific 
RAM antibodies demonstrated. Interestingly, when Fg-RAM-S36A was transfected, 
additional bands of higher molecular weight were detected by RAM western blot. This 
suggest that in the absence of RAM phosphorylation, other PTM like ubiquitination or 
sumoylation may modify RAM. In order to confirm that, further investigation is needed.  
Since RAM K10N exhibited similar phosphorylation levels at Serine-36 as RAM WT, 
RAM phosphorylation at Serine-36 appears not be involved in the expression defects 
observed in RAM K10N mutant. However, it may have other important biological 
significance. Preliminary studies demonstrate a reduction in cell proliferation rates 
when Fg-RAM S36A is transfected in the cells. The effect of RAM Serine-36 
phosphorylation upon cellular cap methylation is an active research area in Victoria 
Cowlingʼs lab.  
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Figure 6.6: RAM is phosphorylated at Serine-36. 
(a) HA-RNMT/HA-RAM complexes were isolated from HEK-293 cells transiently 
transfected with pcDNA5-HA-RAM and pcDNA5-HA-RNMT (RAM&RNMT) or 
vector control (Vec). 50 mg of cell extracts were immunoprecipitated using 50 µg 
anti-HA antibodies conjugated to agarose. Immunoprecipitates were resolved by 
gradient 4-12% SDS-PAGE and stained by Coomassie blue. Migration of RAM, 
RNMT, as well as antibody heavy chain (HC) and light chain (LC) are indicated. 
(b) Mass spectrometry analysis was performed for the excised RAM Coomassie 
stained gel band. The RAM post-translational modifications identified are 
presented in the table.  
(c) Mass spectrometry analysis was performed for the excised Coomassie stained 
gel bands with around 35 kDa and 110 kDa molecular weight [indicated by * in 
(a)]. A table of the proteins detected in the immunoprecipitate sample transfected 
with pcDNA5-HA-RAM and pcDNA5-HA-RNMT (RAM&RNMT) but not vector 
control (Vec) is presented.  
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Figure 6.6: RAM is phosphorylated at Serine-36. 
(d) HEK-293 cells were transiently transfected with either vector control (Vec) or 
pcDNA5-HA-RNMT and pcDNA5-Fg-RAM WT (WT) or pcDNA5-Fg-RAM S36A 
(S36A). Cells were incubated with 32P orthophosphate and Fg-RAM/HA-RNMT 
complexes were purified by immunoprecipitation of 5 mg cell extract with 5 µg 
anti-Flag antibodies conjugated to agarose. Immunoprecipitates were resolved by 
15% SDS-polyacrylamide gel followed by autoradiography (lower panel). Inputs 
and immunoprecipitates were also analysed by western blot to detect RAM with α-
RAM and α-Flag antibodies (upper panels). 
(e) U2OS cells stably transfected with doxycycline-inducible GFP-RAM WT, GFP-
RAM S36A or GFP alone were induced with doxycycline for 18 hrs. GFP-RAM 
was purified from 1 mg cell extracts with 1 µg anti-GFP antibodies. 
Immunoprecipitates were analysed by western blot to detect PAN RAM and RAM 
phosphorylated at Serine-36 using phospho-specific antibodies against RAM 
Serine-36 phosphorylation site.  
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Figure 6.7: RAM K10N mutation does not affect RAM Serine-36 
phosphorylation. 
HEK-293 cells were transiently transfected either with vector control (Vec) or with 
pcDNA5-HA-RNMT and pcDNA5-Fg-RAM WT (WT), pcDNA5-Fg-RAM K10N 
(K10N) or pcDNA5-Fg-RAM S36A (S36A). Fg-RAM/HA-RNMT complexes were 
purified from 5 mg cell extracts with  5 µg anti-Flag antibodies conjugated to 
agarose. Inputs and immunoprecipitates were analysed by Western blot to detect 
HA-RNMT, RAM and RAM P-S36. 
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6.2.6 RAM and RNMT can be sumoylated in vitro 
An inspection of the RAM amino acids sequence flanking Lysine-10 (PKFE; where K 
is Lysine-10) indicated that it resembles the sumoylation consensus motif (ψKχE; 
where ψ is a large hydrophobic residue, χ any amino acid and K is the sumoylated 
Lysine). Although RAM Lysine-10 residue was not detected to be sumoylated after 
mass spectrometry analysis further investigation was performed since it is common 
that PTM fail to be identified in the absence of enzymatic inhibitors that abolish their 
removal. Furthermore, RAM sumoylation would shift RAM to ~25 kDa molecular 
weight and it would therefore have been excluded from the mass spectrometry 
analysis.  
The hypothesis that RAM is sumoylated at Lysine-10 was investigated in vitro. 
Recombinant purified RAM 1-90 WT and RAM 1-90 K10N were subjected to in vitro 
sumoylation in the presence of SUMO1 or SUMO2, SAE1/2 SUMO-activating 
enzymes and Ubc9 SUMO-conjugating enzyme. The reactions were performed over 
a 5 hours time-course with samples removed at 45 min, 2 hr and 5 hr. Reaction 
products were resolved by SDS-PAGE followed either by Coomassie staining (Figure 
6.8a; upper panels) or western blot for RAM detection (Figure 6.8a; lower panels). 
RAM sumoylation was not detected by Coomassie staining but it was observed after 
RAM western blotting. Both SUMO1 and SUMO2 appeared to be able to sumoylate 
RAM. However, the proportion of RAM that became sumoylated in the in vitro 
reaction was low as demonstrated by the proportion of the western blot signal 
corresponding to RAM and sumoylated RAM (Figure 6.8a; lower panel; compare 
RAM with RAM-SUMO). RAM sumoylation appeared to be independent of RAM 
K10N mutation suggesting that in vitro RAM is sumoylated on another residue. H. 
sapiens RAM amino acid sequence contains two additional Lysine residues, K24 and 
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K31 (Figure 3.3), either of which could be potentially sumoylated in vitro although 
they do not possess a sumoylation consensus sequence.  
Since RAM and RNMT are found in a complex in vivo, it was investigated whether 
the interaction between RAM and RNMT can affect RAM sumoylation. Initially the 
sumoylation state of monomeric RNMT was investigated. Recombinant purified 
RNMT was subjected to an in vitro sumoylation assay like described previously 
(Figure 6.8b). RNMT appeared to be highly sumoylated as demonstrated both by 
Coomassie staining and western blot for detecting RNMT. This was a surprise 
considering that RNMT does not contain any sumoylation consensus motif. Both 
SUMO1 and SUMO2 were able to sumoylate RNMT in vitro and the proportion of 
sumoylated RNMT was high (Figure 6.8b; compare RNMT with RNMT-SUMO). To 
summarise, Figure 6.8 demonstrates that both monomeric RAM and RNMT can be 
sumoylated in vitro.  
Having establish that both monomeric RAM and RNMT can be sumoylated in vitro, 
recombinant purified RAM 1-90/RNMT complex (Figure 6.4b) was subjected to in 
vitro sumoylation in parallel with RAM and RNMT monomers (Figure 6.9a). Similar 
amounts of RAM 1-90 and RAM 1-90/RNMT were incubated for 3 hrs with SUMO1 or 
SUMO2 and the enzymes required for in vitro sumoylation as described previously. 
The reaction products were resolved by SDS-PAGE followed by western blot for 
RAM detection (Figure 6.9a; left panel). Although RAM can be sumoylated as a 
monomer (Figure 6.8a), in the presence of RNMT, RAM can be sumoylated more 
efficiently (Figure 6.9a; left panel). This suggests that RNMT may alter RAM 
conformation enabling its sumoylation. 
Conversely, RNMT sumoylation was drastically decreased in the presence of RAM 
(Figure 6.9a; right panel). This may occur because RAM binding to RNMT hinders 
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the RNMT sumoylation sites. To summarise, the in vitro sumoylation assays 
demonstrated that RNMT sumoylation is decreased in the presence of RAM.  
The observation that RAM and RNMT can be sumoylated and that monomeric RNMT 
can be sumoylated more efficiently in vitro was attempted to be recapitulated in the 
cells. HeLa cells were transiently transfected with expression vectors encoding Fg-
RAM, HA-RNMT or both Fg-RAM and HA-RNMT simultaneously. In order to equalise 
the expression levels of monomeric RAM and RNMT with their enhanced expression 
when RAM and RNMT expression vectors were co-transfected, cells were treated 
with MG132 or vehicle control. As described previously, MG132 proteasomal inhibitor 
prevents the degradation of monomeric RNMT and RAM. Cells were lysed and cell 
extracts were analysed by western blot to detect RNMT, RAM or β-Tubulin as 
loading control (Figure 6.9b). Long exposure of the RNMT blot resulted in detection 
of an RNMT “ladder” when monomeric RNMT was transfected. The “ladder” may 
signify a chain of post-translational modification linked to RNMT. Often protein 
sumoylation results in “ladder” formation. When RAM was co-transfected with RNMT 
the “ladder” disappeared. Interestingly, in the presence of MG132 the detection of the 
RNMT “ladder” was increased. A possible explanation for that is that the modification 
responsible for the RNMT “ladder” formation disposes RNMT for proteasomal 
degradation. It should also be noted that MG132 has a similar effect as heat shock 
with regards to increasing SUMO2 conjugation to substrate proteins. This is due to 
an accumulation of unfolded proteins in the presence of MG132 that are targeted for 
degradation by the SUMO2 conjugation pathway (Tatham et al., 2011).  
On the other hand, RAM was not detected to be modified after western blot analysis 
either as a monomer or in a complex with RNMT in the cells. To summarise, the 
above experiment demonstrates that monomeric RNMT can be post-translationally 
modified within cells that leads to formation of a protein “ladder”. The “ladder” 
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formation was increased in the presence of MG132 proteasomal inhibitor suggesting 
that modified RNMT is degraded by the proteasome.  
The nature of this RNMT “ladder” needs to be further investigated. Our hypothesis is 
that SUMO2/3 is responsible for this modification. The experiment that needs to be 
performed to prove this hypothesis is immunoprecipitation of monomeric RNMT from 
HeLa cells followed by western blot for SUMO2/3 detection.   
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Figure 6.8: RAM can be sumoylated in vitro independently of K10N mutation. 
(a) Recombinant monomeric RAM WT and RAM K10N were subjected to in vitro 
sumoylation in the presence of SUMO1, SUMO2 or no SUMO protein (-) for the 
time points indicated above the panels. The reaction products were analysed by 
Coomassie stained SDS-PAGE (upper panels) or western blot to detect RAM 
(lower panels). Ubc9, SUMO1, SUMO2, RAM and sumoylated RAM (RAM-SUMO) 
are indicated.  
(b) Recombinant monomeric RNMT was subjected to in vitro sumoylation in the 
presence of SUMO1, SUMO2 or no SUMO protein (-) for the time points indicated 
above the panels. The reaction products were analysed by Coomassie stained 
SDS-polyacrylamide gel (upper panel) or western blot to detect RNMT (lower 
panel). RNMT and sumoylated RNMT (RNMT-SUMO) are indicated.  
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Figure 6.9: RNMT is sumoylated as a monomer but not in a complex with 
RAM. 
(a) Recombinant RAM/RNMT complex and recombinant monomeric RAM (left 
panel) or recombinant monomeric RNMT (right panel) were subjected to in vitro 
sumoylation in the presence of SUMO1, SUMO2 or no SUMO protein (-) for 3 hrs. 
The reactions products were analysed by western blot to detect RAM and 
sumoylated RAM (left panel) or RNMT and sumoylated RNMT (right panel). 
(b) HeLa cells were transfected with a vector control (Vec), pcDNA5-Fg-RAM and 
pcDNA5-HA-RNMT alone or together and treated with MG132 proteasome 
inhibitor or vehicle as indicated above the panel. Cell extracts were analysed by 
western blot to detect RNMT, RAM and β-Tubulin (Tub) as loading control.  
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6.3 Discussion 
6.3.1 Biochemical characterisation of RAM K10N mutation 
This chapter is focused on the regulation of the RNA guanine-7 methyltransferase 
complex. The identification of a single nucleotide polymorphism (SNP) in RAM 
nucleotide sequence was demonstrated to be responsible for a reduction in RAM 
expression by promoting proteasomal degradation. In addition, several post-
translational modifications (PTM) in both RAM and RNMT proteins were identified. 
PTMs are the most commonly used mechanism for rapidly regulating protein activity, 
stability or localisation. Future studies are required in order to elucidate the 
biochemical function of these modifications. 
SNPs have been associated with a variety of pathologies responsible for human 
diseases. The identification of a RAM non-synonymous SNP responsible for an 
amino acid substitution (K10N) was potentially interesting although it is not linked 
with any disease. According to NCBI database 4.5% of human RAM alleles contain 
this SNP. We decided to investigate the biochemical function of RAM K10N.  
RAM K10N was expressed around four-fold less in comparison with RAM WT and 
this was not due to a reduction in mRNA levels. Overexpression of RNMT, that was 
previously shown to stabilise RAM (Chapter 4), could rescue the expression defects 
of RAM K10N suggesting that RAM K10N was less stable than RAM WT. Indeed, 
proteasome inhibitors could equalise the expression of RAM K10N with RAM WT. 
Furthermore, cellular protein stability studies using cycloheximide demonstrated that 
RAM K10N is degraded faster than RAM WT.  
The mechanism, by which RAM K10N is less stable than WT protein, was further 
investigated. Non-synonymous SNPs can frequently cause structural changes in 
proteins (Cohuet et al., 2008). Possibly, RAM K10N mutation predisposes RAM to a 
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misfolded state that is recognised and degraded by the proteasome. Unfortunately, 
the absence of a crystal structure for RAM means this cannot be investigated directly. 
An alternative way to determine conformational changes is by using size-exclusion 
chromatography. The elution profiles of RAM 1-90 WT and K10N after size-exclusion 
chromatography were almost identical (Figure 6.4d), which suggests that RAM WT 
and K10N have not any conformational differences. However, the possibility that 
RAM K10N is structurally different than RAM WT cannot be excluded and 
crystallographic studies need to be performed for addressing this hypothesis. RAM 
crystallographic studies are currently being performed and hopefully the crystal 
structure will be available soon. Alternatively, circular dichroism spectroscopy studies 
can be performed in order to establish whether RAM K10N mutation can alter RAM 
conformation.   
Since RNMT has been demonstrated to stabilise RAM the interaction efficiency 
between RNMT and RAM K10N was investigated. By utilising both recombinant and 
cellular proteins, RAM K10N appeared to interact with RNMT as efficiently as RAM 
WT. This, together with the fact that RNMT overexpression can rescue RAM K10N 
expression defects, suggests that monomeric RAM K10N can be degraded faster by 
the proteasome than monomeric RAM WT. This is further supported by the 
observation that both RAM WT and K10N can rescue the expression levels of 
endogenous RNMT to the same effect, when endogenous RAM is depleted, while 
RAM WT expression remains higher than K10N. The above indicate that 
overexpressed RAM WT as a monomer is more stable than RAM K10N. In vitro 
degradation studies are required to directly prove this hypothesis.  
An obvious criticism of the above hypothesis is that endogenous RAM appears not to 
exist as a monomer within cells as demonstrated in chapter 3. Although this is true 
under normal physiological conditions that we performed the interaction studies, the 
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possibility that under stress conditions RAM and RNMT could exist as monomers 
cannot be excluded. Furthermore, although no monomeric RAM and RNMT were 
detected in our initial studies, this may be attributed to the limitations of using 
western blotting as a detection method. Therefore, the possibility that a small 
proportion of cellular RAM and RNMT is monomeric cannot be excluded. This 
hypothesis is supported by the observation that siRNA against RAM has more 
dramatic effect in the reduction of cell proliferation rates (Cowling Lab; unpublished 
observations) in comparison with siRNA against RNMT, although siRNA against 
RNMT depletes RAM and RNMT more efficiently than siRNA against RAM (Figure 
4.6b).  
On the other hand, it is also possible that RAM overexpression results in an artificial 
situation that is never encountered within cells and most of the results presented in 
this chapter have no physiological relevance. However, preliminary experiments 
performed by Dr. Cowling suggest that although overexpression of monomeric RAM 
WT can rescue the proliferation rates of cells that have been treated with siRNA 
against RAM, the rescue of the proliferation rates when RAM K10N is overexpressed 
is less efficient. 
To summarise, RAM K10N mutation results in a reduction of RAM stability. The 
precise molecular mechanisms that are involved have not been elucidated yet. In 
addition, whether RAM K10N mutation has any biological significance remains 
unclear and requires further investigation.  
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6.3.2 Identification of RNA guanine-7 methyltransferase 
complex post-translational modifications 
In an attempt to elucidate the molecular mechanism that disposes RAM K10N to be 
less stable we performed mass spectrometry analysis to identify post-translational 
modifications of Lysine-10. Although no modifications were associated with Lysine-10, 
Serine-36 was identified as being phosphorylated. Orthophosphate labelling further 
validated this phosphorylation site as did phospho-specific antibodies raised against 
phosphorylated RAM Serine-36.  
Although RAM K10N mutation is not required for RAM S36 phosphorylation, RAM 
phosphorylation at S36 appears to increase cell proliferation as preliminary 
proliferation assays using the RAM S36A mutant suggest. One of our future plans is 
to investigate the function and the biological significance of RAM S36 
phosphorylation. In addition, the identification of the signalling pathway that is 
responsible for RAM S36 phosphorylation is required. Currently, human knock-in cell 
lines expressing RAM S36A are being prepared. 
The phosphorylation of S36 has been identified in several different 
phosphoproteomics studies (Dephoure et al., 2008; Olsen et al., 2010; Weber et al., 
2012). Interestingly, in one of those studies RAM S36 phosphorylation has been 
shown to be reduced after rapamycin treatment in HeLa cells (Chen et al., 2009). 
Rapamycin is a drug that inhibits mTORC1 (mTOR complex 1) (Thoreen et al., 2009). 
mTOR signaling pathway can regulate protein synthesis in response to nutrient 
availability, mitogens, energy sufficiency and stress (Ma and Blenis, 2009).  
Interestingly, mTORC1 has been demonstrated to regulate both the pioneer round 
and the steady-state of translation (Maquat et al., 2010). As discussed in the 
introduction, a common feature of both these states of translation is the N-7 
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methylguanosine cap. This suggests that an additional mechanism by which 
mTORC1 may regulate translation is via N-7 methylguanosine cap formation. 
However, further investigation is required in order to demonstrate whether mTOR 
pathway is mediating RAM Serine-36 phosphorylation. 
Finally, during these studies, it was identified that RNMT can be sumoylated in vitro. 
Interestingly, RNMT can be sumoylated more efficiently as a monomer than in a 
complex with RAM. Our future studies will focus on investigating whether RNMT can 
be sumoylated in vivo and whether RNMT sumoylation can interfere with RAM/RNMT 
interaction. Since heat shock has been shown to stimulate protein sumoylation 
(Saitoh and Hinchey, 2000), the effect of heat shock on RAM/RNMT interaction will 
be investigated. MG132 treatment, that exhibits similar effects as heat shock with 
regards to protein sumoylation (Tatham et al., 2011), resulted in the detection of 
RNMT as a series of bands that resemble a “ladder” when monomeric RNMT was 
transfected into HeLa cells. Whether this “ladder” is due to RNMT sumoylation or 
another PTM needs to be established.  
To conclude, this chapter contains preliminary results that investigate answers of 
mechanisms by which the RNA guanine-7 methyltransferase complex can be 
regulated in cells. We have identified a DNA nucleotide polymorphism that affects 
RAM stability. In addition, we have demonstrated that RAM and RNMT can be post-
translationally modified by phosphorylation and sumoylation respectively. Our future 
goal is to understand how cells respond to environmental conditions by regulating 
RAM/RNMT interaction, activity, stability or localisation.  
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Chapter 7:  Final discussion and future work 
7.1 Summary 
The aim of this thesis was to elucidate the molecular mechanisms of RNA guanine-7 
methylation in mammalian cells, which is an essential process for cell viability and 
gene expression (Shibagaki et al., 1992; Mao et al., 1995; Tsukamoto et al., 1997; 
Chu and Shatkin, 2008; Cowling, 2010c). Interestingly, recent studies have 
demonstrated that RNA guanine-7 methylation is a regulated process within cells 
(Cowling and Cole, 2007; Fernandez-Sanchez et al., 2009; Jiao et al., 2010; Chang 
et al., 2012). Myc overexpression has been shown to increase RNA guanine-7 
methylations by various mechanisms (Cowling and Cole, 2007; Fernandez-Sanchez 
et al., 2009; Cole and Cowling, 2009). Moreover, overexpression of c-Myc is 
synthetic lethal with genetic and pharmaceutical inhibition of the mammalian RNA 
guanine-7 methyltransferase, RNMT (Fernandez-Sanchez et al., 2009). Although it is 
clear that the formation of N-7 methylguanosine cap is essential for cellular function, 
the mechanistic details that control this process remain unclear.  
In order to elucidate the mechanics of RNA guanine-7 methylation, RNMT complexes 
were purified from human cells and novel proteins that interact with RNMT were 
identified. A protein of unknown function named Fam103A1 was found to interact 
with RNMT. We designated Fam103A1 as RAM (RNMT activating mini-protein). 
RAM, like RNMT, was detected to be a nuclear protein and was shown to interact 
directly with RNMT. Furthermore, RAM and RNMT were identified in the same 
complexes and under physiological condition there is no evidence of any monomeric 
RNMT or RAM in all the cell types that were investigated. However, the possibility 
that a minor proportion of RAM and RNMT exist apart from each other cannot be 
excluded. 
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The domains responsible for the interaction between RAM and RNMT were identified, 
demonstrating that the well-conserved RAM N-terminus interacts with the catalytic 
domain of RNMT. RAM has the ability to bind RNA via its Arginine-rich intermediate 
domain and to recruit RNA to RNMT as in vitro RNA band-shift assays suggested. 
Furthermore, RAM binding to RNMT resulted in a five-fold increase of RNMT 
enzymatic activity in vitro and this was found to be independent of the RNA-binding 
capacity of RAM. As will be described later, the biological significance of RAM RNA-
binding domain requires further investigation. Recently, two reports demonstrated 
that RAM binds mRNA directly in HEK-293 and HeLa cells (Baltz et al., 2012; 
Castello et al., 2012). This is an interesting observation demonstrating that the cap 
methyltransferase complex can interact in vivo with mRNAs containing a poly(A) tail, 
suggesting a possible function of the complex independently of transcription initiation 
where it is believed to function predominantly (see introduction). 
Within cells RAM and RNMT expression was found to be co-dependent, suggesting 
that the complex protects each component from proteasomal degradation. Depletion 
of RAM from human cells resulted in a reduction of guanine-7 methylated transcripts 
as demonstrated after mRNA immunoprecipitations with antibodies raised against the 
N-7 methylguanosine cap moiety. This is partially because RAM is required for 
RNMT stability but also because RAM is essential for optimal RNMT activity in vivo. 
Not surprisingly, since RAM is required for cellular mRNA cap methylation and 
because cap methylation is required for transcription elongation and transcript 
stability (Kim et al., 2004; Lenasi et al., 2011; Shimotohno et al., 1977; Murthy et al., 
1991), RAM depletion results in a reduction of several transcripts in a gene-specific 
manner (Gonatopoulos-Pournatzis et al., 2011). Furthermore, RAM depletion results 
in a decrease of protein synthesis rates (Gonatopoulos-Pournatzis et al., 2011), 
partially due to the reduction of transcript levels but also because guanine-7 
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methylated transcripts are required for protein synthesis (Muthukrishnan et al., 1975; 
Both et al., 1975).  
RAM, like RNMT, is required for cell viability. RAM depletion from HeLa cells results 
in a reduction of cell accumulation with a mild increase in apoptosis (Gonatopoulos-
Pournatzis et al., 2011). To summarise, RAM was demonstrated to be a novel and 
essential component of RNA cap methylation machinery and therefore essential for 
gene expression. Figure 7.1 illustrates the above findings in a graphic model. 
  
           
RAM 
m7GpppN 
RNMT 
Cytoplasm!
Nucleus!
Figure 7.1: Schematic model of RAM function in vivo.  
The human RNA guanine-7 methyltransferase complex is responsible for 
methylating guanosine capped (GpppN) RNA pol II transcripts using S-
adenosylmethionine (SAM) as methyl donor. RAM N-terminus interacts with RNMT 
catalytic domain. RAM is a RNA-binding protein that recruits RNA to RNMT. The 
C-terminal domain of RAM is Glutamine, Tyrosine and Proline rich (QYP) and is 
yet to be functionally characterised.  
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In order to elucidate how RAM increased RNMT enzymatic activity we decided to 
pursue crystallographic studies in collaboration with the van Aalten Laboratory. The 
crystal structure of the monomeric RNMT has already been solved 
(http://www.thesgc.org/structures/details?pdbid=3EPP/); therefore, the focus of this 
project was to obtain crystals of monomeric RAM and RAM/RNMT complex. Both 
RAM and RAM/RNMT complex were purified to over 95% homogeneity and assayed 
for crystal formation. Unfortunately, no crystal formation has been observed to date. 
Further investigation of the nucleotide sequence of RAM lead to the identification of a 
single nucleotide polymorphism (SNP), responsible for an amino acid substitution 
(K10N) in RAM protein. RAM K10N was detected to be less stable than RAM WT as 
demonstrated after ectopic expression of cDNA encoding for RAM WT or K10N. Both 
RAM WT and K10N interacted equally with RNMT. More studies are required in order 
to elucidate the biological significance of RAM K10N. 
Finally, this thesis described the identification of two novel post-translational 
modifications of the RNA guanine-7 methyltransferase complex. Mass spectrometry 
analysis and orthophosphate labeling demonstrated that RAM can be phosphorylated 
at Serine-36. Phospho-specific antibodies have been raised and the biological 
significance of this phosphorylation is currently being investigated. In addition, it was 
demonstrated that RNMT can be sumoylated in vitro, predominantly in the absence 
of RAM. This suggests that RAM and SUMO may compete for the same RNMT 
binding site.  
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7.2 RAM evolution 
RNA guanine-7 methylation is a conserved process in all eukaryotic cells and absent 
from the bacterial and archaeal forms of life. It is believed that cap methylation was 
evolved in eukaryotes to compensate for the loss of Shine-Dalgarno base-pairing as 
means of recruiting ribosomes to the mRNA for translation initiation. Furthermore, 
cap methylation correlates with the appearance of 5ʼ exoribonucleases that exist only 
in eukaryotic cells (Shuman, 2002). Human RNMT can rescue cell viability of 
Saccharomyces cerevisiae strains that are RNA guanine-7 methyltransferase 
(Abd1p) deficient suggesting that cap methylation enzymatic activities are well-
conserved (Saha et al., 1999). Surprisingly, RAM is only present in vertebrates and 
absent from lower eukaryotes according to BLAST sequence search of RAM H. 
sapiens amino acid sequence. The possibility that a protein with similar structure or 
function as RAM, but with no amino acid homology, is present in lower eukaryotes 
cannot be excluded. S. cerevisiae proteomic studies are required to investigate this 
hypothesis. An obvious and intriguing question is the purpose of RAM evolution. 
Taking into account that RAM is an RNA-binding protein, it is possible for RAM to 
have evolved in response to the increasing complexity of 5ʼ UTRs associated with the 
evolution of higher eukaryotes. RAM may have evolved in order to recruit specific 
transcripts to guanine-7 methyltransferase. Thus, the identification of the RNA 
population that binds to RAM is an active research area in the Cowling Laboratory.  
A subset of eukaryotic DNA viruses encode their own enzymes for N-7 
methylguanosine cap formation (Shuman, 2002). Poxviruses encode all three 
enzymatic activities required for N-7 methylguanosine structure formation on a single 
polypeptide called D1 (Shuman, 1990). Interestingly, the RNA guanine-7 
methyltransferase has minimal activity in the absence of an activating D12 subunit 
(Mao and Shuman, 1994; Higman et al., 1994). Although poxvirus D12 and RAM 
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have little sequence homology, they both have high isoelectric point of over 8.8. Their 
alkaline nature may promote RNA binding and activation of the methylation reaction. 
The crystal structure of the D1/D12 poxvirus complex revealed that D12 can stabilise 
the D1 subunit and it can also increase D1 methyltransferase activity via an allosteric 
mechanism (De la Peña et al., 2007). As presented in this thesis RAM, similar to D12 
can also stabilise and activate RNMT. The crystallographic studies of RAM/RNMT 
complex that are currently being pursued will elucidate the mechanism by which 
RAM activates RNMT.  
 
7.3 RNA guanine-7 methylation in cancer 
Protein synthesis is a tightly regulated process essential for cell growth and 
proliferation (White, 2008). Deregulation of protein synthesis has been associated 
with the formation and development of cancers because aberrant cell signalling 
pathways converge upon the protein synthesis machinery (Blagden and Willis, 2011). 
An essential feature of mRNA translation is the N-7 methylguanosine cap moiety. 
Eukaryotic initiation factor of translation 4E (eIF4E) is a N-7 methylguanosine cap 
binding protein and part of the eIF4F complex (Sonenberg et al., 1980). eIF4F is 
required for the recruitment of the small ribosomal subunit to 5ʼ UTR for translation 
initiation (Sonenberg and Hinnebusch, 2009). 
eIF4E cap-binding protein illustrates the importance of deregulated translation in 
tumour formation. Aberrant Ras and Akt signal transduction pathways mediate cell 
transformation by enhancing eIF4E capacity to bind N-7 methyguanosine capped 
mRNAs and to promote their translation (Mamane et al., 2004). Therefore, it is not a 
surprise that eIF4E overexpression in tissue culture cell lines causes their 
tumourigenic transformation as determined by anchorage-independent growth and 
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tumor formation in nude mice (Lazaris-Karatzas et al., 1990). Furthermore, 
transgenic mice expressing higher levels of eIF4E display a significant increase in 
tumourigenesis (Pandolfi, 2004), which correlates with Ras and Akt driven translation 
activation (Wendel et al., 2007). eIF4E overexpression has been detected in human 
tumors of the breast, head and neck, colon, prostate, bladder, cervix and lung, and 
has been related to disease progression (De Benedetti and Graff, 2004). Therefore, 
eIF4E is a promising target for cancer treatment. eIF4E has been a target for drug 
design and drugs inhibiting cap-dependent translation have been trialed in 
haematologic malignancies, while antisense oligonucleotides against eIF4E are also 
due to enter clinical trials (Blagden and Willis, 2011). The therapeutic effects of 
blocking cap-dependent translation are partially mediated by decreasing the 
expression of short-lived oncoproteins like c-Myc and Cyclin D1 (Schatz et al., 2011). 
Similar to eIF4E, Myc can also interfere with the cellular cap guanine-7 methylation. 
Myc is a dominant oncogene and a key regulator of cell growth and proliferation. 
Approximately 70% of human tumors have elevated Myc expression (Cole and 
Cowling, 2008). Myc is a transcription factor regulating the transcription of RNA 
polymerase II genes (protein-encoding mRNAs, and miRNAs regulating mRNA 
translation and stability), as well as RNA polymerase I (rRNA) and RNA polymerase 
III (tRNA) genes. Thus, Myc can coordinately regulate the protein synthesis 
machinery in order to promote protein synthesis (Cowling, 2010b).  
Recently it was demonstrated that c-Myc up-regulates mRNA guanine-7 methylation 
(Cowling and Cole, 2007; Cole and Cowling, 2009). Although c-Myc transcriptional 
effects are broad (~ 15% of the genome is c-Myc responsive), c-Myc is a rather weak 
transcriptional factor regulating each gene by less than 2-fold (Cole and Cowling, 
2008). In contrast, c-Myc can increase N-7 methylguanosine cap levels of its target 
genes (and not only) up to 8-fold (Cowling, 2010c) resulting in increased mRNA 
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translation (Cowling and Cole, 2007). Most importantly, the Cowling laboratory has 
demonstrated that inhibition of Myc-induced cap methylation is sufficient to abolish c-
Myc induced protein synthesis, cell proliferation and cell transformation (Fernandez-
Sanchez et al., 2009).  
eIF4E-induced tumorigenic activity when considered together with the finding that 
inhibition of cap methylation is synthetic lethal with elevated c-Myc expression, 
demonstrates the importance of the N-7 methylguanosine cap in tumour formation. In 
addition, RNMT overexpression results in cell transformation in vitro (Cowling, 
2010a). These indicate the potential of novel means to treat cancer. We reason that 
the uniqueness of RAM/RNMT interface can be used to generate relatively specific 
inhibitors of the cellular cap methyltransferase activity. A primary goal of the Cowling 
Laboratory is the identification of a RAM/RNMT inhibitor utilising Alpha screen 
assays as described in chapter 5. The effect of the inhibitor upon protein synthesis 
and cell proliferation of normal and transformed cell lines will be investigated.  
 
7.4 Future Work 
Although RAM has been identified as a novel RNMT binding protein that enhances 
its RNA guanine-7 methyltransferase activity, further research is required to identify 
by which means this occurs. In order to investigate this, crystallographic and 
biophysical methods are being pursued. The effect of RAM upon RNMT for S-
adenosyl-methionine (SAM) and cap binding will be determined by biolayer 
interferometry as described in chapter 5. Furthermore, biophysical assays will be 
utilised for performing screens for the identification of RAM/RNMT interaction 
inhibitors. The effect of such an inhibitor upon cell proliferation, protein synthesis and 
cellular cap methylation in normal and transformed cell lines will be explored. 
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The identification of the transcripts that require RAM for their expression can be 
performed by collectively utilising a series of biochemical methods. PAR-CLIP 
(Photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation) 
can be used in order to identify the specific subset of transcripts bound to RAM. 
Subsequently, in order to determine the effect of RNA guanine-7 methylation on gene 
expression, the RAM/RNMT complex can be depleted (either bi siRNA or optimal by 
an identified inhibitor of RAM/RNMT interaction) and its effect on transcriptome and 
proteome can be determined by RNA sequencing and SILAC (stable isotope labeling 
with amino acids in cell culture) approach. The above experiments collectively will 
elucidate the effects of N-7 methylguanosine cap on transcription, splicing, stability 
and protein synthesis of specific transcripts.  
The RAM domain responsible for RNMT activation was demonstrated to be separate 
from the RNA-binding domain of RAM. However, the biological significance of RAM 
RNA-binding domain is as yet unknown. Knock-in human cell lines expressing RAM 
1-55, which interacts and activates RNMT in vitro but does not bind RNA, will be 
prepared. The effect of RAM RNA-binding upon cell proliferation, protein synthesis 
and cellular cap methylation will be explored. 
Finally, our research has raised the question of how RNA guanine-7 
methyltransferase complex is regulated in vivo. The biological and biochemical 
function of RAM Serine-36 phosphorylation and RNMT sumoylation will be 
investigated. Since rapamycin has been demonstrated to down-regulate Serine-36 
phosphorylation in a phosphoproteomic study (Chen et al., 2009), the effect of mTOR 
pathway in Serine-36 phosphorylation will be investigated and the significance of this 
phosphorylation in cap methyltransferase activity and protein synthesis will be 
determined. As regards to RNMT sumoylation, it would be interesting to investigate 
whether it can regulate RAM/RNMT interaction or RNMT stability.  
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The major questions that have been raised after the discovery of RAM are 
summarised below.  
1. What are the molecular mechanistic details of RNMT activation by RAM? 
Determination of RAM/RNMT crystal structure coupled by biophysical assays. 
2. What is the biological significance of RAM RNA-binding domain?  
CLIP-seq of RAM/RNMT complex. 
Production of knock-in cell lines expressing RAM RNA-binding mutant and 
investigation of the effects on cell proliferation rates and protein synthesis. 
3. Which signaling pathways regulate the RNA cap methyltransferase complex? 
Investigation of whether mTOR signaling pathway can phosphorylate RAM 
Serine-36. 
What is the effect of RAM Serine-36 phosphorylation on global and specific 
transcript cap methylation.  
Is RAM/RNTM interaction regulated under stress condition? 
Does sumoylation regulate RAM/RNMT interaction? 
4. Can RAM/RNMT interaction be targeted for development of cancer 
therapeutic drugs? 
Inhibitor screening for the identification of RAM/RNMT interaction inhibitors. 
Determine the effect of any positive hit on cell growth and proliferation of 
normal and transformed cell lines. 
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